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ABSTRACT OF THESIS 
 
 IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM  
ALONE AND IN COMBINATION AGAINST CARBAPENEM-RESISTANT 
ENTEROBACTERIACEAE 
 
Background: Infections caused by carbapenem-resistant Enterobacteriaceae such as 
Escherichia coli and Klebsiella pneumoniae are among the most urgent threats of the 
infectious disease realm. The incidence of these infections has only been increasing over the 
years and due to very limited treatment options, mortality is estimated at about 50%.  
Methods: To evaluate the in vitro activity of meropenem and polymyxin B against 
carbapenem-resistant Enterobacteriaceae, antimicrobial susceptibility testing and time-kill 
studies were performed on K. pneumoniae clinical isolates representing a wide range of 
meropenem resistance (MICs 4 – 128 mg/L).  
Results: Regrowth was observed at clinically relevant concentrations of meropenem alone (4, 
16, and 64 mg/L) or polymyxin B alone (0.25 and 1 mg/L) within 24 hours. However, 
meropenem and polymyxin B in combination were consistently bactericidal, achieving 
synergistic activity in strains with lower meropenem resistance (MICs ≤32 mg/L).  
Conclusions: Our findings are in agreement with the limited available literature, but we add 
that the synergistic interaction between meropenem and polymyxin B is dependent on the 
degree of meropenem resistance in KPC-producing K. pneumoniae. This data suggests that 
lower level resistance to carbapenems may be amenable to antimicrobial combinations 
involving a carbapenem and a polymyxin. 
KEYWORDS: Klebsiella pneumoniae, time-kill, meropenem, polymyxin B, synergy 
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Chapter One: 
 
Antimicrobial Resistance 
  
Infectious disease treatment and management in patients is made difficult when 
resistance to contemporary antimicrobial agents is involved. In fact, expression of 
resistance renders antimicrobial agents less effective and has been overwhelmingly 
associated with poor clinical outcomes, including increased mortality.1-10 Unfortunately, 
resistance always follows the development of any novel antimicrobial, given enough time 
(Figure 1.1).11 Commonly known pathogens such as Escherichia coli and Klebsiella 
pneumoniae are among the most notorious for expression of drug resistance because they 
exist as part of the normal flora in the gastrointestinal tract of humans. Frequent 
antimicrobial consumption fosters development of drug resistance among these enteric 
bacteria for which novel antimicrobials are dwindling and currently available 
antimicrobials are few.12 With this in mind, efforts such as the present work contribute 
information to questions such as what antimicrobials alone or in combination provide 
patients with the greatest chance of survival when confronted by these highly resistant 
pathogens? Do particular agents work better together than others? How many 
antimicrobial agents are sufficient to ensure a high probability of recovery? 
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Figure 1.1: Antimicrobial Resistance Timeline. Reprinted11 
 3 
 
In March 2015, the U.S. Department of Health and Human Services (HHS) 
established the President's Advisory Council on Combating Antibiotic-Resistant Bacteria 
(PACCARB) which is responsible for providing advice, information, and 
recommendations to the Secretary of Health and Human Services regarding programs and 
policies from the National Action Plan. Within this plan is the Centers for Disease 
Control and Prevention (CDC) 2013 report which categorized a variety of antimicrobial 
resistance problems based on seven factors associated with resistant infections – clinical 
impact, economic impact, incidence, 10-year projection of incidence, transmissibility, 
availability of effective antibiotics, and barriers to prevention.  
Three threat levels (concerning, serious, and urgent) were identified using these 
seven factors (Figure 1.2). Serious threats include organisms such as extended-spectrum 
β-lactamase (ESBL)-producing Enterobacteriaceae, vancomycin-resistant Enterococcus 
(VRE), methicillin-resistant Staphylococcus aureus (MRSA), multidrug resistant 
Pseudomonas aeruginosa, and drug-resistant Tuberculosis, among others. Antimicrobial 
resistance in gram-negative organisms, specifically carbapenem-resistant 
Enterobacteriaceae (CRE), were among the highest of threat levels, designated as urgent 
(Figure 1.2).11 The present work focuses on this group of urgent threat level pathogens. 
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Figure 1.2: Antimicrobial Resistance Threat Levels. Reprinted11 
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MECHANISMS OF RESISTANCE 
 Understanding mechanisms of resistance is important because these shape the 
direction of research and also the choice of therapy. For example, in the interest of 
obtaining clinically relevant information, it may be more advantageous to focus on 
characterizing the more common mechanisms of resistance rather than the least common 
where particular knowledge about a certain mechanism of resistance may afford certain 
therapeutic advantages (e.g. the sustained activity of aztreonam against exclusively 
metallo-β-lactamase producing organisms). For this reason, a general discussion of 
mechanisms of resistance is valuable and specifics to the present work will be covered in 
Chapter 2. 
Resistance mechanisms can be broadly grouped into four categories. 1) efflux 
pumps which actively remove antimicrobials from the target site of action, 2) enzymatic 
degradation of the antimicrobial agent (e.g. β-lactamases),13 3) changes in cell wall 
permeability which may slow or prevent the antimicrobial from reaching the target site 
(e.g. mutations in channels called porins), and 4) target site alterations that prevent the 
antimicrobial from binding (Figure 1.3). Bacteria are not limited to simply one 
mechanism and in fact often exhibit multiple mechanisms which may confer resistance to 
multiple classes of antimicrobials at once. For β-lactam antimicrobials, enzymatic 
degradation is the most common mechanism.14 
  
 6 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Mechanisms of Antibiotic Resistance. Reprinted15 
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HISTORY OF β-LACTAM RESISTANCE DEVELOPMENT 
 Penicillin, the original β-lactam, was first administered to Anne Miller in 1942 as 
treatment for a streptococcal bloodstream infection. However, bacteria have been 
evolving to survive long before the introduction of antibiotics to humans. In fact, Edward 
Abraham and Ernst Chain16 identified a mechanism of penicillin resistance in 1940, two 
years before penicillin was even administered to Anne Miller. They discovered that a 
particular strain of Escherichia coli produced AmpC ("Classification of β-lactamases"), 
an enzyme capable of inactivating penicillin, and in later experiments it was found that 
previously penicillin-sensitive Staphylococcus aureus could be made penicillin resistant 
after continuous subculture in the presence of penicillin in vitro.17 By 1943, one year 
following human introduction to penicillin, four penicillin-resistant staphylococci strains 
were isolated from patients during the course of treatment.18 The predominant mechanism 
of resistance among Staphylococcus aureus at this time was discovered to be β-lactamase 
production,19,20 termed "penicillinases." 
In response, the dose of penicillin was increased to compensate for reduced 
susceptibility;21 but by 1947, a majority of hospital Staphylococcus aureus isolates were 
entirely resistant to penicillin.22 To counter the growing resistance rates, chemists 
developed anti-staphylococcal penicillins (e.g. methicillin) for gram-positive organisms 
such as Staphylococcus aureus and Staphylococcus epidermidis and aminopenicillins 
(e.g. ampicillin) for gram-negative organisms such as Escherichia coli, Klebsiella 
pneumoniae, and Serratia marcescens.23 These novel antimicrobials were not hydrolyzed 
by early penicillinase-producing organisms. 
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 Primarily in gram-negative organisms, β-lactamases developed that conferred 
resistance to aminopenicillins (classified as TEM-1 and TEM-2 in organisms like E. coli 
and SHV-1 in K. pneumoniae). These enzymes were countered by the development of β-
lactam/β-lactamase inhibitor combinations (e.g. ampicillin/sulbactam) and 
cephalosporins. These compounds functioned in the presence of early β-lactamases such 
as TEM-1, TEM-2, and SHV-1, but once again, resistance developed with AmpC and 
ESBL-production. At first, ESBLs in the U.S. were point mutations of the TEM and SHV 
families, of which there are now hundreds of different subtypes. However, other ESBL 
families also developed and spread from other parts of the world, such as the second-
largest group, CTX-M, originally from the chromosome of Kluyvera spp.24 OXA-type β-
lactamases are another example of an ESBL, originally discovered in a Pseudomonas 
aeruginosa25 isolate from Turkey. There are myriad other β-lactamase families (PER,26,27 
VEB,28 GES,29,30 BES,31 TLA,32 SFO,33 and IBC34,35), discovered from diverse 
geographic locations, and even some chromosomally located ESBLs.36 
 Today, the CDC estimates that 19% of healthcare-associated Enterobacteriaceae 
infections in the U.S. are caused by ESBL-producing organisms. Of the top two 
Enterobacteriaceae, 23% of Klebsiella pneumoniae and 14% of Escherichia coli 
infections now produce ESBL.11 For perspective, ten years ago, the National Healthcare 
Safety Network (NHSN) estimated 1% of Klebsiella pneumoniae infections and 0.5% of 
E. coli infections produced ESBLs. In other parts of the world, ESBL-producing bacteria 
are as high as 52% in Thailand,37 and 70% in Egypt.38 Eastern Europe has also reported 
rates as high as 25-50%.39 Generally speaking, the rate of ESBLs in Europe is higher than 
that of the U.S., but lower than Latin American or Asia.40 
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The antimicrobial agents of choice for ESBL-producing organisms are the 
carbapenems. Currently there are four – imipenem, ertapenem, meropenem, and 
doripenem. However, we now enter the current era of the resistance mechanisms – 
carbapenemases. These will be discussed in more detail in "Chapter 2: Carbapenem 
Resistant Enterobacteriaceae (CRE)," but the two most common groups are Klebsiella 
pneumoniae carbapenemases (KPC; more common in the U.S.) and metallo-β-lactamases 
(MBL; more common in Europe and Southeast Asia;13 Figure 1.4). 
 
 
Figure 1.4: The Evolution of β-lactamases. Reprinted13  
ESBL = extended-spectrum β-lactamase; KPC = Klebsiella pneumoniae carbapenemase 
MBL = metallo-β-lactamase  
TEM-1, TEM-2, SHV-1, TEM, SHV, CTX-M = types of β-lactamases 
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CLASSIFICATION OF β-LACTAMASES 
 To date, many attempts have been made to categorize β-lactamase enzymes, but 
these classification schemes can be summarized in two major approaches – classification 
based on biochemical and functional characteristics or classification based on molecular 
structure of the enzymes.41 For the former, criteria such as the spectrum of antimicrobial 
substrates, hydrolysis rate (Vmax), binding affinity (Km), isoelectric focusing (pI), 
molecular weight, and amino acid composition42 have been used to develop classes and 
many subclasses,43 but will not be discussed here. The simpler, molecular classification 
scheme uses four classes (Ambler class A-D) which are described below. 
 Ambler class A is the broadest class and is most simply described as a catch-all 
class to enzymes not fitting one of the other classes, consisting of β-lactamase enzymes 
that are located on plasmids, transposons, or chromosomes (e.g. TEM, SHV, PER, PSE, 
hundreds of others).41,44,45 Class A enzymes range from hydrolyzing a narrow spectrum 
of β-lactams (e.g. penicillinases) to a broad spectrum (e.g. ESBL or carbapenemases). A 
very high degree of sequence variability and kinetic properties exist for this class.  
Ambler class B enzymes, also called metallo-β-lactamases (MBLs), require zinc 
to carry out their function. Common MBLs in CRE organisms are imipenem-type 
carbapenemases (IMP), Verona integron-encoded metallo-β-lactamases (VIM), and New 
Delhi metallo-β-lactamase (NDM). Class B enzymes hydrolyze all β-lactam 
antimicrobials except monobactams (e.g. aztreonam) and are not inhibited by any current 
β-lactamase inhibitors such as clavulanic acid, sulbactam, tazobactam, and avibactam. 
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Ambler class C enzymes, commonly known as the cephalosporinases46 or AmpC 
enzymes, are chromosomally encoded with highly conserved sequences.47,48 AmpC 
enzymes hydrolyze most extended spectrum β-lactams and β-lactam/β-lactamase 
inhibitor combinations such as ceftriaxone or piperacillin/tazobactam, but usually not 
carbapenems. However, CMY-10 is among the first AmpC enzymes that hydrolyze 
carbapenems.49 Additionally, non-carbapenem hydrolyzing AmpC production in 
combination with porin channel mutations can also confer resistance to carbapenems.41 
Ambler class D enzymes are also known as oxacillinases (OXA) due to their 
ability to hydrolyze isoxazolyl β-lactamases such as oxacillin and methicillin.50 There is a 
lot of structural similarity between class D and class A enzymes which can make 
differentiation, or even detection, difficult.41 Class D enzymes are usually not inhibited 
by β-lactamase inhibitors such as clavulanic acid, sulbactam, and tazobactam, but they 
are inhibited in vitro by sodium chloride concentrations of 100mM.51-55 Additionally, 
these enzymes are relatively inactive against cephalosporins.14 Although the OXA 
enzyme family consists of more than a hundred unique subtypes, 9 are considered ESBL 
and 37 are considered to be carbapenemases.56 
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DEVELOPMENT OF RESISTANCE 
 Resistance to antimicrobials can be inherent, "natural" resistance such as 
inadequate uptake of an antimicrobial due to lack of transporters (e.g. Pseudomonas 
aeruginosa and tetracycline antimicrobials), lack of drug-activating mechanisms (e.g. 
metronidazole and aerobic organisms), or lack of target sites (e.g. penicillin binding 
proteins of enterococci and all cephalosporin class antimicrobials); or resistance to 
antimicrobials can be acquired through normal mutation, vertically through 
reproduction, or horizontally through transformation, transduction, and conjugation 
(Figure 1.5). Sometimes, observable resistance requires a combination of the above. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Horizontal Acquisition of Resistance. Reprinted57 
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Acquired resistance is an area of great concern because, unlike intrinsic 
resistance, these resistance profiles can be dynamic and unique for each species of 
bacteria and can change even during the course of therapy, making clinical decisions 
difficult and outcomes worse. Spontaneous mutation frequency that confers antimicrobial 
resistance is approximately on the order of 10-8 to 10-9 which means that one in every 
hundred billion to one trillion bacteria in an infection will develop resistance to an 
antimicrobial through random mutation.58 Once exposed to an environment containing an 
antimicrobial, resistant organisms are preferentially selected for survival and this 
resistance can then be passed along through reproduction or through horizontal gene 
transfer. 
 In the setting of horizontal gene transfer, genetic material can be exchanged 
between individual bacteria of the same or different species.58 One of the most common 
methods is conjugation where bacteria come into direct cell-to-cell contact and exchange 
small pieces of DNA called plasmids which may contribute to the explanation of why 
Ambler class A β-lactamases are so diverse in protein structure whereas class C β-
lactamases (i.e. AmpC β-lactamases, which are typically located chromosomally) retain 
such highly conserved protein sequences. Another method of gene transfer is 
transformation where parts of DNA are taken up by bacteria from the environment which 
usually originated from the death or lysis of another bacterium.58 The final method is 
transduction where bacteria-specific viruses called bacteriophages inject DNA into the 
bacteria cell (Figure 1.5). 
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Chapter Two: 
 
Carbapenem-resistant Enterobacteriaceae (CRE) 
 
This chapter will discuss epidemiology, therapeutic agents, and current literature 
on carbapenem-resistant Enterobacteriaceae – the group of drug resistant pathogens 
labeled an urgent threat by the CDC.11 Enterobacteriaceae include organisms such as 
Escherichia coli, Klebsiella spp., Enterobacter spp., Salmonella spp., Shigella spp., 
Proteus spp., Serratia spp., Citrobacter spp., and  Yersinia pestis. CRE-specific 
resistance mechanisms are often more complex, not always entirely understood, and can 
be multifaceted. One commonality between CRE and other gram-negative organisms is 
that enzyme production (e.g. β-lactamase) is still the most common resistance 
mechanism, but can also be present in combination with changes in cell wall permeability 
(e.g. porin channel mutations), upregulation of efflux pumps, or target site alterations 
which can further contribute to carbapenem resistance.14 Additionally, β-lactamases 
without intrinsic carbapenemase activity but with cephalosporinase activity (e.g. DHA, 
ACT, CMY, SHV-5, CTX-M-15) can contribute to carbapenemase resistance when 
combined with other non-enzyme mediated mechanisms of resistance.59-62  
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EPIDEMIOLOGY OF CARBAPENEM RESISTANCE  
Understanding the epidemiology of CRE will attest to the relevance of the present 
work and help predict the ultimate direction of future studies. Interestingly, substantial 
geographic diversity exists for CRE. For example, in the United States, Klebsiella 
pneumoniae with KPC-2 or KPC-3 (two Ambler class A serine-based enzymes) comprise 
about 80% of CRE cases.14,63-65 In contrast, MBL (Ambler class B) or OXA-like (Ambler 
class D) enzymes are more clinically significant world-wide such as in India and Pakistan 
(NDM),66 Greece and Italy (VIM),67 or Turkey, Spain and North Africa (OXA-48).14,68-72  
Some countries (e.g. China) have low CRE prevalence, but significant diversity of 
carbapenemase enzymes.73,74 Coexistence of various sequence types of MBLs and KPCs 
within the same Klebsiella pneumoniae strains has also been observed.67,75-77 Ultimately, 
no two countries are the same when it comes to CRE characteristics and the prevalence 
can be drastically different, even between acute-care centers within the same country.14 
Regarding the U.S. specifically, there are no national requirements to report CRE, 
but requirements for reporting CRE do vary by state.78 To facilitate data collection 
nationally, the CDC maintains two voluntary surveillance systems for CRE monitoring – 
Healthcare Associated Infections Community Interface (HAIC) which uses 10 sites 
across the nation for determining communities having or at risk for having CRE 
infections, and the National Healthcare Safety Network (NHSN) which tracks 17,000 
facilities nationwide for healthcare-associated infections.79 Figures 2.1-2.4 show the data 
reported to the CDC, separated by β-lactamase type (KPC, NDM, VIM, OXA-48) and by 
state. 
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Figure 2.1: States with KPC-producing CRE Reported to the CDC. Reprinted79 
 
 
 
Figure 2.2: NDM-producing CRE Isolates Reported to the CDC. Reprinted79 
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Figure 2.3: OXA-48-producing CRE Isolates Reported to the CDC. Reprinted79 
 
 
 
Figure 2.4: VIM-producing CRE Isolates Reported to the CDC. Reprinted79 
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Klebsiella pneumoniae Carbapenemase (KPC; Class A) 
A KPC-producing CRE was first identified in the United States from Klebsiella 
pneumoniae cultured from a patient in North Carolina in 1996, but reported in 2001.80 
Thereafter named KPC-1, it was not the first carbapenemase to be reported in 
Enterobacteriaceae because MBLs had been identified in Enterobacteriaceae in Japan as 
early as 1991.81-83 It was, however, the first Ambler class A, serine-based carbapenemase 
to be found in Enterobacteriaceae. Subtype variants KPC-2 (later identified as identical to 
KPC-1) and KPC-3, initially concentrated in eastern states such as New York and New 
Jersey,3,80,84-90 but have since spread to all but two states, Idaho and Maine (Figure 2.1). 
Among CRE sent to the CDC, KPC has primarily been identified in Klebsiella 
pneumoniae, Escherichia coli, and Enterobacter spp.,91 and the KPC-2 and KPC-3 
subtype variants are the most common in the United States. As of July 2015, Lahey 
Clinic had 24 KPC subtypes reported,92 but only subtypes 1/2, 3, 4, 6, 7, 8, 11 and 12 
have been reported in Klebsiella pneumoniae.93-95 
Outside the U.S., the first KPC-producing Enterobacteriaceae was identified in 
2005 from a hospital in Paris, France where a patient had been recently hospitalized in 
New York.96 Currently, 34 of 38 surveyed European countries have reported KPC-
producing CRE (Figure 2.5),97,98 as well as Israel99 and China.100 
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Figure 2.5: KPC-producing Enterobacteriaceae in 38 European Countries Based on Self-
Assessment by National Experts. Reprinted98 
 
Imipenem-like Carbapenemase (IMP; Class B) 
In 1991, the very first MBL identified in Enterobacteriaceae was IMP-1, found in 
a Serratia marcescens clinical isolate in Japan.81,82 IMP also emerged in Italy and 
Portugal in 1997 and 1998, respectively.101 The differences in European IMP subtypes 
and Japanese IMP subtypes have led to the belief that European IMP-production emerged 
locally rather than global dissemination from Japan.101 IMP has also been identified in 
Canada, China, Korea, Singapore, Taiwan and Australia to name a few more regions 
outside the U.S. IMP-producing CRE in Europe is depicted in Figure 2.6.101 
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Figure 2.6: IMP-producing Enterobacteriaceae in 38 European Countries Based on Self-
Assessment by National Experts. Reprinted98 
 
From 2009 - 2010, the first IMP-producing CREs were isolated in the U.S. from 
three pediatric patients with no history of travel or receipt of medical care outside the 
United States.102 Before this, the first IMP-producing isolate was Pseudomonas 
aeruginosa, reported in 2006.103 Otherwise, there have been no other reports of IMP-
producing CRE in the U.S. As of July 2015, Lahey Clinic had reported 53 subtypes of 
IMP-type β-lactamases.92 
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Verona Integron-encoded Metallo-β-lactamase (VIM; Class B) 
A VIM-producing CRE was first identified in Greece from Escherichia coli in 
2001,104,105 and then later from other E. coli and K. pneumoniae isolates.101,106 VIM-
production has also been reported in Japan, South Korea, Portugal, Spain, Poland, 
Croatia, Chile, Venezuela, Argentina, Belgium and most recently in the United States.107-
113 Figure 2.7 depicts VIM-production in Europe whereas Figure 2.4 describes VIM-
production in the United States.  
The first VIM-producing CRE identified in the U.S. was in an adult patient with 
Klebsiella pneumoniae in 2006.114 Additionally, a recent publication describes the first 
and only cluster of VIM-producing CRE in the U.S. Perirectal cultures of eight isolates (4 
E. cloacae, 1 Raoultella sp., 1, E. coli, 2 Klebsiella pneumoniae) from six patients were 
obtained – six from a neonatal intensive care unit, and two from an adult trauma and 
surgical intensive care unit.115 To date, this is the only VIM-producing CRE colonization 
reported to include a neonatal population. Previous VIM-producing CRE have only 
involved a single species, and only one VIM-producing CRE-colonized patient had been 
reported (2013) in the same hospital. As of July 2015, Lahey Clinic had reported 46 
subtypes of VIM-type β-lactamases.92 
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Figure 2.7: VIM-producing Enterobacteriaceae in 38 European Countries Based on Self-
Assessment by National Experts. Reprinted98 
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Oxacillinase Group β-lactamase (OXA; Class D) 
In 2001, OXA-48 was the first Ambler class D carbapenemase isolated in 
Enterobacteriaceae. It was first found in a Klebsiella pneumoniae isolate from Turkey.54 
Interestingly, this particular OXA enzyme has the highest hydrolysis rate of imipenem 
compared to all other published OXA enzymes.56 OXA-48 has also been identified in 
Russia,116 South Korea,117 Argentina, India,118 Taiwan,119 North Africa,65 and the U.S.79 
(Figure 2.3). Figure 2.8 depicts OXA-48 dissemination in Europe. Other OXA group 
carbapenemases include OXA-163 and OXA-181.120 
 
 
Figure 2.8: OXA-48-producing Enterobacteriaceae in 38 European Countries Based on 
Self-Assessment by National Experts . Reprinted98 
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New Delhi Metallo-β-lactamase (NDM; Class B) 
In 2009, an NDM-producing CRE was first identified in Sweden from Klebsiella 
pneumoniae, cultured from a patient of Indian descent who had recently traveled to New 
Delhi, India and acquired a urinary tract infection (UTI).121 This novel MBL was 
designated NDM-1. Currently, at least sporadic NDM-producing CRE has been reported 
in most European countries (Figure 2.9), but a more thorough description of NDM spread 
across Europe is described by Cantón et al.122 As of July 2015, Lahey Clinic had reported 
16 NDM-type β-lactamases.92 
 
 
Figure 2.9: NDM-producing Enterobacteriaceae in 38 European Countries Based on 
Self-Assessment by National Experts. Reprinted98 
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In the U.S., the first NDM-producing Enterobacteriaceae was among nine isolated 
from 2009 - 2011 (5 K. pneumoniae, 2 E. coli, 1 E. cloacae, and 1 Salmonella enterica) 
from eight patients across five states (5 California, 1 Illinois, 1 Maryland, 1 
Massachusetts, and 1 Virginia). All patients had recently been to India or Pakistan. Eight 
of these isolates were confirmed by the CDC to encode NDM-1, but the ninth isolate (E. 
coli) coded for what is now called NDM-6.66 NDM-producing isolates were also being 
described in other parts of the world by this time, consistently in patients with recent 
travel to India or Pakistan.91 Since 2012, the epidemiology in the U.S. appears to be 
changing as more NDM-producing CRE are being isolated from patients without recent 
travel outside country, suggesting local acquisition.91 
 
CRE Incidence and Prevalence 
 Regarding the top 3 CRE reported in the U.S., 69% were Klebsiella 
pneumoniae/oxytoca, 18% were E. coli, and  13% were Enterobacter spp.123 Nationwide, 
carbapenem resistance among Klebsiella pneumoniae/oxytoca was <1% in 2000,124 but 
by 2010, the CDC reported carbapenem resistance up to 12.8% and 12.5% for central-line 
associated bloodstream infections (CLABSIs) and catheter-associated urinary tract 
infections (CAUTIs),123 respectively. An academic medical center in New York reported 
carbapenem-resistant Klebsiella pneumoniae rates of 38% in 2008.125 A collective report 
of 14 hospitals in New York also noted overall 38% Klebsiella pneumoniae carbapenem 
resistance in 2006, but has recently reported a decrease to 29% in 2009.126 This study 
focuses on KPC-producing Klebsiella pneumoniae which will be further discussed later. 
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"TYPICALLY SUSCEPTIBLE" ANTIMICROBIALS 
 CRE are complex and diverse – what may work for some organisms may not be 
universally applicable to others. In general, CRE are resistant to all β-lactams and β-
lactam/β-lactamase inhibitor combinations with the exception of ceftazidime/avibactam, 
a newly approved β-lactam/β-lactamase-inhibitor combination for KPC-producing gram-
negative bacteria.14 Additionally, exclusively MBL-producing CRE may be susceptible to 
aztreonam. However, due to the complexity and commonly multi-factored resistance that 
accompanies most CRE, this is seldom applicable.127 
 Regarding other classes of antimicrobials, CRE are typically only susceptible 
(>85%) to colistin, polymyxin B, tigecycline, fosfomycin, and variably susceptible (35-
75%) to aminoglycosides. There are limitations with each of the antimicrobials for which 
CRE are typically susceptible, ranging from pharmacologic characteristics and rapid 
resistance development to toxicity and adverse events.14 
 
Polymyxins 
 The polymyxin class of antibiotics was introduced in the mid-1950s, consisting 
now of two agents – polymyxin B and polymyxin E (colistin). Both agents are cationic 
polypeptides that share a ring of amino acids and a fatty acid tail (Figure 2.10). The 
structural difference of colistin involves a substitution of the phenylalanine in polymyxin 
B with D-leucine. Additionally, both polymyxins have two major components based on 
the fatty acid chain length – polymyxin B1 and B2 and colistin A and B.14 
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Figure 2.10: Structure of Polymyxin B. Reprinted128 
 
 The mechanism of action of the polymyxin class involves binding to negatively-
charged moieties in the lipopolysaccharide (LPS) present in the outermost membrane of 
gram-negative bacteria (Figure 2.11). This interaction results in the loss of intracellular 
products, killing the bacteria. 
 
Figure 2.11: Polymyxin B/Colistin Mechanism of Action. Reprinted129 
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 Polymyxins have a broad gram-negative spectrum of activity – including 
Enterobacteriaceae (except Proteus spp. and Serratia spp.), Pseudomonas aeruginosa, 
and Acinetobacter baumannii. However, their utility had been limited by the 
development of safer antimicrobials like the aminoglycosides and cephalosporins. In fact, 
this antimicrobial class was primarily reserved for cystic fibrosis patients, gastrointestinal 
(GI) tract decontamination, and topical antimicrobial therapy.14 In the '90s, this class was 
"reintroduced" to address problems with carbapenem-resistant organisms. One of the first 
published successes of polymyxin treatment for CRE involved a critically ill patient with 
a carbapenem-resistant Klebsiella pneumoniae bloodstream infection.130 
 Polymyxin B and colistin differ significantly in their pharmacokinetics. However, 
routes of administration are similar between the polymyxins with the exception that 
polymyxin B cannot be administered orally. Otherwise, both polymyxins can be 
administered intravenously, intramuscularly, intrathecally, topically, or by inhalation. 
Clinically, colistin is administered as a prodrug (colistimethate sodium; CMS) which 
must be first hydrolyzed into various derivatives (e.g. colistin) before having any 
antimicrobial effect, whereas polymyxin B is administered as an active agent. The rates 
of hydrolysis are variable according to the physical environment within the patient (e.g. 
pH and temperature). Differences in rates and extents of hydrolysis have been observed 
brand-to-brand or even batch-to-batch.131 Since there is no appreciable antimicrobial 
activity from the parent compound, rational dosing of CMS is very challenging.132,133 
 Additional challenges in CMS dosing exist in its elimination, which is primarily 
renal, and its conversion to colistin, which is non-renal. In fact, patients with normal renal 
function are often so efficient at eliminating CMS that a dose 4 to 5 times that which is 
 29 
 
needed to attain required plasma concentrations of colistin must be administered.133 
Colistin can also be found concentrated in the urine, but this is primarily due to post-renal 
conversion of the parent compound because colistin is primarily eliminated through a 
non-renal mechanism. As a result, large interpatient and intrapatient variability exists for 
CMS dosing.134 In stark contrast, polymyxin B, which is administered as an active agent, 
is eliminated mainly by non-renal mechanisms and very little polymyxin B can be found 
in the urine.135,136 Figure 2.12 summarizes the different elimination pathways for colistin 
vs. polymyxin B.133 
 
 
Figure 2.12: Elimination Pathways for Colistin and Polymyxin B. Reprinted133 
Thickness of the arrows indicates relative magnitude of clearance mechanism 
 The clinical implication of these pharmacokinetic differences are that, even with a 
loading does of CMS, it takes several hours to achieve effective plasma levels of colistin 
and delay in appropriate antimicrobial therapy has been associated with increased 
mortality in critically ill patients.137,138 Furthermore, low colistin plasma levels have been 
 30 
 
associated with growth of colistin-resistant subpopulations139-142 and as renal function 
improves (or declines), the rate and extent of conversion of parent drug to colistin 
changes, and dosing strategies accounting for this change have not yet been perfected, 
rending it impossible to reliably achieve effective steady-state plasma concentrations in 
patients with creatinine clearance above 80 mL/min.134,143 For example, at the maximal 
approved dose of CMS (300 mg colistin base activity / day), patients with creatinine 
clearance > 80 mL/min achieved plasma concentrations < 2 mg/L.134 Nephrotoxicity, 
another independent predictor of mortality, is the dose limiting adverse effect of 
colistin.144 Polymyxin B, however, can rapidly achieve desired plasma levels that can be 
effectively maintained136 and nephrotoxicity with polymyxin B has been reported to be 
lower than with CMS,145,146 being closer to about 14%,147 compared to colistin which has 
been reported closer to 45% using RIFLE criteria.144  
Polymyxin-resistant CRE infections are another concern altogether. Rapid 
resistance development has been observed when colistin or polymyxin B are used 
alone.139-141 Colistin-resistant (MIC >2 µg/mL) CRE have occurred in various parts of the 
globe including Italy,148 Greece,149 Spain,72 and the United States.150,151 In fact, a tertiary 
center in Spain reports an increase from 13.5% to 31.7% in colistin resistance among 
Klebsiella pneumoniae isolates.72 A retrospective multi-center observational study in 
Italy showed a threefold increase in colistin-resistant KPC-producing Klebsiella 
pneumoniae from 2010 to 2013 (20% resistance overall), and colistin-resistance was 
determined to be an independent risk factor for 14-day mortality (47% vs. 31%; P = 
0.001).152 
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 Mechanisms that lead to resistance to polymyxins in Enterobacteriaceae are not 
fully understood. One proposal is that modifications in components that make up the LPS 
layer of gram-negative organisms, like lipid A, may play a role in polymyxin-resistance. 
Specifically, phoP/phoQ and pmrA/pmrB can be activated by environmental stimuli (e.g. 
low magnesium concentrations or polymyxin exposure), or can harbor mutations which 
typically lead to constitutive expression. One result is that phosphate head-groups in lipid 
A are substituted with 4-amino-4-deoxy-L-arabinose (L-Ara4N) which inhibits 
polymyxin binding. Figure 2.13 shows possible mutations (red star symbols) and how the 
phoP/phoQ and pmrA/pmrB system modifies the LPS layer, which ultimately leads to 
lower binding affinity (resistance) to polymyxin class antibiotics. 
 
 
Figure 2.13: Proposed Polymyxin Resistance Pathway in Gram-negative Organisms. 
Reprinted153 
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Additional mechanisms of resistance include modification of outer membrane 
proteins (e.g. OprH) which can block polymyxin merger with the cell membrane as well 
as efflux pumps.153 Regarding K. pneumoniae specifically, alterations in the mgrB gene 
(removal a negative feedback loop on the phoP/phoQ system) has been associated with 
an epidemic dissemination of colistin-resistant CRE in Italian hospitals154,155 but has also 
been identified in other parts of Europe, Asia, Africa and the United States.154 As a final 
addition, lipid A modifications in K. pneumoniae have been associated with cross-
resistance to host defense systems as well,156 which may contribute to the observed 
increase in mortality associated with colistin-resistant CRE. 
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Tigecycline 
 Tigecycline is a glycylcycline (Figure 2.14), a class related to the tetracyclines, 
that also inhibits protein synthesis by binding to the 30S ribosomal subunit.157-159 The 
charged aminoacyl-tRNA can no longer bind to the ribosome in the presence of 
tigecycline due to the distorted ribosomal acceptor site, which halts the reproduction 
process of the bacteria. As a result, tigecycline is bacteriostatic and has a broad spectrum 
of activity including both gram-positive organisms and gram-negative organisms, even 
anaerobic and atypical organisms, but it does not clinically impact Pseudomonas spp. or 
Proteus spp.160,161 
 
 
Figure 2.14: Structure of Tigecycline. Reprinted162 
 
 Clinical experience with tigecycline has set its role in complicated skin and skin 
structure infections (cSSSIs) and complicated intra-abdominal infections (cIAIs).163 
Tigecycline has been associated with increased mortality when compared to other 
antimicrobial agents and so is typically reserved after failure of other antimicrobials or in 
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situations where antimicrobial choices are limited such as in CRE or other multidrug 
resistant (MDR) organisms.164,165 An AUC/MIC ratio > 12.5 correlates with clinical 
outcome in cSSSI, which suggests clinical breakpoints of 0.25-0.5,166 but CLSI currently 
has not established a breakpoint for Enterobacteriaceae. The susceptibility breakpoint 
established by the FDA is ≤2 µg/mL.167 Of note, peak serum concentrations of 0.60 
µg/mL after a 100 mg infusion render tigecycline unable to effectively treat bloodstream 
infections.14 
 Resistance to tigecycline (MIC >2 µg/mL) is not common, but when it has been 
characterized, it is usually associated with mutations in the ramA gene which leads to 
upregulation of AcrAB-TolC, a multidrug efflux pump in Enterobacteriaceae.168 
Additionally, overproduction of marA, rarA, acrAB, and oqxAB genes can lead to 
tigecycline resistant phenotypes.169 Tigecycline resistance has been recently reported in 
China,170 Europe,171-173 and the United States.172,174 
 
Fosfomycin 
 Fosfomycin is bacterial cell-wall inhibitor, discovered in Spain in 1969,175,176 and 
it is relatively unique in structure by containing an epoxide (Figure 2.15). Peptidoglycan 
synthesis is inhibited by fosfomycin which blocks the formation of N-acetylmuramic acid 
by competitively inhibiting phosphoenol pyruvate synthetase (Figure 2.16).14 
 35 
 
 
Figure 2.15: Structure of Fosfomycin. Reprinted177 
 
 
Figure 2.16: Fosfomycin Mechanism of Action. Reprinted178 
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Like other cell-wall inhibitors (e.g. β-lactam antibiotics), fosfomycin is 
bactericidal and has a broad spectrum of activity that includes both gram-positive and 
gram-negative bacteria. In Europe, fosfomycin is primarily used in combination with 
other antimicrobials for CRE treatment, particularly strains with reduced susceptibility to 
colistin and tigecycline.179,180 In the U.S., fosfomycin is only approved orally for 
uncomplicated urinary tract infections due to its excellent genitourinary penetration. The 
optimal dosing strategy for treatment is still unclear. The FDA label indicates a single 3 
gm daily dose whereas other clinical trials have evaluated 3 gm every 2 or 3 days for 
urinary tract infections.181 
In CRE infections, a multicenter (11 ICUs), prospective case-series study from 
Greece showed favorable outcomes when fosfomycin was used in combination with 
another antimicrobial (usually colistin or tigecycline) in a majority of patients with 
fosfomycin-susceptible carbapenem-resistant infections, a majority of which (41 out of 
68) were Klebsiella pneumoniae. Bacterial eradication was observed in 56.3% of cases 
overall and in 60% of cases caused by colistin-resistant CRE. Fosfomycin resistance 
developed during the course of treatment in three cases.182 
Fosfomycin resistance has been characterized, and usually results from either 
mutations in the transport systems (GlpT and UhpT) that are located on the chromosome 
of bacteria or through inactivating enzymes (fosA family) located on bacterial plasmids. 
The chromosomal mutations prevent the uptake of fosfomycin into the cell and, although 
these mutations are relatively quickly acquired, a high fitness cost is observed in E. coli 
which limits fosfomycin resistance when not under direct antimicrobial pressure.183 The 
same fitness cost has not been observed in Klebsiella spp. and Enterobacter spp., and 
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therefore fosfomycin monotherapy may select for resistant isolates among these 
Enterobacteriaceae.184 Regarding plasmid-mediated resistance, a plasmid carrying both 
blaKPC-2 and fosA3 is circulating among carbapenem-resistant Klebsiella pneumoniae in 
China and accounts for 60% of the observed fosfomycin resistance in that country.185 
 
Aminoglycosides 
 The aminoglycoside class was introduced in the 1940s with streptomycin.14 
Today, three aminoglycosides are primarily used (four in the Europe)– tobramycin, 
gentamicin, amikacin and kanamycin (in Europe). Although generally similar in structure 
(Figure 2.17) and function, those structural differences that do exist among this class 
often confer differences in stability against a variety of aminoglycoside modifying 
enzymes that would inactive these antimicrobials. 
 
 
Figure 2.17: Structure of Amikacin. Reprinted186 
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 Like tigecycline, aminoglycosides function by binding to the 30S ribosomal 
subunit, but these antimicrobials can additionally facilitate the insertion of incorrect 
amino acid sequences into proteins rather than only preventing their translation (Figure 
2.18). As a result, aminoglycosides exhibit bactericidal activity against gram-positive and 
gram-negative organisms, including Pseudomonas spp., but have little affect against 
anaerobes. 
 
 
Figure 2.18: Mechanism of Action of Aminoglycosides. Reprinted187 
 
 Aminoglycosides are sometimes a viable option against aminoglycoside-
susceptible CRE. In fact, a superior rate of microbiologic clearance was observed in a 
retrospective cohort study of CRE bacteriuria when an aminoglycoside was used (88%) 
compared to either polymyxin B (64%) or tigecycline (43%).188 Additionally, 
aminoglycosides are associated with less nephrotoxicity (~10-20%)189 than colistin 
(~45%),144,190,191 but perhaps similar to polymyxin B (~14%),147 while maintaining 
bactericidality and the ability to treat bloodstream infections over tigecycline.14 
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 Resistance to aminoglycosides is primarily mediated by aminoglycoside-
modifying enzymes (analogous to β-lactamase production) but is highly variable, 
showing regional dependence as well as differences among hospitals within the same 
geographic region. Resistance rates can even vary by strain, but in general, rates of non-
susceptibility have been reported as ranging from 35% to 63% for gentamicin, 61% to 
98% for tobramycin, and 16% to 82% for amikacin.192-194 Other resistance mechanisms 
have been identified as well, including modification of the ribosome target,195 reduced 
permeability of the bacterial cell wall, and also efflux pumps.196,197 
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ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT 
ENTEROBACTERIACEAE 
 A majority of cases, cases series, and the published experience of medical centers 
indicate that combination therapy might provide a mortality benefit when compared to 
monotherapy,10,68,184,198-202 considering the antimicrobial agents available today. 
Additionally, polymyxin B, colistin, tigecycline, and fosfomycin have all demonstrated 
rapid selection for resistance when used as monotherapy against CRE.120,184 There are no 
randomized-controlled clinical trials comparing single agents or their combinations, but 
rather retrospective or prospective (non-randomized) analyses which results in a 
significant limitation on analyzing such data. Some conclude that a systematic review and 
meta-analysis is not possible regarding CRE treatment due to the heterogeneity of 
available evidence.203 
 
In Vitro Studies 
Polymyxin combinations 
 The interaction between antimicrobial agents has primarily been characterized by 
time-kill methodology, where polymyxins are most frequently investigated in 
combination with either a carbapenem, tigecycline, fosfomycin, rifampin, an 
aminoglycoside, or sometimes with three or four agents from multiple drug classes.120 
The goal of in vitro testing in this setting is to quickly evaluate combinations of 
antimicrobials that might show synergistic interactions when used to treat CRE. Most in 
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vitro testing has been performed on KPC-producing CRE whereas MBL- and OXA-48- 
producing CRE have more limited data.14 
 In KPC-producing Enterobacteriaceae, time-kill studies have shown polymyxin B 
exhibiting synergistic activity (≥102 CFU/mL more killing than the more active agent 
alone at 24 hours) when in combination with rifampin and when in combination with 
imipenem.204 Polymyxin B in combination with both doripenem and rifampin were 
determined to interact synergistically and exhibit bactericidal activity (≥103 CFU/mL 
killing at 24 hours).205 Colistin and tigecycline have also been evaluated in combination 
together and determined to be synergistic.206 In a broth microdilution checkerboard assay 
of 12 KPC-producing Klebsiella pneumoniae isolates, polymyxin B was synergistic in 
combination with either tigecycline, doxycycline or rifampin, but no synergy was 
detected for combinations with imipenem or gentamicin.207 
In 42 VIM-producing K. pneumoniae isolates from Greece, colistin was found to 
be synergistic with imipenem in about 50% of colistin-susceptible isolates, regardless of 
imipenem MIC, and indifferent (CFU/mL killing is the same as the more active agent 
alone at 24 hours) in the rest. For the colistin-non-susceptible isolates, the combination 
was antagonistic (CFU/mL killing was less than the more active agent alone at 24 hours) 
for 56% of the isolates and synergistic for only 11%.208 
In nine colistin-resistant KPC-producing Klebsiella pneumoniae and three 
colistin-susceptible KPC-producing Klebsiella pneumoniae, colistin in combination with 
two carbapenems (doripenem and ertapenem) showed synergy in 8 of 12 isolates. 
Colistin in combination with one carbapenem (doripenem) showed synergy in 6 of 12 
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isolates and colistin in combination with the other carbapenem (ertapenem) showed 
synergy in 5 of 12 isolates. Interestingly, the authors noticed an association between 
synergy of the triple combination of colistin-doripenem-ertapenem and porin expression 
levels. Specifically, the eight isolates showing synergy had the highest porin expression, 
and receiver operator characteristic (ROC) analysis designated this group of eight as 
significantly different from the remaining four in terms of porin expression (P = 0.002). 
The authors speculated that permeability for both carbapenems was limited by porin 
channel expression and that higher expression provided easier access to the sites of action 
of both carbapenems.209 
A systematic review and meta-analysis of in vitro interactions between 
polymyxins and any carbapenem against polymyxin-susceptible CRE found an overall 
synergy rate of 55%. This analysis also indicated that Etest® and checkerboard synergy 
testing typically reported lower than did time-kill methodology, and that the use of 
combination therapy led to less resistance development in vitro when post-exposure 
resistance testing was performed.210  
Colistin (COL), meropenem (MEM), and tigecycline (TIG) interactions were 
evaluated using a 3-D checkerboard assay in 20 carbapenem-resistant K. pneumoniae 
clinical isolates. Among these, 13 were resistant to colistin and 6 were resistant to 
tigecycline. Synergy rates were 10% for MEM and TIG; 30% for COL and MEM; 30% 
for COL and TIG; and 30% COL, MEM, and TIG. It was noted by the authors that 
synergy was correlated with higher TIG MICs (>2 µg/mL) and higher COL MICs (>8 
µg/mL), there was no antagonism, and addition of a third antimicrobial agent did not 
contribute to synergy.211 COL, MEM, and TIG were also evaluated in a time-kill study of 
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eight CRE clinical isolates (4 K. pneumoniae, 2 E. coli, 1 E. cloacae, 1 S. marcescens). 
MEM and TIG were not synergistic in any of the eight strains. TIG and COL showed 
synergy at concentrations above the MICs for most strains.206 
 
Other combinations 
 Time-kill assays involving double and triple antimicrobial combinations of 
aztreonam, ciprofloxacin, colistin, daptomycin, fosfomycin, meropenem, rifampin, 
telavancin, tigecycline, and vancomycin against MBL-producing (2 VIM and 2 NDM) 
polymyxin-susceptible K. pneumoniae isolates were used to evaluate potential 
combination therapy against MBL-producing CRE. Sample times were 0, 1, and 24 
hours. Synergy was found in double combinations of colistin with either aztreonam, 
fosfomycin, meropenem, or rifampin and in triple combinations with colistin and 
meropenem with either aztreonam, fosfomycin, or rifampin. The most effective 
combination was meropenem, colistin, and rifampin demonstrating bactericidal and 
synergistic activity throughout 24 hours for all four strains. Ciprofloxacin, tigecycline, 
daptomycin, telavancin, and vancomycin alone and in combination with colistin was 
without synergy or bactericidal activity at 24 hours.212 
In KPC-producing Klebsiella pneumoniae, fosfomycin in combination with either 
meropenem or colistin was synergistic in 64.7% and 11.8% of isolates, respectively. 
Fosfomycin in combination with gentamicin was indifferent.213 Synergy was evaluated in 
another study with fosfomycin in combination with imipenem (74%), meropenem (70%), 
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doripenem (74%), colistin (36%), netilmicin (42%), and tigecycline (30%) for 50 KPC-
producing Klebsiella pneumoniae.214 
 Amikacin (AMK) 16 µg/mL was evaluated alone and in combination with 
ertapenem (ETP) 2 µg/mL, imipenem (IPM) 4 µg/mL, and meropenem (MEM) 4 µg/mL 
against four K. pneumoniae clinical isolates resistant to all four antimicrobials (MICs >8 
µg/mL for ETP, IPM, and MEM; MIC 32 µg/mL for AMK). Alone, none of the 
antimicrobials achieved bactericidal activity. Synergy was found in combinations of 
AMK with either MEM or IPM throughout 24 hours in all isolates. Bactericidal activity 
was found in 2 of 4 isolates for MEM and AMK and 1 of 4 isolates for IPM and AMK. 
ETP with AMK was not synergistic or bactericidal in any isolate.215 
  
In Vitro Pharmacodynamic Models 
 Human pharmacokinetics of meropenem were simulated to optimize meropenem 
dosing against carbapenemase-producing Klebsiella pneumoniae using a one-
compartment, chemostat model. An advantage to the 0.5 hour infusion of 1 gm every 8 
hours was found in a high dose/prolonged infusion regimen (3 hour infusion of 2 gm 
every 8 hours). Using this regimen, bactericidal activity (≥103 CFU/mL killing) was 
obtained by 6 hours against all KPC-producing Klebsiella pneumoniae isolates. However, 
regrowth was observed for 9 of 11 isolates with meropenem MICs ≥ 8 µg/mL, but not for 
two isolates whose meropenem MICs were 2 and 8 µg/mL. Measured meropenem levels 
were lower than expected using the model, but this was attributed to the production of 
carbapenemase enzymes by the K. pneumoniae isolate.216 
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Human pharmacokinetics of tigecycline (as 50 mg every 12 hours) in combination 
with either meropenem (as 2 gm infused over 3 hours every 8 hours)216 or rifampin (as 
600 mg every 12 hours) in lung-epithelial fluid were modeled using a one-compartment, 
chemostat model. Tigecycline alone and in combination with rifampin against 
carbapenemase-producing Klebsiella pneumoniae isolates showed little activity when 
used against isolates with meropenem MICs ≤ 2 µg/mL. However, when tigecycline was 
used in combination with meropenem, a synergistic, bactericidal effect was observed for 
isolates with tigecycline MICs up to and including 2 µg/mL and meropenem MICs up to 
and including 16 µg/mL. However, none of the regimens maintained bactericidal activity 
for the full 48-hour study period.217 
 Using time-kill methodology and a 3-dimensional response model, six 2-agent 
combinations of amikacin (AMI), doripenem (DOR), levofloxacin (LEV) and rifampin 
(RIF) were evaluated against a KPC-2-producing K. pneumoniae (MICs AMI: 64 µg/mL, 
DOR: 16 µg/mL, RIF: >64 µg/mL, LEV: 128 µg/mL) and a KPC-3-producing K. 
pneumoniae (MICs AMI: 32 µg/mL, DOR: 32 µg/mL, RIF: >256 µg/mL, LEV: 8 
µg/mL). Clinically relevant concentrations (AMI: 4-80 µg/mL; DOR 4-32 µg/mL; LEV 
0.5-10 µg/mL; RIF 0.25-6 µg/mL) were used in combinations to determine synergy based 
on the 3-D response model and 24-hour colony count. DOR and AMI was the only 
combination determined to be synergistic; DOR and RIF, DOR and LEV, and LEV and 
RIF were additive; AMI and RIF, and AMI and LEV were antagonistic. Murine 
pneumonia models were used to confirm results obtained through the time-kill 
experiments and the model for DOR and AMI, and AMI and LEV. As predicted by the 
model, DOR and AMI showed improved survival for both isolates whereas AMI and 
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LEV displayed inferior survival rates. Although limited in design, this study is one of few 
models that analyzed polymyxin-sparing regimens.218 
 
Dual-Carbapenem therapy 
Doripenem and ertapenem alone and in combination were evaluated against a 
carbapenemase-producing K. pneumoniae clinical isolate (doripenem MIC 4 µg/mL; 
ertapenem MIC 64 µg/mL) using a one-compartment chemostat model. The free 
doripenem concentrations simulated a 3-hour infusion of 2 gm every 8 hours in humans, 
and the free ertapenem concentrations simulated a dose of 1 gm every 24 hours in 
humans. Adding doripenem to ertapenem extended the bactericidal activity from 6h with 
monotherapy of either agent to 16h in the combination. Doripenem levels were above the 
MIC of the organism for a majority of the dosing interval.219  
 
Animal Studies 
KPC-producing Enterobacteriaceae 
 In both an immunocompetent and a neutropenic murine thigh model, doripenem 
was administered to simulate human administration of a 4-hour infusion of 1 gm and 2 
gm doripenem every 8 hours. These regimens were evaluated against KPC-producing 
Klebsiella pneumoniae with doripenem MICs ranging from 4 to 32 µg/mL. 1- and 2- gm 
doses of doripenem achieved bacteristasis in both models against K. pneumoniae isolates 
with doripenem MICs up to and including 8 and 16 µg/mL, respectively. Expectedly, 
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there was significantly more killing (0.5-1 CFU/mL) in the immunocompetent murine 
model compared to the neutropenic murine model at 24 hours.220 
Doripenem and ertapenem alone and in combination were evaluated against three 
KPC-producing K. pneumoniae clinical isolates (doripenem MICs 8, 16, and 32 µg/mL; 
ertapenem MICs >64 µg/mL) using a murine thigh model of both immunocompetent and 
neutropenic mice. The free doripenem concentrations simulated a 4-hour infusion of 2 
gm every 8 hours in humans, and the free ertapenem concentrations simulated a dose of 1 
gm every 24 hours in humans. Although a higher degree of bacterial killing was observed 
in the combination regimens when compared to monotherapy, only the combination 
against the lowest doripenem MIC isolate (MIC 8 µg/mL) in the immunocompetent mice 
was statistically significant, and only at 72 hours (not 24 or 48).221 
Meropenem, tigecycline, and polymyxin B were evaluated in a rat model alone 
and in double and triple regimen combinations (n=10 for each regimen) against KPC-2-
producing Klebsiella pneumoniae. Additionally, time-kill assays were performed on each 
agent alone and in combination. No pharmacokinetic studies were performed to verify 
equivalent human dosing, but all combinations involving polymyxin B showed 
significantly superior results in terms of mortality (Figure 2.19) and culture clearance. 
Interestingly, meropenem and tigecycline combinations were antagonistic by time-kill 
analysis, but this interaction was seemingly overcome by the addition of polymyxin B. 
This was observed in the rat model as well, but there was not an observable advantage in 
triple-combination therapy compared to polymyxin B in combination with either 
meropenem or tigecycline.222 
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Figure 2.19: Survival curves of a rats infected with KPC-2-producing Klebsiella 
pneumoniae. Reprinted222  
* P-value of <0.05 compared with other groups 
** P-value of <0.05 compared with control 
  
MBL-producing Enterobacteriaceae 
 Two animal models (one murine, one rabbit) have evaluated carbapenem 
monotherapy in VIM-1-producing K. pneumoniae or E. coli. In both studies, isolate MICs 
to carbapenems were relatively low (imipenem MICs ≤4 µg/mL for all but one isolate). 
Dosing regimens were selected to simulate dosing in humans and optimize T>MIC, the 
pharmacodynamic index correlating with clinical outcome.223 In both studies, 
carbapenems were effective in significantly reduced colony counts (CFU/mL) compared 
to placebo, but were either not as effective as observed in the non-VIM producing 
isolate,224 or were surpassed by aztreonam activity, which is relatively stable in the 
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presence of MBL enzymes.225 These data suggest that while carbapenems are still active 
as monotherapy against MBL-producing CRE, there may be other factors than time 
above the MIC that play a role in optimizing treatment. 
 Doripenem and ertapenem as monotherapy were evaluated in a murine thigh 
model against a wild-type K. pneumoniae, and an isogenically derived NDM-1- and a 
KPC-2- producing K. pneumoniae. Four clinical isolates of NDM-1-producing K. 
pneumoniae were also included for comparison. Dosing regimens of doripenem and 
ertapenem simulated a 4-hour infusion of 2 gm every 8 hours and 1 gm every 24 hours, 
respectively. Interestingly, at least 101 CFU/mL killing was observed at 24 hours for the 
wild-type K. pneumoniae, the isogenic NDM-1- and the NDM-1-producing clinical 
isolates with doripenem MICs ≤ 8 µg/mL. However, the isogenic KPC-producing K. 
pneumoniae showed growth (Figure 2.20), despite a 4-fold lower MIC to ertapenem and 
doripenem.226 The results of the KPC-producing isolate were consistent however with 
previous work performed in this lab.221 
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Figure 2.20: Change in log10 CFU/mL after 24 hours. Reprinted226 
Wild-type K. pneumoniae strain and its derived isogenic strains harboring either an 
NDM-1 or a KPC-2 plasmid after treatment with either doripenem at 2 gm every 8 hours 
(black) or ertapenem at 1 gm every 24 hours (white) in an immunocompetent mouse 
thigh infection model. Each value is the mean ± standard deviation for infected thighs for 
each isolate. 
 
OXA-48-producing Enterobacteriaceae 
Doripenem, ertapenem, ceftazidime, and levofloxacin were evaluated in a murine 
thigh model against an isogenic pair of wild-type K. pneumoniae and OXA-48-producing 
K. pneumoniae as well as six OXA-48-producing Enterobacteriaceae clinical isolates, 
with and without other ESBLs (doripenem MICs 0.38 - 8 µg/mL). Levofloxacin, 
ertapenem and ceftazidime exhibited efficacy correlating with pharmacodynamic targets 
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and in vitro MIC. However, similar to experiments involving isolates producing NDM-
1,226 the observed efficacy of doripenem treatment was surprising. However, whereas 
doripenem seemed efficacious against low-MIC NDM-1-producing isolates,226 there was 
variable efficacy observed by doripenem across all OXA-48-producing isolates, despite 
achieving the pharmacodynamic target of at least 40% T>MIC.223 It was concluded by 
the authors that genotypic expression may be more important than phenotypic MIC and 
pharmacodynamic targets in selecting appropriate therapy.227 
 
Other Studies 
In a rather unique study, gene transcription levels of carbapenemase enzymes 
were analyzed in clinical isolates harboring either CTX-M-15 (ESBL; 1 K. pneumoniae 
and 1 E. coli), OXA-48 (E. coli), NDM-1 (K. pneumoniae) or KPC-2 (Salmonella spp.) 
after infecting mice or inoculating test tubes. The aim of the study was to determine 
carbapenemase enzyme induction, inhibition, or lack of effect by single antimicrobials or 
combinations. For the mice studies, rifampin alone, colistin alone and colistin in 
combination with ertapenem, meropenem, imipenem, fosfomycin, kanamycin, 
tigecycline, ceftazidime, or rifampin were evaluated. For in vitro studies, colistin, 
meropenem, rifampin and tigecycline alone were evaluated as well as colistin in 
combination with meropenem, fosfomycin, rifampin, or tigecycline.228 
The authors listed likely beneficial combinations based on carbapenemase 
transcription levels observed in vitro and in vivo and mortality observed in vivo according 
to enzyme type. For OXA-48, colistin in combination with a carbapenem, rifampin, 
 52 
 
fosfomycin, or tigecycline seemed most beneficial, but monotherapy with any agent was 
not recommended. For NDM-1, colistin in combination with rifampin, fosfomycin, or 
tigecycline were most effective, but again, monotherapy was not recommended with any 
agent. Finally, for KPC, colistin in combination with a carbapenem, fosfomycin or 
kanamycin were most beneficial.228 
 
Human Studies 
 Reiterating, comparisons between monotherapy and combination therapy for CRE 
treatment in humans is limited, but most conclude that combination therapy is preferred. 
Perez et al. selectively compared  retrospective reports of CRE bloodstream infections in 
hundreds of patients receiving either combination or monotherapy. Their analysis 
concluded a mortality risk reduction of approximately 50% when combination 
antimicrobials were used compared to monotherapy. These studies were primarily in 
KPC-producing K. pneumoniae and combinations were usually carbapenem-containing in 
addition to a polymyxin or tigecycline.14 
Despite known resistance to carbapenems, when CRE are treated with 
combinations containing a carbapenem, there appears to be added benefit on top of the 
benefit for combination therapy, particularly in strains with lower carbapenem MIC's 
(MIC ≤ 8 µg/mL). Zouvelekis et al. evaluated studies using monotherapy with 
carbapenems (meropenem or imipenem) and determined that the failure rate of 50 CRE 
patients across 15 studies was found to be proportional to the MIC for the respective 
carbapenem used. Note, clinical failure definitions varied from physician to physician 
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and study to study. Some definitions were patient death, superinfection or reinfection 
with same organism, prolonged hospital stay, and resistance development while on 
antimicrobial therapy, but overall clinical failure was estimated to be 75% for CRE 
infections with carbapenem MICs above 8 µg/mL. This failure rate decreased to 33.3%, 
28.6%, and 25% when carbapenem MICs were 8, 4, and 2 µg/mL or less, respectively.120 
This observation fits in the context of the PK/PD studies in humans and the 
pharmacodynamic index for carbapenems – 40% to 50% time above the MIC (T>MIC) in 
that higher carbapenem MICs render target attainment of 50% T>MIC more difficult. It is 
estimated that for a meropenem MIC of 4 µg/mL, the probability of attaining 50% 
T>MIC is 69% for a dosing regimen of a 30 minute infusion of 1 gm every 8 hours. 
When a high dose/prolonged infusion is used (e.g. 3-hour infusion of 2 gm every 8 
hours), the probability of target attainment increases to 100%. When the MIC is 8, the 
probability of attaining 50% T>MIC of a high dose/prolonged infusion of meropenem is 
85%.229 
Adding to the evidence of carbapenem-based combination regimens are two 
articles evaluating CRE treatment in Greece. For the first study, 103 K. pneumoniae 
isolates producing either VIM or KPC were treated with combination therapy (30% 
carbapenem-based) and 72 isolates were treated with monotherapy and mortality was 
significantly lower in the combination therapy group (27.2% vs. 44.4%, p=0.018). Lower 
mortality was observed for carbapenem-containing regimens when compared to regimens 
without carbapenems (19.3% vs. 30.6%).202 For the second study, 132 VIM-producing K. 
pneumoniae and 102 KPC-producing K. pneumoniae isolates were included across nine 
studies where it was determined combination therapy was superior to monotherapy (p = 
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0.01; odds ratio 2.41; 95% confidence interval 1.2-4.7) and those regimens that included 
carbapenems were associated with a 6.7% failure rate compared to a 26.9% failure rate of 
those regimens without a carbapenem (P-value 0.04).184 
In Italy, 14 day mortality was assessed in 661 patients with KPC-producing K. 
pneumoniae. Independent predictors of 14 day mortality were determined to be 
bloodstream infection, presentation with septic shock, inadequate empirical antimicrobial 
therapy, chronic renal failure, high APACHE III score, and colistin resistance. 
Combination therapy with at least two drugs showing in vitro activity against the isolate 
was associated with lower mortality (odds ratio 0.52; (95% confidence interval 0.35-
0.77). Combinations that included meropenem were associated with significantly higher 
survival rates when the meropenem MIC was ≤ 8 µg/mL.152 
A review article of published case reports and case series from 2001-2011 
included 105 total cases of KPC-producing infections (101 of which were 
Enterobacteriaceae). Cases receiving monotherapy were 49 (47%) whereas cases 
receiving combination therapy were 56 (53%), 19 (34%) of which included a 
carbapenem. Treatment failure was associated more with monotherapy than combination 
therapy (49% vs. 25%; p = 0.01). Other significant differences were between 
monotherapy vs. combination therapy involving pulmonary infections, polymyxins, or 
carbapenems, (Table 2.1).200 
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Table 2.1 Treatment Failure: Monotherapy vs. Combination Therapy 
 Monotherapy (%) Combination (%) P 
Overall Treatment Failure 24/49 (49) 14/56 (25) 0.01 
Source:    
Blood 12/24 (50) 9/32 (28) 0.09 
Pulmonary 10/15 (67) 5/17 (29) 0.03 
Urine 1/8 (13) 0/3 (0) 0.4 
Polymyxin Treatment Failure 8/11 (73) 10/34 (29) 0.02 
Carbapenem Treatment Failure 12/20 (60) 5/19 (26) 0.03 
Tigecycline Treatment Failure 2/7 (29) 7/19 (37) 0.4 
Aminoglycoside Treatment Failure 0/6 (0) 4/24 (17) 0.6 
Reprinted200 
 
Another review article systematically obtained CRE case reports, case series, and 
observational studies from the across the globe (e.g. U.S., Spain, Ireland, Columbia, 
China, Israel, Brazil, Taiwan, Switzerland, and Greece). A total of 301 patients infected 
with Klebsiella pneumoniae were identified, about half KPC-producing and half MBL-
producing. Patients were stratified into seven groups based on treatment regimens (Figure 
2.21). Once more, combination therapy with a carbapenem was significantly superior to 
alternative combinations analyzed.120 
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Figure 2.21: Outcomes of infections caused by carbapenemase-producing Klebsiella 
pneumoniae, according to treatment regimen. Reprinted120  
Regimen A, combination therapy with ≥2 active drugs, one of which was a carbapenem; 
regimen B, combination therapy with ≥2 active drugs, not including a carbapenem; 
regimen C, monotherapy with an aminoglycoside; regimen D, monotherapy with a 
carbapenem; regimen E, monotherapy with tigecycline; regimen F, monotherapy with 
colistin; regimen G, inappropriate therapy. Regimen A was superior to regimens B, E, F, 
and G (for A versus B, E, F, and G, the P value was 0.02, 0.03, <0.0001, and <0.0001, 
respectively). Regimens B, C, and D were superior to regimen G (for B versus G, P = 
0.014; for C versus G, P = 0.04; and for D versus G, P = 0.03).  
 
 Only two observational human studies have evaluated fosfomycin against CRE, 
both were prospective. The first was a multicenter case-series of 41 carbapenemase-
producing K. pneumoniae and 17 carbapenemase-producing P. aeruginosa. Fosfomycin 
(median dose 24g/day) was usually combined with either colistin or tigecycline with a 
clinical success rate at day 14 of 54%. 28 day mortality was 37.5%. Interestingly, 
resistance to fosfomycin developed in only three cases.182 The second study followed 11 
ICU patients infected with fosfomycin susceptible, carbapenem-resistant K. pneumoniae 
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where fosfomycin was administered in combination with colistin (6 patients), gentamicin 
(3 patients), or piperacillin/tazobactam (1 patient). The combination used for the 11th 
patient was not mentioned by the authors. All-cause in-hospital mortality was 18.2% 
(2/11 ICU patients).230 
 
Novel Antimicrobials against Carbapenem-resistant Enterobacteriaceae 
 Ceftazidime/avibactam (AVYCAZ®) is the first of few upcoming antimicrobials 
with activity against CRE. The FDA approved its use in complicated urinary tract 
infections (cUTIs) and complicated intra-abdominal infections (cIAIs) in February 2015. 
Its spectrum of activity is similar to ceftazidime (i.e. wild-type Enterobacteriaceae and 
Pseudomonas spp.) but avibactam (a diazabicyclooctanase)231 adds Ambler class A232 
and D233 carbapenemase-producing Enterobacteriaceae in addition to ESBL-producing 
Enterobacteriaceae with porin channel mutations to the spectrum.232 However, limited 
activity against MBLs has been observed. Ceftazidime/avibactam has also been tested in 
vitro against KPC-producing isolates with OmpK36 porin channel mutations. All 72 
KPC-producing isolates studied were resistant to ceftazidime (MICs >64 µg/mL) but 
tested susceptible (ceftazidime MICs <4 µg/mL) with the addition of avibactam.234 
Experience treating bacteremia caused by CRE is limited at this time, but cases of 
success have been reported.232 
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SUMMARY 
 
1. CRE are among the top threats in infectious disease according to the CDC and the 
President's Advisory Council on Combating Antibiotic-Resistant Bacteria.11 
 
2. CRE are present throughout the world, but the characteristics of carbapenem 
resistance can vary widely depending on the country, state, or even acute care center. 
Within the U.S., KPC-producing Enterobacteriaceae comprise 80% of CRE cases.14 
 
3. Significant mortality is associated with CRE infection, ranging from 24-70%.1-10 
 
4. CRE are challenging to treat, often only being susceptible to polymyxins, fosfomycin, 
or tigecycline, for which there are no randomized controlled trials directing 
antimicrobial therapy.  
 
5. A review of the literature favors combination therapy, usually with a carbapenem 
and/or a polymyxin, but genotypic expression may yet play a larger role on optimal 
therapy than phenotypic expression and pharmacodynamic targets. 
 
6. There are fewer and fewer antimicrobials in development, and there is not a "magic 
bullet" that will treat all CRE. 
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HYPOTHESES 
 The study hypotheses were: 1) meropenem and polymyxin B in combination 
would exhibit synergistic, bactericidal activity against carbapenem-resistant Klebsiella 
pneumoniae having low and high levels of carbapenem resistance, described by the 
minimum inhibitory concentration of meropenem and 2) meropenem and polymyxin B 
used alone against carbapenem-resistant Klebsiella pneumoniae would not prevent 
bacterial growth by 24 hours 
 
SPECIFIC AIMS 
 The specific aims of this study were: 
1. To evaluate the minimum inhibitory concentration of meropenem and polymyxin B using 
broth microdilution against carbapenem-resistant Klebsiella pneumoniae clinical isolates 
from the University of Kentucky Chandler Hospital 
2. To describe the growth of carbapenem-resistant Klebsiella pneumoniae when exposed to 
meropenem and polymyxin B alone and in combination using time-kill methodology 
3. To characterize the in vitro interaction of the combination of meropenem and polymyxin 
B against Klebsiella pneumoniae clinical isolates representing low and high levels of 
carbapenem resistance which is described by the minimum inhibitory concentration of 
meropenem 
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Chapter Three: 
 
Methods 
 
Bacterial Isolates 
 Clinical isolates of 229 non-duplicate, multidrug resistant (MDR), gram-negative 
organisms were collected between November 9, 2008 and December 31, 2016 from the 
Clinical Microbiology Laboratory at the University of Kentucky Chandler Medical 
Center in Lexington, Kentucky. All isolates were cultured and identified during routine 
testing in the clinical laboratory according to guidelines from the Clinical and Laboratory 
Standards Institute (CLSI).235 All isolates were frozen at -80˚C in 10% glycerol in water 
solution until needed for study ("Storage of Bacterial Isolates").236 Multidrug resistance 
was defined as non-susceptibility to at least one agent in three or more antibiotic 
classes.165 Isolates were designated carbapenem-resistant Enterobacteriaceae (CRE) if 
they were Enterobacteriaceae with documented carbapenemase production or non-
susceptibility to any of the carbapenem antimicrobials (ertapenem, imipenem, 
meropenem, or doripenem; Table 3.8).79  
 Each isolate was subcultured once in cation-adjusted Mueller-Hinton broth 8-12 
hours prior to experiments. Inoculation of conical tubes (15 mL polypropylene conical 
centrifuge tubes; USA Scientific, Ocala, FL) containing about 5 mL of cation-adjusted 
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Mueller-Hinton broth was accomplished using a sterile loop applicator (Fisherbrand™; 
ThermoFisher Scientific, Waltham, MA). These cultures were then incubated at 35˚C in a 
shake incubator (Figure 3.1; MaxQ 6000; ThermoFisher Scientific, Waltham, MA) at 220 
oscillations per minute until turbid. All isolate manipulations were performed in 
Biological-Pharmaceutical Complex (BPC) room 374B. Three ATCC® quality control 
(QC) organisms were used: E. coli ATCC® 25922, P. aeruginosa ATCC® 27853, and K. 
pneumoniae ATCC® 700603. The QC E. coli strain is recommended for antimicrobial 
susceptibility testing on Enterobacteriaceae for antimicrobials other than carbapenems 
and polymyxins for which QC P. aeruginosa is recommended. QC K. pneumoniae is a 
negative control for MBL testing by Etest®.237 
 
Figure 3.1: MaxQ 6000 (ThermoFisher Scientific, Waltham, MA) 
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Antimicrobial Agents 
 Antimicrobial powders were obtained from the manufacturers or supply 
companies listed in Table 3.1. After adjusting for potency, these powders were used in all 
studies. 
 
Table 3.1: Sources of Antimicrobial Powders 
Antimicrobial Manufacturer/Supply Company 
Amikacin Sigma-Aldrich® St. Louis, MO 
Cefepime USP Rockville, MD 
Colistin Sigma-Aldrich® St. Louis, MO 
Levofloxacin Sigma-Aldrich® St. Louis, MO 
Meropenem USP Rockville, MD 
Minocycline Sigma-Aldrich® St. Louis, MO 
Piperacillin Sigma-Aldrich® St. Louis, MO 
Polymyxin B Sigma-Aldrich® St. Louis, MO 
Rifampin Sigma-Aldrich® St. Louis, MO 
Tazobactam LKT Laboratories, Inc. St. Paul, MN 
Tigecycline TSZ Chem. Framingham, MA 
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IN VITRO SUSCEPTIBILITY TESTING 
Broth Microdilution MIC Testing 
In vitro susceptibility testing was performed in duplicate using broth 
microdilution according to CLSI guidelines as isolates were identified.235 Susceptibility 
testing was only performed on the first 24 Klebsiella pneumoniae received by the lab. 
MICs were determined for amikacin, cefepime, levofloxacin, meropenem, minocycline, 
polymyxin B, and tigecycline. Colistin, rifampin, and piperacillin/tazobactam were only 
evaluated for the first 12 Klebsiella pneumoniae isolates. Quality control organisms used 
in each experiment were E. coli ATCC® 25922 for antimicrobials other than carbapenems 
and polymyxins and P. aeruginosa ATCC® 27853 for carbapenems and polymyxins. 
 
 
 
        
 
 
 
 
 
 
          High Drug Concentration……….Low Drug Concentration  
Figure 3.2: Example Broth Microdilution 96-well Tray 
MIC 
 NO GROWTH GROWTH 
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Automated MIC Testing 
 BD Phoenix™ is an automated system designed to identify the organism and 
perform antimicrobial susceptibility testing. The University of Kentucky Clinical 
Microbiology Laboratory evaluated each isolate with BD Phoenix™ in order to obtain 
MICs for amikacin, ampicillin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, 
cefoxitin, ceftazidime, ceftriaxone, cefuroxime, ciprofloxacin, ertapenem, gentamicin, 
levofloxacin, meropenem, nitrofurantoin, piperacillin/tazobactam, tetracycline, 
tobramycin, and sulfamethoxazole/trimethoprim. This data was originally reported for 
clinical use in the management of patients infected with these isolates. 
 
 
Figure 3.3: BD Phoenix™. Reprinted238 
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Kirby-Bauer Disk Diffusion 
 Kirby-Bauer disk diffusion was used to evaluate susceptibility of CRE isolates to 
ceftazidime/avibactam. This method does not measure MICs, but instead indicates 
susceptible, intermediate, or resistant to the antibiotic of choice based on the diameter of 
the zone of inhibition ("Kirby-Bauer Disk Diffusion Procedure" and Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Kirby-Bauer Disk Diffusion 
Zone of Inhibition 
Bacterial Growth 
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Etest® 
Etest® strips (MBL MP/MPI 8/2; bioMérieux, Inc., Durham, NC) were primarily 
used to detect metallo β-lactamase (MBL) production in CRE isolates non-susceptible to 
ceftazidime/avibactam from Kirby-Bauer testing ("Kirby-Bauer Disk Diffusion 
Procedure"). However, Etest® strips can measure MICs (Figure 3.5) like broth 
microdilution and were used for determining fosfomycin MICs for the first 12 Klebsiella 
pneumoniae isolates identified by the University of Kentucky Clinical Microbiology 
Laboratory. Klebsiella pneumoniae ATCC® 700603 was used as a quality negative 
control for MBL Etest® strips and E. coli ATCC® 25922 was used as a quality control 
organism for fosfomycin MIC testing with Etest® strips. 
 
 
 
 
 
 
Source: bioMérieux, Inc., Durham, NC 
Figure 3.5: Example of Doripenem Etest® 
  
Zone of inhibition 
Bacterial growth 
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Glassware, Plastic Tubing, and Pipette Tip Preparation 
 All glassware and autoclavable plastic were provided pre-sterilized by the 
manufacturer and were either disposable or sterilized by autoclave at 121°C for at least 
20 minutes and verified by autoclave indicator tape (Fisherbrand™, ThermoFisher 
Scientific, Waltham, MA) prior to use in experiments. Equipment that could not be 
autoclaved (e.g. automated plate pourer or the laser colony counter) was sterilized by 
70% ethanol in a spray bottle. A dispenser (Oxford®; Cole-Parmer®, Vernon Hills, IL) 
was sterilized by two 70% ethanol washes followed by two 0.22 µm filtered, distilled 
water washes and verified by negative growth of water dispensed onto an agar plate. 
 
Media Preparation 
Cation-adjusted Mueller-Hinton broth (Difco™; Becton Dickinson, Sparks, MD) 
was used for antimicrobial dilution and bacterial culture. Preparation involved dissolving 
63 grams of broth powder in 3 liters of filtered, distilled water (Q-POD® Millipore using 
a 0.22 µm Millipak® 40 filter; Merck KGaA, Darmstadt, Germany). The solution was 
then autoclaved at 121˚C for 30 minutes. The manufacturer reports reconstituted Mueller-
Hinton broth solutions are stable for up to one year after reconstitution (Becton, 
Dickinson and Company; personal communication, February 24, 2016). All broth was 
utilized within one to two weeks of reconstitution. 
A 10 mg/mL stock solution of calcium and a 10 mg/mL stock solution of 
magnesium were prepared by adding 3.68 g of CaCl2*2H2O to 100 mL of filtered, 
distilled water and adding 8.36 g of MgCl2*6H2O to 100 mL of filtered, distilled water. 
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Each stock solution was filter sterilized again using a 0.22 micron filter (Corning® 150 
mL Bottle Top Filter 0.22 µm; Corning Inc., Corning, NY). For every liter of Mueller-
Hinton broth, 2.5 mL of calcium chloride stock solution and 1.25 mL of the magnesium 
sulfate stock solution were added for a final concentration of 25 mg/L calcium chloride 
and 12.5 mg/L magnesium sulfate. 
Mueller-Hinton agar (Difco™; Becton Dickinson, Sparks, MD) was prepared by 
suspending 38 grams of agar powder in 1 L of filtered, distilled water. The suspension 
was then autoclaved at 121˚C for 30 minutes. Following sterilization, the suspension was 
poured by an automated machine (Figure 3.6; MP-1000 PourMatic 100mm; John Morris 
Scientific, Chatswood, Sydney, Australia) onto Petri dishes (Falcon® 100x15 mm sterile 
petri dishes; Corning Inc., Corning, NY) which were subsequently sealed in manufacturer 
supplied bags and stored in a walk-in refrigerator at <4°C until needed for use. The 
manufacturer reports Mueller-Hinton agar is stable for up to 3-5 months after 
reconstitution (Becton, Dickinson and Company; personal communication, February 24, 
2016). All agar plates were utilized within one month of being reconstituted. 
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Figure 3.6: MP-1000 PourMatic® 100mm 
 
 For subpopulation analysis experiments, an extra step was added to the 
preparation of Mueller-Hinton agar plates. That is, after sterilization, but before the 
PourMatic® distributed the agar suspension onto petri dishes, antimicrobial agents were 
added to the agar suspension. Specifically, three unique types of antimicrobial plates 
were made – meropenem 16 µg/mL, meropenem 64 µg/mL, and polymyxin B 4 µg/mL. 
 Sterilized Mueller-Hinton agar was measured in a 1000 mL graduated cylinder 
(Fisherbrand™, ThermoFisher Scientific, Waltham, MA) to the 1 L mark. A stir bar 
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(Fisherbrand™, ThermoFisher Scientific, Waltham, MA) was dropped inside the cylinder 
and 1.56 mL of the 10.24 mg/mL meropenem stock solution ("Antimicrobial Solution 
Preparation") was added to the cylinder for a total concentration of 16 µg/mL 
meropenem. The agar was stirred on a hotplate (Fisherbrand™, ThermoFisher Scientific, 
Waltham, MA) for five minutes before being poured by the PourMatic® onto petri dishes 
which were subsequently sealed in manufacturer supplied bags and stored in a walk-in 
refrigerator at <4°C until needed for use. This process was repeated for the other two 
antimicrobial concentrations, but 6.25 mL of 10.24 mg/mL meropenem was used for the 
64 µg/mL final concentration and 1.56 mL of the 2.56 mg/mL stock solution of 
polymyxin B was used for the 4 µg/mL final concentration plates. 
 
Antimicrobial Solution Preparation 
 Stock solutions were prepared for each antimicrobial agent using CLSI 
recommended diluents (usually sterile water).237 For water sterilization, filtered (Q-POD® 
Millipore using a 0.22 µm Millipak® 40 filter; Merck KGaA, Darmstadt, Germany) water 
was autoclaved at 121˚C for 15 minutes in 1 L batches. Primary stock solutions were 
prepared using the antimicrobial powders described under "Antimicrobial Agents." 10 
mL of each antimicrobial agent was prepared using a volumetric flask (Kimax® 10 mL 
volumetric flask; Kimble; Cole-Parmer®, Vernon Hills, IL) and powder was weighed 
using an analytical balance (Mettler AE200, Figure 3.7; Marshall Scientific, Hampton, 
NH). Rifampin was prepared using 1.5 mL dimethyl sulfoxide (DMSO; Sigma-Aldrich®, 
St. Louis, MO) which was added to aid in solubility into sterile water and a 50 mL 
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volumetric flask to avoid conical vial cracking and assist in dissolution of drug particles 
once frozen. The other exception to sterile water as a diluent was cefepime, which was 
prepared in a phosphate buffer at a pH of 6.0. A phosphate buffer stock solution at a pH 
of 6.0 was previously prepared from 13.2 mL of a 0.1M dibasic potassium phosphate 
solution (Dry Powder; Sigma-Aldrich®, St. Louis, MO) and 86.8 mL of a 0.1M 
monobasic potassium phosphate solution (Dry Powder; Sigma-Aldrich®, St. Louis, MO). 
Levofloxacin was completely soluble in sterile water at the stock concentration utilized. 
Primary stock solutions were frozen at -20˚C until needed for an experiment, frozen and 
thawed no more than 5 times, and were not used beyond 6 months after making.239  
 
 
 
 
 
 
 
 
Figure 3.7: Analytical Balance 
 72 
 
Table 3.2: Primary Antimicrobial Stock Solutions 
Antimicrobial Powder (mg) Potency (mg/mg) Concentration (mg/mL) 
Amikacin 263.9 0.776 20.48 
Cefepime 124.0 0.826 10.24 
Colistin 32.7 0.7827 2.56 
Levofloxacin 12.9 0.99 1.28 
Meropenem 117.3 0.873 10.24 
Minocycline 28.7 0.892 2.56 
Piperacillin 216.5 0.946 20.48 
Polymyxin B 34.4 0.7450 2.56 
Rifampin* 66.0 0.97 1.28 
Tazobactam 16.1 0.994 1.60 
Tigecycline 25.8 0.9937 2.56 
*10 mL volume primary stock prepared for each agent above except Rifampin, which 
was a 50 mL volume stock 
  
All prepared antimicrobial stock solutions were stored in plastic conical vials (15 
mL polypropylene conical centrifuge tubes; USA Scientific, Ocala, FL). Secondary stock 
solutions were prepared using broth instead of sterile water on the day of testing in 
similar plastic conical vials and used immediately following preparation. See "Broth 
Microdilution Procedure" for addition of antibiotics to the microtiter trays (Costar® non-
treated, sterile, polystyrene 96-well; Sigma-Aldrich®, St. Louis, MO). 
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Table 3.3: Antimicrobial Secondary Stock Concentrations and testable MIC range 
Antimicrobial Concentration (mg/mL) Concentration Range (mg/L) 
Amikacin 2.048 0.25 – 512 
Cefepime 1.024 0.125 – 256 
Colistin 0.256 0.031 – 64 
Levofloxacin 0.128 0.016 – 32 
Meropenem 1.024 0.125 – 256 
Minocycline 0.256 0.031 – 64 
Piperacillin/Tazobactam 2.048 / 0.160 0.25/4 – 512/4 
Polymyxin B 0.256 0.031 – 64 
Rifampin 0.128 0.016 – 32 
Tigecycline 0.256 0.031 – 64 
 
 
Preparation of Inocula for Susceptibility Testing 
 Inocula were prepared by the McFarland Standard Method using 0.5 and 1 
McFarland standards and a Wickerham Card (Figure 3.8 Remel™ McFarland Turbidity 
Standard; ThermoFisher Scientific, Waltham, MA). An actively growing bacterial 
suspension ("Bacterial Isolates") was added drop-wise using an ErgoOne micropipette 
(Figure 3.9; USA Scientific, Ocala, FL)  to a glass test tube (Fisherbrand™ Disposable 
Culture Tubes 16x125mm Borosilicate Glass; ThermoFisher Scientific, Waltham, MA) 
containing about 5 mL 0.22 micron filtered, distilled water. Using the Wickerham Card, 
the turbidity of the glass test tube was matched as closely as possible to the 0.5 
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McFarland standard which is approximately equivalent to 1.0 - 1.5 x 108 CFU/mL. See 
Figure 3.8 for setup before inoculating the glass test tube. 
 
 
Figure 3.8: Test Tube with Water, McFarland Standards and Wickerham Card 
 
 
 
Figure 3.9: ErgoOne Micropipette 
 75 
 
For susceptibility testing using broth microdilution, the McFarland-matched 
suspension was subsequently diluted 1:200 in two steps by first adding 100 µL to 9.9 mL 
cation-adjusted Mueller-Hinton broth, and then secondly adding 50 µL of this solution to 
50 µL of broth and antimicrobial agent during the final inoculation step of the broth 
microdilution susceptibility testing ("Broth Microdilution Procedure"). The final bacterial 
concentration in each well was approximately 5.0 - 7.5 x 105 CFU/mL. 
In preparing microtiter trays for susceptibility testing of piperacillin/tazobactam, a 
1:200 dilution was made in two different steps by first adding 200 µL of McFarland-
matched suspension to 9.8 mL cation-adjusted Mueller-Hinton Broth and then secondly 
adding 25 µL of this solution to 75 µL of broth and piperacillin/tazobactam ("Broth 
Microdilution Procedure"), resulting in an approximate final concentration of 5.0 - 7.5 x 
105 CFU/mL. 
For Kirby-Bauer disk diffusion and Etest®, the McFarland-matched suspension 
was not diluted prior to inoculating agar plates ("Inoculation of Agar Plates"). 
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Broth Microdilution Procedure 
 
Figure 3.10: BioStack™ (Left) Attached to Precision™ Pipetting System (Right). 
A) The BioStack™ consists of the two black columns (left) which hold the unfilled and 
filled 96-well trays. B) The arm is the mechanical device that transfers 96-well trays to 
and from deck C. C) This deck holds 96-well trays for broth, antimicrobial, and organism 
deposition. D) This deck holds the 4 row by 1 column (4x1) reservoir (shown) as well as 
the 1x6 reservoir (not shown). E) This deck holds the sterile pipette tips for the manifold 
F. F) The manifold transfers fresh broth first, antibiotic second, serially dilutes the 96-
well tray third, and lastly, adds the inoculated suspension to the 96-well tray. G) The 
sharps disposal container is placed here to catch used pipette tips. 
A 
B 
C 
D 
E 
F 
G 
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After all necessary preparations ("Media Preparation," "Antimicrobial Solution 
Preparation," and "Preparation of Inocula for Susceptibility Testing"), a stack of 96-well 
trays were added to the left column of the BioStack™ (Figure 3.10), sterile pipette tips 
were added to deck E, and the freshly prepared cation-adjusted Mueller-Hinton broth was 
added to each reservoir in the 4x1 reservoir. The computer that manages the Precision™ 
pipetting system is not shown in Figure 3.10, but the Precision Power™ software was 
launched and the program labeled "1 BTK Broth MIC testing (Initial 50 mcl broth 
only).PGM" was loaded and run. The arm then transferred a 96-well tray from the left 
column on the BioStack™ to deck C. The manifold picked up 12 pipette tips from deck E 
and extracted broth from the 4x1 reservoir into each. The manifold then deposited 50 µL 
into each well of the 96-well tray. The arm transferred the 96-well tray back to the right 
column of the BioStack™ and picked up a new plate from the left column of the 
BioStack™ to repeat this whole process for each and every 96-well tray. 
Once all 96-well trays contained 50µL of broth, the manifold disposed of the 
pipette tips into container (G) and the program terminated. The right column of the 
BioStack™ was manually exchanged with the left column, hereafter always referred to 
by relative position to each other (i.e. the old right column is now the left column) 
because each program tells the arm to pull 96-well trays from the left column. The 4x1 
reservoir was exchanged with another 4x1 reservoir that contained 1 compartment of 
broth without an antimicrobial agent and 3 out of 10 of the freshly prepared secondary 
stock solutions ("Antimicrobial Solution Preparation") which were at concentrations 4x 
what was needed in the first well of the 96-well trays. This would in the next step provide 
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the 8x12 tray with 2 rows of a growth control and 2 rows of each of the 3 antibiotics in 
the 4x1 reservoir with 12 serial dilutions (Figure 3.11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Complete set of 4 unique 96-well trays 
  
At this point, all 96-well trays were filled with 50 µL of cation-adjusted Mueller-
Hinton broth and were in the left column of the BioStack™, ready for serial dilution of 
antimicrobials. The program "2 BTK multiDrug MIC testing (12 dilutions).PGM" was 
run which, similar to the first program, instructed the arm to take a 96-well tray from the 
left column BioStack™ and place it on deck C. The manifold picked up 12 pipette tips, 
withdrew 50 µL of antimicrobials into each tip from the 4x1 reservoir, and deposited the 
contents into the first well. Following mixing, 50 µL were withdrawn from the first well 
Growth Control 
Polymyxin B 
Meropenem 
Amikacin 
Growth Control 
Rifampin 
Levofloxacin 
Minocycline 
Growth Control 
Colistin 
Cefepime 
Tigecycline 
Growth Control 
Blank 
Blank 
Piperacillin/Tazobactam 
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and added to the second well. This repeated from well to well until all remaining wells 
(12 total) had been serially diluted and mixed. The manifold disposed of the pipette tips 
into the sharps disposal container and picked up 12 more sterile pipette tips while the arm 
exchanged the antimicrobial filled 96-well tray with a new one, placing the former into 
the right column BioStack™. This process repeated until all 96-well trays were filled 
with the set of antimicrobials. This program was repeated for each antimicrobial set as in 
Figure 3.11, exchanging the 4x1 reservoir for a new set of antimicrobials as needed as 
well as adding new pipette tips and changing the contents of the BioStack so that 96-well 
trays without antibiotic were on the left and the freshly serially diluted trays were set 
aside (removed from the right column) in groups. 
 For the piperacillin/tazobactam group, only piperacillin was placed in the 4th row 
of the 4x1 reservoir to be serially diluted so that a constant concentration of tazobactam 
can be later placed into each well. Once this group of 96-well trays was finished, the 
columns of the BioStack™ were exchanged and another program was loaded and run, 
"2.5 BTK Drug PIP TAZO MIC testing.PGM." However, prior to running this, pipette 
tips were replaced if needed and a 1x6 reservoir replaced the 4x1 reservoir with the 1st 
row being filled with tazobactam at 4x the needed concentration, or 16 mcg/mL 
("Antimicrobial Solution Preparation"). This program instructed the arm to retrieve a 96-
well tray from the left column BioStack™ and place it on deck C. The manifold obtained 
12 sterile pipette tips and aspirated tazobactam from the 1st row of the 1x6 reservoir. 25 
µL of tazobactam were dispensed into each well, very similarly to the program that 
initially dispensed broth into each well before the serial dilutions. This program finished 
once all piperacillin group 96-well trays had a total of 75 µL of volume in each well. 
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 Once all 96-well trays had antimicrobials serially diluted across all 12 rows, each 
well now contained 50 µL of broth with antimicrobial agent (except the 
piperacillin/tazobactam group trays) and the 96-well trays were placed by group of 
common antimicrobials (Figure 3.11), one group at a time, in the left column of the 
BioStack as before. At first, all of the growth control, polymyxin B, meropenem, and 
amikacin 96-well plates were placed in the left column BioStack while the other 3 groups 
were set aside. Pipette tips were replaced as necessary and the 4x1 reservoir was 
exchanged with a 1x6 reservoir which contained 6 unique 0.5 McFarland-matched 
bacterial suspensions that had been diluted 1:100 (step 1 of "Preparation of Inocula for 
Susceptibility Testing"). Note that the bacterial suspensions for the 
piperacillin/tazobactam 96-well trays were at the time diluted 1:50. 
 Before running the final program, a checklist was used to ensure that the left 
column of the BioStack contained only 1 group of 96-well trays and that the right column 
of the BioStack was empty to receive the completed trays. The pipette tips were replaced 
in deck E if needed and the 1x6 reservoir contained a different bacterial suspension in 
each of the 6 compartments. Furthermore, unless the group of piperacillin/tazobactam 96-
well trays were being used, the 1:50 diluted suspensions were not needed yet. 
 "3 BTK multiBug MIC testing (Lay bug 50 mcl).PGM" was loaded and run in the 
software. This program instructed the arm to add a 96-well tray to deck C and instructed 
the manifold to pick up 12 sterile pipette tips,  aspirate bacterial suspension from the 1st 
column of 6 of the 1x6 reservoir and to dispense 50 µL into each of the 96 wells, 
finishing the 2nd step of the 1:200 dilution and resulting in an initial bacterial 
concentration of approximately 5.0 - 7.5 x 105 CFU/mL in each well. The arm then 
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placed the complete 96-well tray into the right column BioStack™ and retrieved another 
96-well tray. The manifold disposed of the previously used pipette tips and obtained new 
ones. Following this, the 2nd column of 6 of the 1x6 reservoir was aspirated and 50 µL of 
suspension was dispensed into each well. This repeated until 6 plates were completed 
with a unique suspension in each. The program was repeated after replacing pipette tips if 
needed and changing the 1x6 reservoir for 6 new bacterial suspensions. It was not 
necessary to change the BioStack™ columns at this time because there was an equivalent 
number of 96-well trays remaining as there were bacterial suspensions. Once all bacterial 
suspensions had been used for the first group of antimicrobial 96-well trays, these trays 
were placed in an incubator (Heratherm™ Incubator, Figure 3.12; ThermoFisher 
Scientific, Waltham, MA) at 35˚C and this entire processes was repeated again for the 
2nd and 3rd group of a 96-well trays. 
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Figure 3.12: Heratherm™ Incubator 
 
 For the 4th group of 96-well trays, also known as the piperacillin/tazobactam 
group, a different program was needed because only 25 µL of a 1:50 bacterial suspension 
needs to be placed into each well. "3.5 BTK multiBug PIP TAZO MIC testing (Lay bug 
25 mcl).PGM" was loaded and run. This program is similar to the one in the previous 
paragraph except that the 1x6 reservoirs contained 6 unique bacterial suspensions each at 
a 1:50 dilution and only 25 µL of this suspension was dispensed into each well. 
 In summary, every 96-well tray had 50 µL of cation-adjusted Mueller-Hinton 
broth and a group of antimicrobial agents (Figure 3.11) serially diluted across the 12 
columns. 50 µL of a 1% 0.5 McFarland-matched bacterial suspension was added to each 
well for a total volume of 100 µL in each well. The only exception were the 
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piperacillin/tazobactam group trays which had 25 µL of 16 mcg/mL tazobactam added 
and 25 µL of a 2% 0.5 McFarland-matched bacterial suspension for a total volume of 100 
µL in each well. See Table 3.3 for the concentration ranges of antimicrobial agent. 
 
Incubation 
 Once inoculated, all 96-well microtiter trays and Mueller-Hinton agar plates were 
sealed using the manufacturer supplied lids and incubated at 35˚C for 18-24 hours in an 
incubator (Heratherm™ Incubator; ThermoFisher Scientific, Waltham, MA). Agar plates 
were inverted and stacked no more than four high. 
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Minimum Inhibitory Concentration (MIC) Determination 
 MIC is defined as the lowest concentration of antimicrobial agent required to 
completely inhibit the growth of the microorganism to the unaided eye. On the 96-well 
microtiter trays, this would be a complete absence of turbidity, individual colonies, and 
strings. An example is shown on Figure 3.2. The resulting growth by well was depicted 
on data sheets for each tray (Figure 3.13). 
 
 
Figure 3.13: Antimicrobial Susceptibility 8x12 Microtiter Data Sheet 
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Inoculation of Agar Plates 
 After preparing the agar plates ("Media Preparation") and bacterial suspensions 
for inoculation ("Preparation of Inocula for Susceptibility Testing"), a wooden, sterile, 
cotton-tipped applicator (Fisherbrand™; ThermoFisher Scientific, Waltham, MA) was 
dipped into the 0.5 McFarland-matched bacterial suspension and then rolled on the side 
of the same glass tube to remove excess suspension. The agar plate was streaked in a 
back-and-forth motion as if painting the entire plate from top to bottom (Figure 3.14). 
The plate was rotated 90˚ and the same cotton swap was used to streak the plate again but 
without dipping into the bacterial suspension a second time. This coated the agar plate 
with a lawn of bacteria. 
 
 
  
 
 
 
 
 
 
Figure 3.14: Inoculation of Mueller-Hinton Agar Plate 
 
 86 
 
Kirby-Bauer Disk Diffusion Procedure 
 Following inoculation of the agar plate ("Inoculation of Agar Plates"), a 
ceftazidime/avibactam (30 µg / 20 µg) impregnated disk (Actavis; Parsippany, New 
Jersey) was placed on the plate using sterile forceps (Fisherbrand™, ThermoFisher 
Scientific, Waltham, MA). The plate was then incubated (Heratherm™ Incubator; 
ThermoFisher Scientific, Waltham, MA) at 35˚C for 18-24 hours and the diameter of the 
zone of inhibition (Figure 3.4) was measured in millimeters to the nearest whole number 
and recorded. Susceptibility was determined based on CLSI guidelines (≥21 mm 
susceptible; 18-20 mm intermediate; ≤17 mm resistant).237  
At the time of experiment, 152 unique MDR isolates had been collected, 
consisting of 75 CRE (Enterobacteriaceae with an ertapenem MIC >0.5 or a meropenem 
MIC >1). All 75 isolates underwent Kirby-Bauer disk diffusion testing for susceptibility 
to ceftazidime/avibactam. Isolates that had a zone of inhibition ≤ 21mm (borderline 
susceptible, intermediate, or resistant) underwent a second test to verify resistance. If a 
discrepancy between the results occurred, the test was repeated once more. 
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Etest® Procedure 
 Following inoculation of the agar plate ("Inoculation of Agar Plates"), an Etest® 
strip was placed on the plate using sterile forceps. The plate was then incubated 
(Heratherm™ Incubator; ThermoFisher Scientific, Waltham, MA) at 35˚C for 18-24 
hours.  
MBL MP/MPI Etest® strips were interpreted as positive for MBL if 1) the MIC 
ratio of meropenem (MP) to meropenem with EDTA (MPI) was ≥8 (Figure 3.5 for MIC 
reading of Etest®), 2) if there was a phantom zone (i.e. an extra inhibition zone between 
the MP and MPI regions; Figure 3.15), or 3) if a deformation of the MP or MPI ellipses 
was present. All CRE isolates with ceftazidime/avibactam zones of inhibition measuring 
≤ 21mm (borderline susceptible, intermediate, or resistant; "Kirby-Bauer Disk Diffusion 
Procedure") were tested for MBL production by Etest® except four isolates which were 
already known to produce MBL by PCR from previous work. 
Fosfomycin Etest® strips were read for MIC and recorded (Figure 3.5). Only the 
first 12 Klebsiella pneumoniae isolates were tested with fosfomycin Etest®. 
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Source: bioMérieux, Inc., Durham, NC 
 
Figure 3.15: MBL MP/MPI Etest® Interpretation 
 
Selection of Bacterial Isolates for Further Testing 
 Clinical isolates were selected for further testing based on the meropenem and 
polymyxin B MICs. For subsequent time-kill studies, four isolates showing polymyxin B 
susceptibility, defined as ≤2 mg/L based on CLSI breakpoints for A. baumannii and P. 
aeruginosa,237 with varying degrees of meropenem resistance were chosen. In order of 
increasing meropenem resistance, those isolates selected were named KP 34 (4 mg/L), 
KP 22 (16 mg/L), KP 24 (32 mg/L), and KP 44 (128 mg/L). 
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TIME-KILL STUDIES 
 Time-kill experiments can be used to evaluate bacteria colony count at various 
time points during exposure to a set concentration of one or more antimicrobial agents. 
All time kill assays were performed at least in duplicate with a positive growth control 
and samples collected at 0, 1, 2, 4, 8, 24, and 48 hours, diluted as necessary, and aliquots 
(50µL) logarithmically plated onto Mueller Hinton agar using a spiral plater (Figure 3.16; 
AutoPlate® spiral plater; Advanced Instruments, Inc., Norwood, MA), which helped 
control for antibiotic carryover.240 Colonies were counted using a laser colony counter 
(Figure 3.17; QCount Automated Colony Counter; Spiral Biotech, Advanced 
Instruments, Inc., Norwood, MA) with a lower limit of quantification of 102 CFU/mL.  
Cation-adjusted Mueller-Hinton broth was used for growth media ("Media 
Preparation" and "Inocula Preparation"). Meropenem and polymyxin B alone were 
evaluated at three (4, 16, and 64 mg/L) and seven (0.0625, 0.125, 0.25, 0.5, 1, 2, and 4 
mg/L) clinically relevant concentrations, respectively.241,242 For combination studies, 
polymyxin B concentrations of 0.25 and 1 mg/L were evaluated with all three 
concentrations of meropenem against KP 22, KP 24, KP 32, and KP 44. However, for the 
highly meropenem resistant isolate (KP 44), polymyxin B at 4 mg/L was also evaluated 
in combination with the three concentrations of meropenem. Repeat MICs for polymyxin 
B were determined for regrowing bacteria at 24 hours ("Resistance Development 
Testing"). 
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Figure 3.16: AutoPlate® spiral plater; Advanced Instruments, Inc., Norwood, MA 
 
 
 
 
 
 
 
 
 
Figure 3.17: QCount Automated Colony Counter; Spiral Biotech, Advanced Instruments, 
Inc., Norwood, MA 
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Time-Kill Procedure 
 Meropenem, polymyxin B, or both agents in combination were added to cation-
adjusted Mueller-Hinton broth ("Media Preparation") in conical vials (50 mL 
polypropylene conical centrifuge tubes; USA Scientific, Ocala, FL) up to a total volume 
of 30 mL measured by ErgoOne micropipettes and a Pipet-Aid® (Drummond Scientific 
Co., Figure 3.18; Broomall, PA). Portions of the primary stock vials of antimicrobials 
("Antimicrobial Solution Preparation") were added directly to the 50 mL conical vial 
according to Table 3.4 and the desired concentrations. 
 
 
 
 
 
 
 
 
 
Figure 3.18: Drummond Pipet-Aid® 
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Table 3.4: Time-Kill Volume Table 
 
Meropenem Alone 
Antimicrobial Concentration (µg/mL) 4 16 64 
Volume of Stock Soln. (µL) 117 469 1875 
Volume of 0.5 McFarland Suspension (µL) 150 150 150 
Volume of Broth in 50 mL vial (mL) 29.8 29.4 28.0 
Total Volume (mL) 30 30 30 
Polymyxin B Alone 
Antimicrobial Concentration (µg/mL) 0.063 0.125 0.25 0.5 1 2 4 
Volume of Stock Soln. (µL) 2 4 7 15 29 59 117 
Volume of 0.5 McFarland Suspension (µL) 150 150 150 150 150 150 150 
Volume of Broth in 50 mL vial (mL) 29.8 29.8 29.8 29.8 29.8 29.8 29.8 
Total Volume (mL) 30 30 30 30 30 30 30 
Combination* 
Meropenem Concentration (µg/mL) 4 16 64 
Volume of Stock Soln. (µL) 117 469 1875 
Volume of 0.5 McFarland Suspension (µL) 150 150 150 
Volume of Broth in 50 mL Vial (mL) 29.7 29.4 28.0 
Total Volume (mL) 30 30 30 
*Polymyxin B volume contribution ignored 
After the antimicrobial agents were added to their respective conical vials, a 1:200 
dilution of the 0.5 McFarland matched suspension was made by adding 150 µL of the 
suspension to the conical vial. Immediately following this addition, the conical vial was 
mixed swiftly using the pipette tip of the ErgoOne micropipette and a 0.5 mL sample was 
drawn and serially diluted in 1:10 dilutions in glass test tubes (Fisherbrand™ Disposable 
Culture Tubes 16x125mm Borosilicate Glass; ThermoFisher Scientific, Waltham, MA) 
containing 4.5 mL sterile water. A dispenser (Oxford®; Cole-Parmer®, Vernon Hills, IL) 
was calibrated and used to equally measure 4.5mL volumes. Vials were then placed in a 
shake incubator (MaxQ 6000; ThermoFisher Scientific, Waltham, MA) at 35˚C and 220 
oscillations per minute for the remainder of the experiment. 
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Samples were drawn by an ErgoOne micropipette at times 0, 1, 2, 4, 8, 24, and 48 
hours. Since the laser colony counter (QCount Automated Colony Counter; Spiral 
Biotech, advanced Instruments, Inc., Norwood, MA) most optimally measures 103 - 105 
CFU/mL, at time 0, a 1:10 and a 1:100 dilution were made from a 0.5 mL serially diluted 
sample due to an initial colony count of about 5.0 - 7.5 x 105 CFU/mL. At each time 
point, it was noted whether the conical vial contents were clear or turbid because the 
unaided eye can see turbidity at approximate 107 CFU/mL based on previous work 
performed in our laboratory. If clear, an undiluted 2 mL sample was drawn and a 1:100 
dilution sample was made from a 0.5 mL serially diluted sample, both plated via spiral 
plater, and both placed in an incubator (Heratherm™ Incubator; ThermoFisher Scientific, 
Waltham, MA). If turbid, a 1:104 and a 1:106 dilution were made from a 0.5 mL serially 
diluted sample, both plated via spiral plater, and both placed in an incubator. Subsequent 
0.5 mL samples drawn after a turbid time point were diluted 1:105 and 1:107, both plated 
via spiral plater, and both placed in an incubator.  
As previously mentioned, the target measurement for the laser colony counter is 
103-105 CFU/mL and dilution choices were made based on previous time-kill studies 
performed in the laboratory. All plates incubated for 18-24 hours and were read by a laser 
colony counter. The lower limit of quantification was 102 CFU/mL which was the value 
used for any time point reading less than this. 
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Resistance Development Testing 
Following two separate time-kill studies, MIC determination by broth 
microdilution was performed on colonies growing on the 24-hour time point agar plates 
("Time-Kill Procedure") but were tested only for changes in polymyxin B MIC ("In vitro 
Susceptibility Testing"). Resistance development was defined as a ≥4-fold increase in 
MIC from colonies growing at 24 hours when compared to the baseline MIC of the 
organism. An MIC > 2  was considered non-susceptible according to CLSI breakpoints 
for A. baumannii and P. aeruginosa.237 
 
Subpopulation Analysis and Microfiltration 
A modified time-kill procedure was used to evaluate subpopulations of the four K. 
pneumoniae isolates selected for time-kill studies ("Time-Kill Studies"). The results of 
this study would allow us to explain observed regrowth in the other time-kill experiments 
by quantifying the subpopulations of each isolate. These subpopulations often have a 
different MIC than the MIC of  the majority or overall population.142 Instead of adding 
antimicrobial agents to the 50 mL conical vials, 29.8 mL of cation-adjusted Mueller-
Hinton broth ("Media Preparation") with 150 µL of 0.5 McFarland matched bacterial 
suspension ("Preparation of Inocula for Time-Kill") were used for a total of 30 mL of 
approximately 5.0 - 7.5 * 105 CFU/mL of bacteria. Additionally, instead of using 
Mueller-Hinton agar plates, the antimicrobial-impregnated plates were used ("Media 
Preparation"). Finally, sampling time points were 0, 2, 3, 4, 6, and 24 hours. All other 
aspects of this modified study were similar to the "Time-Kill Procedure." 
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 It was hypothesized that the subpopulations we wished to quantify may be below 
the lower limit of quantification (102 CFU/mL) for the laser colony counter. To address 
this, two comparable approaches were used. First, instead of using aliquots of 50 µL 
logarithmically plated by the spiral plater, a uniform 500 µL setting was used. Second, 
we implemented a process called microfiltration which involved taking a specific sample 
volume at each time point (Tables 3.5 - 3.8), passing sample through a 0.22 µm filter, and 
then placing the filter (bacteria-side up) directly onto the antimicrobial-impregnated agar 
plate where nutrients could diffuse through the filter paper to the bacteria. In both cases, 
the plates were incubated (Heratherm™ Incubator; ThermoFisher Scientific, Waltham, 
MA) at 35˚C for 18-24 hours and then manually counted so that a colony count 
(CFU/mL) could be calculated based on the volume utilized for each sample. The lower 
limit of quantification associated with microfiltration ranges from 30-300 CFU/mL, 
decreasing as larger sample volumes are used.243,244 
 
Figure 3.19: Vacuum Filter Apparatus  
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Table 3.5: Microfiltration Sample Volumes at Each Time Point for KP 34 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 24 (hours) 
MEM 16 
(µg/mL) 500 µL 500 µL 250 µL 100 µL 100 µL No sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 250 µL 250 µL No sample 
 
 
 
Table 3.6: Microfiltration Sample Volumes at Each Time Point for KP 22 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 24 (hours) 
MEM 16 
(µg/mL) 1000 µL 500 µL 250 µL 250 µL 250 µL No sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 250 µL 250 µL No sample 
 
 
 
Table 3.7: Microfiltration Sample Volumes at Each Time Point for KP 24 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 24 (hours) 
MEM 64 
(µg/mL) 1000 µL 500 µL 250 µL 100 µL 100 µL No sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 250 µL 100 µL 500 µL 
 
 
 
Table 3.8: Microfiltration Sample Volumes at Each Time Point for KP 44 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 24 (hours) 
MEM 64 
(µg/mL) 100 µL 100 µL No sample No sample No sample No sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 500 µL 250 µL No sample 
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DATA ANALYSIS 
In Vitro Susceptibility Testing 
For each isolate, MIC results from within the same experiment as well as from 
duplicate or sometimes triplicate experiments were compared and evaluated for essential 
agreement (within one two-fold dilution).237 If MIC results did not agree, broth 
microdilution was repeated for these strains. When MIC results were not the same, but 
were in agreement, the greater of the two results was accepted as the MIC. If three MIC 
results differed, the most common (modal) MIC was accepted. If there was not a modal 
MIC, the middle MIC was accepted if all results were in agreement with the middle MIC 
reading. Additionally, MIC range, MIC50, and MIC90 were determined. Percent 
susceptible was calculated based on breakpoints established by CLSI (Table 3.8).237 
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Table 3.9: Susceptibility Breakpoints for Enterobacteriaceae 
 Susceptible Intermediate Resistant Amikacin ≤16 32 ≥64 
Ampicillin ≤8 16 ≥32 
Ampicillin/Sulbactam ≤8/4 16/8 ≥32/16 
Aztreonam ≤4 8 ≥16 
Cefazolin ≤2 4 ≥8 
Cefepime* ≤2 4-8 ≥16 
Cefoxitin ≤8 16 ≥32 
Ceftazidime ≤4 8 ≥16 
Ceftriaxone ≤1 2 4 
Cefuroxime ≤8 16 ≥32 
Ciprofloxacin ≤1 2 ≥4 
Colistin† ≤2 4 ≥8 
Ertapenem ≤0.5 1 ≥2 
Fosfomycin ≤64 128 ≥256 
Gentamicin ≤4 8 ≥16 
Levofloxacin ≤2 4 ≥8 
Meropenem ≤1 2 ≥4 
Minocycline ≤4 8 ≥16 
Polymyxin B† ≤2 4 ≥8 
Nitrofurantoin ≤32 64 ≥128 
Piperacillin / 
Tazobactam ≤16/4 32/4 - 64/4 ≥128/4 
Tetracycline ≤4 8 ≥16 
Tigecycline§ ≤2 4 ≥8 
Tobramycin ≤4 8 ≥16 
Sulfamethoxazole / 
Trimethoprim ≤2/38 - ≥4/76 
*Cefepime does not have an intermediate susceptibility but instead has a susceptible 
dose-dependent designation 
†Polymyxin B and colistin do not have CLSI breakpoints for Enterobacteriaceae. The 
breakpoints for Pseudomonas aeruginosa and Acinetobacter baumannii were used 
instead237 
§Tigecycline does not have CLSI breakpoints for gram-negative organisms. An FDA-
approved breakpoint of ≤ 2 µg/mL was considered susceptible167 
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Time-Kill Studies 
 Plots of colony count (log10 CFU/mL) versus time were constructed for each 
isolate and antimicrobial(s) studied. Furthermore, combined plots across multiple 
experiments were generated using geometric means of the colony counts and standard 
deviations for each time point. Additionally, plots of 24-hour change in log10 CFU/mL 
were constructed using the logarithm of the geometric mean of the initial (time = 0) 
colony count subtracted from the logarithm of the geometric mean of the 24-hour colony 
count with un-pooled standard deviations. Activity was evaluated as bactericidal, 
bacteriostatic, or growth where bactericidality was defined as a ≥103 decrease in colony 
count at 24 hours, bacteriostatic was defined as a < 103 decrease in colony count at 24 
hours, and growth was any positive change at 24 hours. Synergy was also evaluated for 
combinations, being defined as a ≥ 102 CFU/mL lower colony count at 24 hours when 
compared to the most active agent used alone. 
 
Subpopulation Analysis 
 A table of colony count (log10 CFU/mL) at time 0 was constructed which included 
each isolate studied in time-kill assays. Measurements from microfiltration were 
preferentially used when either microfiltration data were below the lower limit of 
quantification (102 CFU/mL) for the laser colony counter or when the laser colony 
counter data were below the lower limit of quantification. When the laser colony counter 
and microfiltration data were above 102 CFU/mL or if the microfiltration method 
produced too many colonies to count, the laser colony counter value was used. 
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Additionally, reported values were not rounded to the lower limit of quantification 
because higher error was accepted as a limitation for comparing colony counts that were 
expected to be so low. 
 
Statistical Analyses 
 Chi-squared analyses with a Holm-Bonferroni correction were used to compare 
antimicrobial susceptibility data such as broth microdilution, BD Phoenix™, and 
nationally reported data.245,246 However, statistical inferences are limited in that high 
sample sizes may confer statistical significance with a lack of clinical significance. For 
example, a difference in susceptibility of 62% compared to 60% may be statistically 
significant depending on the sample size, but a difference in susceptibility of 100% to 
98% indicating first appearance of resistance may be more clinically significant, 
regardless of statistical significance. 
 Geometric means and standard deviations are most meaningful regarding time-kill 
and log-change studies due to the very high inter-experiment variability (heterogeneity) 
observed across studies. Therefore, statistical parameters describing intra-experiment 
variability (e.g. standard deviation and coefficients of variance) are a better indicator of 
valid results in the face of dynamically growing organisms where external factors are 
difficult to control without many samples. This has been a limitation and described by 
numerous meta-analyses and review articles14,200,203,210 leading to standardized definitions 
for describing and comparing data (e.g. bactericidality and synergy), primarily by 
CLSI.235,237 
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Chapter Four: 
 
Results 
 
Bacterial Isolates 
 Clinical isolates of 229 non-duplicate, MDR,165 gram-negative organisms were 
collected between November 9, 2008 and December 31, 2015 from the Clinical 
Microbiology Laboratory at the University of Kentucky Chandler Medical Center in 
Lexington, Kentucky. The most common MDR species in descending order were 
Klebsiella pneumoniae (28%), Escherichia coli (20%), Enterobacter cloacae (16%), and 
Pseudomonas aeruginosa (15%). CRE make up 48% of the MDR isolates obtained, and 
Klebsiella pneumoniae (40%) and Enterobacter cloacae (32%) make up the majority of 
this group. These isolates are described in Tables 4.1-2. 
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Table 4.1: All MDR Clinical Isolates 
 
Organism Number of Isolates Percentage of Isolates 
Acinetobacter baumannii 10 4.4% 
Burkholderia cepacia 1 0.4% 
Citrobacter amalonaticus 2 0.9% 
Citrobacter freundii 10 4.4% 
Citrobacter youngae 1 0.4% 
Enterobacter aerogenes 4 1.7% 
Enterobacter cloacae 37 16.2% 
Enterobacter gergoviae 2 0.9% 
Enterobacter hormaechei 1 0.4% 
Enterobacter spp. 2 0.9% 
Escherichia coli 46 20.1% 
Escherichia vulneris 1 0.4% 
Klebsiella oxytoca 5 2.2% 
Klebsiella pneumoniae 64 27.9% 
Klebsiella ozaenae 1 0.4% 
Pantoea agglomerans 3 1.3% 
Proteus mirabilis 2 0.9% 
Pseudomonas aeruginosa 34 14.8% 
Pseudomonas putida 2 0.9% 
Sphingomonas paucimobilis 1 0.4% 
TOTAL 229  
 
Table 4.2: Carbapenem-Resistant Enterobacteriaceae (CRE) Clinical Isolates 
 
Organism Number of Isolates Percentage CRE Isolates 
Citrobacter amalonaticus 2 1.8% 
Citrobacter freundii 9 8.3% 
Citrobacter youngae 1 0.9% 
Enterobacter aerogenes 3 2.8% 
Enterobacter cloacae 35 32% 
Enterobacter gergoviae 2 1.8% 
Enterobacter hormaechei 1 0.9% 
Enterobacter spp. 2 1.8% 
Escherichia coli 5 4.6% 
Klebsiella oxytoca 4 3.7% 
Klebsiella pneumoniae 44 40% 
Klebsiella ozaenae 1 0.9% 
TOTAL 109  
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IN VITRO SUSCEPTBILITY TESTING 
Minimum Inhibitory Concentrations (MICs) 
 All isolates underwent identification and antimicrobial susceptibility testing for 
clinical purposes through the University of Kentucky Clinical Microbiology Laboratory 
using BD Phoenix™ prior to collection by our lab. This data (Appendix A, Tables A.1-
A.2) was provided to and verified by our lab using antimicrobial susceptibility testing by 
broth microdilution methodology, the gold standard for determination of MICs.235 The 
primary objective of antimicrobial susceptibility testing through broth microdilution was 
to identify isolates that represented the majority of CRE observed in the U.S., namely 
carbapenem-resistant Klebsiella pneumoniae (CR-KP).11 Resistance was described by the 
measured MIC value,237 and these isolates exhibited low to high levels of resistance to 
meropenem – the most commonly used carbapenem antimicrobial at the University of 
Kentucky Chandler Medical Center. Furthermore, these experiments identified CRE 
susceptible to polymyxin B since polymyxin susceptibility is more frequently observed in 
CRE.14 
The MICs for all 229 isolates are shown for the 20 antimicrobials tested by BD 
Phoenix™ in Appendix A, Tables A.1-A.2. The MIC50, MIC90, and percentage 
susceptible across MDR isolates numbering at least 30 according to CLSI guidelines for 
cumulative susceptibility reporting245 are shown in Appendix B, Tables B.1-B.4. Since 
clinical isolates were continually being sent throughout the study from the University of 
Kentucky Clinical Microbiology Laboratory, only the first 24 received of ultimately 44 
CR-KP organisms underwent antimicrobial susceptibility testing by broth microdilution 
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and MICs to the antimicrobials evaluated are shown in Appendix C, Table C.1. The 
MIC50, MIC90, and percentage susceptible for the first 24 (12 where noted) CR-KP 
organisms tested by broth microdilution and E-test are shown in Table 4.3. 
 
Table 4.3: In Vitro Susceptibility Results for CRE K. pneumoniae 
     MICs (µg/mL) 
Antimicrobial Range MIC50 MIC90 % Susceptible 
Amikacin 0.5 – 128 4 128 67% 
Cefepime ≤0.125 – >256 32 >256 17% 
Colistin* ≤ 0.03 – 8 0.06 0.5 92%† 
Levofloxacin ≤0.03 – 64 8 >32 29% 
Meropenem ≤0.015 – 128 16 128 25% 
Minocycline 1 – >64 8 32 42% 
Piperacillin/ Tazobactam* ≤0.25/4 – >512/4 0.25/4 >512 50% 
Polymyxin B 0.06 – >256 0.125 8 83%† 
Rifampin* 16 – >32 32 >32 N/A 
Tigecycline 0.125 – 4 1 4 88%† 
Fosfomycin§ 12 – >1024 32 >1024 75% 
* Evaluated for the first 12 K. pneumoniae isolates only 
† No CLSI breakpoint for Enterobacteriaceae. Therefore, FDA breakpoint of ≤ 2 µg/mL 
was used for tigecycline167 and CLSI breakpoint for non-Enterobacteriaceae of ≤ 2 
µg/mL was used for polymyxin B and colistin237 
§ Evaluated for the first 12 K. pneumoniae isolates and by E-test only 
 
 
Among the first 24 CR-KP clinical isolates, meropenem resistance (MIC ≥4 
µg/mL)237 ranged from 4 - 128 µg/mL. A majority of the CR-KP isolates were polymyxin 
B susceptible (MIC ≤2 µg/mL)237 and had MIC values of 0.06 - 0.125 µg/mL (Appendix 
C, Table C.1). Other observations, although not the focus of the antimicrobial 
susceptibility testing, included higher susceptibility (≥75%) among colistin, polymyxin 
B, tigecycline, and fosfomycin; modest susceptibility to amikacin (67%); and relatively 
poor (≤50%) susceptibility to other antimicrobial agents evaluated. 
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Selection of Bacterial Isolates for Time-kill Studies 
 Four CR-KP isolates from lowest to greatest meropenem resistance (KP 34, KP 
22, KP 24, and KP 44) were selected to represent the range of meropenem resistance 
described previously (4 - 128 µg/mL) while maintaining polymyxin B susceptibility. 
These isolates were later evaluated in time-kill studies with meropenem (MEM) and 
polymyxin B (PMB) alone and in combination. The isolates and their respective MIC 
values are in Table 4.4 (letter abbreviations indicate susceptible or resistant). 
 
Table 4.4: Microdilution MICs for K. pneumoniae Isolates Selected for Time-Kill  
 
Antimicrobial KP 34 MIC(µg/mL) 
KP 22 
MIC(µg/mL) 
KP 24 
MIC(µg/mL) 
KP 44 
MIC(µg/mL) 
Amikacin 1 (S) 64 (R) 4 (S) 4 (S) 
Cefepime 2 (S) 32 (R) 64 (R) 256 (R) 
Colistin* 0.125 (S) 0.06(S) 0.125 (S) 0.06 (S) 
Levofloxacin 0.06 (S) 64 (R) 64 (R) 64 (R) 
Meropenem 4 (R) 16 (R) 32 (R) 128 (R) 
Piperacillin/Tazobactam ≤0.25 (S) 512 (R) >512 (R) >512 (R) 
Polymyxin B* 0.125 (S) 0.06 (S) 0.125 (S) 0.06 (S) 
Rifampin+ 32 >32 32 >32 
Tigecycline§ 0.25 (S) 2 (S) 0.25 (S) 4 (R) 
Fosfomycin† 12 (S) 16 (S) 24 (S) 48 (S) 
*Breakpoint of P. aeruginosa and A. baumannii of ≤ 2µg/mL used237 
+No CLSI breakpoints for gram-negative organisms237 
§FDA breakpoint of ≤ 2µg/mL used167 
†Evaluated by Etest® 
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TIME-KILL STUDIES 
All time-kill curves (both individual and average), separated by organism and 
antimicrobial, are located in Appendix D, Figures D.1-D.24. However, in order to best 
compare antimicrobial agents within the same organism, the average time-kill results are 
displayed for each isolate at all concentrations tested in combination as well as the 
corresponding concentrations of agents used alone. Using these graphs, the killing 
activity of each antimicrobial alone and their combination can be described as growth – 
any increase in colony count (CFU/mL) from the previous time point, bacteriostatic – any 
decrease in colony count (CFU/mL) from starting inoculum that is <103 CFU/mL, and 
bactericidal –  any decrease in colony count (CFU/mL) from starting inoculum that is 
≥103 CFU/mL. It is important to distinguish between describing antimicrobial activity as 
bactericidal (or bacteriostatic) overall (which implies ≥103 CFU/mL killing compared to 
starting inoculum that persisted up to 24 hours) and describing an antimicrobial as 
exhibiting bactericidal activity for a small window of time, which is a more detailed 
description of killing activity over time. 
Additionally, the interaction of the two antimicrobial agents can be described as 
synergistic – a ≥102 CFU/mL lower colony count of the combination at 24 hours 
compared to the more active agent (the agent with a lower colony count) alone, 
additive/indifferent – an absolute difference in colony count of < 102 CFU/mL between 
the combination and the more active agent alone, or antagonistic – a ≥102 CFU/mL 
higher colony count of the combination at 24 hours compared to the more active agent 
alone. In some cases, the interaction may not be determinable if one of the antimicrobial 
agents alone exhibits enough killing to be <104 CFU/mL at 24 hours because this is 
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within 102 CFU/mL (unable to determine synergy) of the lower limit of quantification 
(102 CFU/mL). A plot of log change in colony count from 0 to 24 hours facilitates 
evaluation of the interaction of meropenem and polymyxin B, which is described later. 
 
Antimicrobial Activity in KP 34 
Figure 4.1 describes KP 34 (MICs: MEM 4 µg/mL, PMB 0.125 µg/mL) and the 
activity of polymyxin B (0.25 and 1 µg/mL), meropenem (4 and 16 µg/mL), and their 
combination at clinically relevant concentrations. Specifically, both concentrations of 
polymyxin B exhibited bactericidal activity within 1 hour, but growth was observed by 4 
hours.  
Meropenem 4 µg/mL (1 x MIC) displayed bacteriostatic activity with growth 
observed by 8 hours. Meropenem 16 µg/mL (4 x MIC) displayed bactericidal activity 
within 2 hours, but growth was observed by 24 hours. Meropenem 64 µg/mL (16 x MIC) 
displayed bactericidal activity by 2 hours and maintained this activity throughout the 48 
hour time period of testing (Appendix D, D.1).  
All combinations tested were bactericidal by 2 hours and maintained this activity 
throughout the 48 hour time period of testing. 
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Figure 4.1: Time-kill curve against KP 34 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 34 (MICs: MEM 4 µg/mL, 
PMB 0.125 µg/mL). Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 2). 
The lower limit of quantification was 102 CFU/mL. 
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Antimicrobial Activity in KP 22 
Figure 4.2 describes KP 22 (MICs: MEM 16 µg/mL, PMB 0.06 µg/mL) and the 
activity of polymyxin B (0.25 and 1 µg/mL), meropenem (4, 16, and 64 µg/mL), and 
their combination at clinically relevant concentrations. Specifically, both concentrations 
of polymyxin B exhibited bactericidal activity within 1 hour, but growth was observed by 
8 hours instead of 4 hours as seen in KP 34.  
Meropenem 4 µg/mL (1/4 x MIC) displayed bacteriostatic activity with growth 
observed by 8 hours. Meropenem 16 µg/mL (1 x MIC) displayed bactericidal activity 
within 4 hours, but growth was observed by 8 hours. Meropenem 64 µg/mL (4 x MIC) 
displayed bactericidal activity by 2 hours and maintained this activity throughout the 48 
hour time period of testing.  
All combinations tested were bactericidal by 1 hour (compared to 2 hours 
observed in KP 34) and maintained this activity throughout the 48 hour time period of 
testing. 
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Figure 4.2: Time-kill curve against KP 22 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 22 (MICs: MEM 16 µg/mL, 
PMB 0.06 µg/mL). Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 2 to 3). 
The lower limit of quantification was 102 CFU/mL. 
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Antimicrobial Activity in KP 24 
Figure 4.3 describes KP 24 (MICs: MEM 32 µg/mL, PMB 0.125 µg/mL) and the 
activity of polymyxin B (0.25 and 1 µg/mL), meropenem (4, 16, and 64 µg/mL), and 
their combination at clinically relevant concentrations. Specifically, polymyxin B 0.25 
µg/mL (2 x MIC) exhibited bactericidal activity within 2 hours whereas polymyxin B 1 
µg/mL (8 x MIC) exhibited bactericidal activity within 1 hour, but growth was observed 
for both concentrations by 8 hours, more similar to KP 22 than KP 34.  
Meropenem 4 µg/mL (1/8 x MIC), 16 µg/mL (1/2 x MIC), and 64 µg/mL (2 x 
MIC) displayed bacteriostatic activity with growth observed by 8 hours.  
All combinations with meropenem concentrations ≥16 µg/mL (≥1/2 x MIC) were 
bactericidal by 1 hour and maintained this activity throughout the 48 hour time period of 
testing. However, both combinations with meropenem concentrations 4 µg/mL (1/8 x 
MIC) were bactericidal by 1 hour with growth observed by 8 hours.  
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Figure 4.3: Time-kill curve against KP24 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 24 (MICs: MEM 32 µg/mL, 
PMB 0.125 µg/mL). Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 2 to 
3). The lower limit of quantification was 102 CFU/mL. 
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Antimicrobial Activity in KP 44 
Figure 4.4 describes KP 44 (MICs: MEM 128 µg/mL, PMB 0.06 µg/mL) and the 
activity of polymyxin B (0.25, 1, and 4 µg/mL), meropenem (4, 16, and 64 µg/mL), and 
their combination at clinically relevant concentrations. Specifically, all concentrations of 
polymyxin B exhibited bactericidal activity within 1 hour, but growth was observed by 8 
hours for polymyxin B at 0.25 and 1 µg/mL (4 x MIC and 16 x MIC, respectively) and 24 
hours for polymyxin B 4 µg/mL (64 x MIC), more similar to KP 22 and KP 24 than KP 
34.  
Meropenem 4 µg/mL (1/32 x MIC) displayed no activity, with growth observed 
by 1 hour. Meropenem 16 µg/mL (1/8 x MIC) exhibited bacteriostatic activity with 
growth observed by 8 hours. Meropenem 64 µg/mL (1/2 x MIC) displayed bacteriostatic 
activity with growth observed by 24 hours.  
Combinations with polymyxin B concentrations ≥1 µg/mL (≥16 x MIC) were 
bactericidal by 1 hour whereas combinations with polymyxin B concentrations of 0.25 
µg/mL (4 x MIC) were bactericidal by 2 hours. Growth was observed by 8 hours for 
combinations with meropenem 4 µg/mL (1/32 x MIC) whereas growth was observed by 
24 hours for combinations with meropenem ≥16 µg/mL (≥1/8 x MIC). The only 
combination that maintained bactericidal activity throughout the 48 hour time period of 
testing was the combination with the highest concentrations of both antimicrobial agents 
– meropenem 64 µg/mL (1/2 x MIC) in combination with polymyxin B 4 µg/mL (64 x 
MIC).
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Figure 4.4: Time-kill curve against KP 44 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 44 (MICs: MEM 128 µg/mL, 
PMB 0.06 µg/mL). Data points are geometric means of replicate experiments (n = 2 to 4). The lower limit of quantification was 102 
CFU/mL. 
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Meropenem and Polymyxin B Interaction in KP 34 
 In addition to synergy, additivity/indifference, and antagonism, the definitions of 
growth, bacteriostatic, and bactericidal can be applied to further characterize the 
interaction of polymyxin B and meropenem at 24 hours. The activity of combinations 
with meropenem 4 µg/mL (1 x MIC) were all bactericidal and synergistic. Combinations 
with meropenem 16 µg/mL (4 x MIC) were all bactericidal, but the interaction was 
indeterminate because the activity of meropenem 16 µg/mL alone was too close to the 
lower limit of quantification to evaluate synergy among the corresponding combinations. 
Table 4.5 summarizes these results. Figure 4.5 describes the change in colony count from 
0 to 24 hours for each antimicrobial tested alone and in combination. 
 
Table 4.5: Meropenem and Polymyxin B Interaction for KP 34 
 
 Meropenem 4 (µg/mL) 
Meropenem 16 
(µg/mL) 
Meropenem 64 
(µg/mL) 
Polymyxin B 0.25 
(µg/mL) S / B I / B Not Tested 
Polymyxin B 1 
(µg/mL) S / B I / B Not Tested 
Polymyxin B 4 
(µg/mL) Not Tested Not Tested Not Tested 
B - Bactericidal 
I - Indeterminate 
S - Synergistic 
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Figure 4.5: 24 hour change in colony count against KP 34 
24 hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 34 (MICs: 
MEM 4 µg/mL, PMB 0.125 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2). 
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Meropenem and Polymyxin B Interaction in KP 22 
 The activity of combinations with meropenem 4 µg/mL and 16 µg/mL (1/4 x MIC 
and 1 x MIC, respectively) were all bactericidal and synergistic. Combinations with 
meropenem 64 µg/mL (4 x MIC) were all bactericidal, but the interaction was 
indeterminate because the activity of meropenem 64 µg/mL alone was too close to the 
lower limit of quantification to evaluate synergy among the corresponding combinations. 
Table 4.6 summarizes these results. Figure 4.6 describes the change in colony count from 
0 to 24 hours for each antimicrobial tested alone and in combination. 
 
Table 4.6: Meropenem and Polymyxin B Interaction for KP 22 
 
 Meropenem 4 
(µg/mL) 
Meropenem 16 
(µg/mL) 
Meropenem 64 
(µg/mL) 
Polymyxin B 0.25 
(µg/mL) S / B S / B I / B 
Polymyxin B 1 
(µg/mL) S / B S / B I / B 
Polymyxin B 4 
(µg/mL) Not Tested Not Tested Not Tested 
B - Bactericidal 
I - Indeterminate 
S - Synergistic 
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Figure 4.6: 24 hour change in colony count against KP 22 
24 hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 22 (MICs: 
MEM 16 µg/mL, PMB 0.06 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2 to 
3). 
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Meropenem and Polymyxin B Interaction in KP 24 
 The activity of combinations with meropenem 4 µg/mL (1/8 x MIC) were all 
additive/indifferent and growth was observed at 24 hours. In contrast, combinations with 
meropenem at 16 and 64 µg/mL (1/2 x MIC and 2 x MIC, respectively) were all 
bactericidal and synergistic. Table 4.7 summarizes these results. Figure 4.7 describes the 
change in colony count from 0 to 24 hours for each antimicrobial tested alone and in 
combination. 
 
Table 4.7: Meropenem and Polymyxin B Interaction for KP 24 
 
 Meropenem 4 (µg/mL) 
Meropenem 16 
(µg/mL) 
Meropenem 64 
(µg/mL) 
Polymyxin B 0.25 
(µg/mL) A / G S / B S / B 
Polymyxin B 1 
(µg/mL) A / G S / B S / B 
Polymyxin B 4 
(µg/mL) Not Tested Not Tested Not Tested 
A - Additive/Indifferent 
B - Bactericidal 
G - Growth 
S - Synergistic 
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Figure 4.7: 24 hour change in colony count against KP 24 
 24 hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 24 (MICs: 
MEM 32 µg/mL, PMB 0.125 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2 to 
3). 
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Meropenem and Polymyxin B Interaction in KP 44 
 The activity of meropenem 4 µg/mL (1/32 x MIC) in combination with 
polymyxin B at 0.25 or 1 µg/mL (2 x MIC and 8 x MIC, respectively) was 
additive/indifferent and growth was observed at 24 hours. However, meropenem 4 µg/mL 
in combination with polymyxin B 4 µg/mL (32 x MIC) was synergistic with 
bacteriostatic activity observed at 24 hours.  
The activity of meropenem 16 µg/mL (1/8 x MIC) in combination with 
polymyxin B 0.25 µg/mL was additive/indifferent whereas in combination with 
polymyxin B at 1 or 4 µg/mL was synergistic. However, at 24 hours, growth was 
observed for the lower two polymyxin B combinations and bacteriostatic activity was 
observed for the combination with polymyxin 4 µg/mL. 
 The activity of meropenem 64 µg/mL (1/2 x MIC) in combination with 
polymyxin B 0.25 was additive/indifferent with growth observed. The combination with 
polymyxin B 1 µg/mL was synergistic with bacteriostatic activity. The only combination 
to produce synergistic, bactericidal activity was meropenem 64 µg/mL in combination 
with polymyxin B 4 µg/mL. 
Table 4.8 summarizes these results. Figure 4.8 describes the change in colony 
count from 0 to 24 hours for each antimicrobial tested alone and in combination. 
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Table 4.8: Meropenem and Polymyxin B Interaction for KP 44 
 
 Meropenem 4 (µg/mL) Meropenem 16 (µg/mL) Meropenem 64 (µg/mL) 
Polymyxin B 0.25 
(µg/mL) A / G A / G A / G 
Polymyxin B 1 
(µg/mL) A / G S / G S / BS 
Polymyxin B 4 
(µg/mL) S / BS S / BS S / BC 
A - Additive/Indifferent 
BC - Bactericidal 
BS - Bacteriostatic 
G - Growth 
S - Synergistic 
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Figure 4.8: 24 hour change in colony count against KP 44 
24 hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 44 (MICs: 
MEM 128 µg/mL, PMB 0.06 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2 to 
4).
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Meropenem and Polymyxin B Alone Summary 
Meropenem alone, at all concentrations tested, achieved bactericidal activity 
(≥103 decrease in CFU/mL) within four hours for KP 34 (MEM MIC 4 µg/mL) and KP 
22 (MEM MIC 16 µg/mL). Regrowth in these strains was observed for the two lowest (4 
and 16 µg/mL) but not the highest (64 µg/mL) meropenem exposures (Figures 4.1 and 
4.2). In contrast, meropenem alone produced only bacteriostatic activity (< 103 decline in 
CFU/mL) in KP 24 (MEM MIC 32 µg/mL) and KP 44 (MEM MIC 128 µg/mL; Figures 
4.3 and 4.4). Regrowth for these two isolates began by 8 hours.  
Polymyxin B alone produced bactericidal activity at all concentrations tested 
against all strains within 2 hours, but regrowth occurred within 8 hours in all instances 
(Figures 4.1-4.4).  
 
Meropenem and Polymyxin B in Combination Summary 
The interaction of meropenem with polymyxin B in combination was 
characterized by synergism and 24-hour bactericidality as described in Chapter 3: 
Methods "Data Analysis". Both combinations of meropenem 4 µg/mL and polymyxin B 
(0.25 or 1 µg/mL) concentrations achieved synergistic activity (≥102 decrease in 
CFU/mL at 24 hours compared to the most active agent alone) against KP 34 (MEM MIC 
4 µg/mL; Figure 4.5), with no regrowth over 48 hours (Figure 4.1). Higher concentrations 
of meropenem alone (16 or 64 µg/mL) eradicated KP 34 and so synergism was 
indeterminate for these combinations.   
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All combinations of meropenem (4 or 16 µg/mL) and polymyxin B (0.25 or 1 
µg/mL) concentrations achieved synergistic activity against KP 22 (MEM MIC 16 
µg/mL; Figure 4.6) with no regrowth over 48 hours (Figure 4.2), but higher 
concentrations of meropenem alone (64 µg/mL) eradicated KP 22 which rendered 
synergism assessment indeterminate. 
Meropenem 4 µg/mL in combination with polymyxin B 0.25 or 1 µg/mL 
produced additive/indifferent activity (<102 change in CFU/mL at 24 hours compared to 
the most active agent alone) against KP 24 (MEM MIC 32 µg/mL; Figure 4.7) with 
regrowth occurring by 8 hours (Figure 4.3), but all remaining combinations of 
meropenem 16 or 64 µg/mL with polymyxin B 0.25 or 1 µg/mL achieved synergistic 
activity with no regrowth over 48 hours (Figures 4.3 and 4.7).  
Combinations of meropenem 4, 16, or 64 µg/mL with polymyxin B 0.25 µg/mL 
displayed additive/indifferent activity against KP 44 (MEM MIC 128 µg/mL; Figure 4.8) 
with variable regrowth (Figure 4.4). Combinations with polymyxin B at 1 or 4 µg/mL 
displayed synergy, but only the highest tested concentration of meropenem (64 µg/mL) 
and polymyxin B (4 µg/mL) also prevented regrowth against KP 44 (Figures 4.4 and 4.8). 
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Resistance Development to Polymyxin B 
Surviving or regrowing bacteria from time-kill studies often exhibit higher MICs 
to the antimicrobials to which they were exposed. This can be as a result of antimicrobial 
pressure which selects for resistant subpopulations or reveals adaptable or development 
of resistance.142 MICs were reevaluated for polymyxin B in all regrowing colonies for 
two time-kill studies through broth microdilution susceptibility testing because others 
have reported rapid resistance development, attributed mostly to the selection of 
subpopulations.139,142 
 For surviving colonies, the MIC to polymyxin B increased at least 256-fold (from 
0.06 - 0.125 µg/mL to 16 - >64 µg/mL) following exposure to polymyxin B alone in 
concentrations from 0.06 to 4 µg/mL (Table 4.6). This observation will eventually lead to 
characterization of any resistant subpopulations ("Subpopulation Analysis"). 
Table 4.9: MIC Testing of Isolates Following Exposure to Polymyxin B Alone 
 PMB 0.06 µg/mL 
PMB 0.125 
µg/mL 
PMB 0.25 
µg/mL 
PMB 1 
µg/mL 
PMB 2 
µg/mL 
PMB 4 
µg/mL 
KP 34 16 64 * * >64 >64 
KP 22 >64 0.125 64 >64 >64 >64 
KP 24 64 64 32 32 >64 >64 
KP 44 64 16 32 64 >64 >64 
*Concentration not tested in particular time-kill studies, but growing colonies previously 
observed 
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 Following exposure to meropenem alone, the polymyxin B MIC of surviving 
colonies remained in essential agreement (within one two-fold dilution) with the 
originally measured MIC of the corresponding isolate (0.06 µg/mL for KP 22 and KP 44 
and 0.125 µg/mL for KP 34 and 24). This was expected given there was no antimicrobial 
pressure for selection of subpopulations resistant to polymyxin B. However, if there was 
cross-resistance or some other dependency relationship between meropenem and 
polymyxin B resistance, we may have seen a change. It appears that cross-resistance may 
not be significant enough to impact the MIC values of polymyxin B (Table 4.7). 
 
Table 4.10: MIC Testing of Isolates Following Exposure to Meropenem Alone 
 MEM 4 µg/mL MEM 16 µg/mL MEM 64 µg/mL 
KP 34 * * § 
KP 22 0.06 0.06 § 
KP 24 ≤0.03 0.125 0.06 
KP 44 0.06 0.06 0.06 
*Concentration not tested in particular time-kill studies, but growing colonies previously 
observed 
§No growth of colonies during time-kill studies 
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 Surviving colonies of meropenem and polymyxin B in combination were also 
evaluated for change in polymyxin B MIC. Results were similar to exposure to 
polymyxin B alone (≥256-fold increase in MIC) suggesting that polymyxin B-resistant 
subpopulations may be a correlating factor with treatment outcomes (Table 4.8). 
 
Table 4.11: MIC Testing of Isolates Following Exposure to Combination   
 
MEM/PMB 
4/0.25 
µg/mL 
MEM/PMB 
4/1  
µg/mL 
MEM/PMB 
16/0.25 
µg/mL 
MEM/PMB 
16/1  
µg/mL 
MEM/PMB 
64/0.25 
µg/mL 
MEM/PMB 
64/1  
µg/mL 
KP 34 § § § § § § 
KP 22 § § § § § § 
KP 24 32 32 § § § § 
KP 44 16 16 16 64 16 16 
§No growth of colonies during time-kill studies 
 
In summary, the polymyxin B MICs of isolates exposed to polymyxin B alone or 
in combination with meropenem generally increased from 0.06 or 0.125 µg/mL at 
baseline to ≥16 µg/mL in all experiments where regrowth occurred. In contrast, the 
polymyxin B MICs for regrowing bacteria exposed only to meropenem remained at 0.06 
or 0.125 µg/mL (Tables 4.6-4.8). 
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Subpopulation analysis 
In order to assess for the presence of subpopulations with increased MIC values 
relative to the overall population, growing bacteria were cultured onto an agar plate 
impregnated with antimicrobials which would inhibit the growth of all colonies with 
MICs less than or equal to the antimicrobial concentration of the agar. Growing colonies 
were counted and then related to the overall population as described in Chapter 3: 
Methods "Subpopulation Analysis and Microfiltration". Table 4.9 summarizes the results 
of the subpopulation time-kill study. The lower limit of quantification for microfiltration 
was estimated to be 30 CFU/mL when 1000 µL samples were used, but the limitation of 
larger error was accepted to report measurements below this so as to better compare 
values between isolates.243,244 
 
Table 4.12: Hetero-resistant Subpopulations of Klebsiella pneumoniae Isolates 
 KP 34 KP 22 KP 24 KP 44 
MEM MIC > 16 7.2 CFU/mL 31.6 CFU/mL - - 
MEM MIC > 64 - - 6.7 CFU/mL 5.3 x 103 CFU/mL 
PMB MIC > 4 <1 CFU/mL 2 CFU/mL <1 CFU/mL 2.4 CFU/mL 
All reported values are proportionally corrected to a 106 CFU/mL overall population 
 
 
 For the isolates with meropenem MICs of 4 and 16 µg/mL, subpopulations with 
MICs > 16 µg/mL were 7 x 100 and 3 x 101 CFU/mL, respectively. For the isolates with 
meropenem MICs of 32 and 128 µg/mL, subpopulations with MICs > 64 µg/mL were 7 x 
100 and 5 x 103 CFU/mL, respectively. Surprisingly, for all isolates, subpopulations with 
polymyxin B MICs > 4 µg/mL were almost non-detectable at < 3 CFU/mL. 
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CEFTAZIDIME-AVIBACTAM DISK DIFFUSION AND MBL ETEST® 
 Ceftazidime/Avibactam is a recently approved antimicrobial for the treatment of 
CRE in the absence of MBL-production. In order to contribute to the growing knowledge 
of this novel antimicrobial agent, we evaluated the susceptibility of all CRE that we had 
collected to date (75 out of 164 isolates). 
Metallo-β-lactamase (MBL)-production information from the University of 
Kentucky Clinical Microbiology Laboratory was available for four of the 75 isolates 
tested (isolates 26, 40, 41, and 42). Since metallo β-lactamases are not inhibited by 
avibactam, it was expected that these isolates would be resistant to 
ceftazidime/avibactam, but only three of four were resistant, verified by duplicate 
experiments. 
Excluding the four known MBL-producers, six isolates met criteria for MBL 
testing. Three isolates were borderline susceptible to ceftazidime/avibactam with a zone 
of inhibition of 21 mm (isolate 21, KP 24, and isolate 29), two isolates were resistant 
(isolates 53 and 134 with zones 17 mm and 15 mm, respectively) and one isolate was 
intermediate (KP 22; zone 20 mm). In a duplicate experiments, only the isolate testing as 
intermediate changed in interpretation with the second test and the third test being 
susceptible (23 mm and 24 mm respectively; Table 4.10). The designation of KP for two 
of the isolates is to indicate that isolate 22 and 24 are the same Klebsiella pneumoniae 
isolates that were tested in the time-kill studies.  
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Table 4.13: Ceftazidime / Avibactam Kirby Bauer Disk Diffusion Results 
Organism Isolate Number 
Ceftazidime / 
Avibactam Zone 
of Inhibition 
(mm) 
Interpretation 
(S/I/R) 
Citrobacter amalonaticus 36 24 S 
Citrobacter amalonaticus 91 25 S 
Citrobacter freundii 27 29 S 
Citrobacter freundii 50 22 S 
Citrobacter freundii 54 30 S 
Citrobacter freundii 101 27 S 
Citrobacter freundii 127 27 S 
Citrobacter freundii 145 31 S 
Citrobacter freundii 147 30 S 
Citrobacter youngae 136 26 S 
Enterobacter  aerogenes 97 30 S 
Enterobacter cloacae 9 27 S 
Enterobacter cloacae 10 28 S 
Enterobacter cloacae 16 27 S 
Enterobacter cloacae 17 27 S 
Enterobacter cloacae 19 29 S 
Enterobacter cloacae 20 27 S 
Enterobacter cloacae 30 25 S 
Enterobacter cloacae 39 27 S 
Enterobacter cloacae* 40 17, 16 R 
Enterobacter cloacae* 41 18, 17 R 
Enterobacter cloacae 52 27 S 
Enterobacter cloacae§ 53 17, 18 R 
Enterobacter cloacae 70 29 S 
Enterobacter cloacae 96 26 S 
Enterobacter cloacae 107 24 S 
Enterobacter cloacae 121 25 S 
Enterobacter cloacae 126 28 S 
Enterobacter cloacae§ 134 15, 14 R 
Enterobacter cloacae 144 27 S 
Escherichia coli 25 30 S 
Escherichia coli 33 25 S 
Escherichia coli 103 25 S 
Enterobacter gergoviae 13 28 S 
Enterobacter gergoviae 95 32 S 
Enterobacter spp. 146 25 S 
Klebsiella oxytoca 8 35 S 
Klebsiella oxytoca 14 29 S 
Klebsiella ozaenae 128 28 S 
Klebsiella pneumoniae 7 32 S 
Klebsiella pneumoniae§ 21 21, 21 S 
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Klebsiella pneumoniae§ KP 22 20, 23, 24 S 
Klebsiella pneumoniae§ KP 24 21, 27 S 
Klebsiella pneumoniae* 26 27, 26 S 
Klebsiella pneumoniae 28 22 S 
Klebsiella pneumoniae§ 29 21, 21 S 
Klebsiella pneumoniae 31 31 S 
Klebsiella pneumoniae 32 33 S 
Klebsiella pneumoniae KP 34 28 S 
Klebsiella pneumoniae 35 29 S 
Klebsiella pneumoniae 37 26 S 
Klebsiella pneumoniae* 42 14, 14 R 
Klebsiella pneumoniae 43 25 S 
Klebsiella pneumoniae KP 44 24 S 
Klebsiella pneumoniae 45 24 S 
Klebsiella pneumoniae 46 27 S 
Klebsiella pneumoniae 47 27 S 
Klebsiella pneumoniae 48 25 S 
Klebsiella pneumoniae 49 27 S 
Klebsiella pneumoniae 51 25 S 
Klebsiella pneumoniae 55 23 S 
Klebsiella pneumoniae 69 25 S 
Klebsiella pneumoniae 77 30 S 
Klebsiella pneumoniae 93 27 S 
Klebsiella pneumoniae 98 23 S 
Klebsiella pneumoniae 99 25 S 
Klebsiella pneumoniae 105 27 S 
Klebsiella pneumoniae 116 27 S 
Klebsiella pneumoniae 119 25 S 
Klebsiella pneumoniae 123 28 S 
Klebsiella pneumoniae 129 23 S 
Klebsiella pneumoniae 130 27 S 
Klebsiella pneumoniae 142 26 S 
Klebsiella pneumoniae 143 24 S 
Klebsiella pneumoniae 152 25 S 
TOTAL 75 
 
93% S 
*MBL identified by PCR at University of Kentucky Clinical Microbiology Laboratory 
§MBL identified by Etest® 
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MBL-production was identified in all but one isolate tested (KP 24 was 
indeterminate twice). MBL-production was identified in two borderline susceptible 
isolates (21 and 29), the initially intermediate isolate (KP 22), and both resistant isolates 
(53 and 134; Table 4.11). KP 24 was indeterminate upon initial testing because the 
resulting MIC ratio was ≥ 4 without a phantom zone or an ellipse deformation (Chapter 
3: Methods "Etest® Procedure"). Isolate 21 was borderline negative after initial MBL 
testing, but tested positive upon retest. All other isolates were interpreted as positive for 
both tests (Table 4.11). 
 
Table 4.14: MBL MP/MPI Etest® Results 
Isolate MP/MPI MIC (µg/mL) Interpretation 
MP/MPI MIC 
(µg/mL) Interpretation 
21 0.5 / 0.064 Negative 1.5 / 0.094 Positive 
22 > 8 / ≤ 0.032 Positive 3 / 0.032 Positive 
24 > 8 /  > 2 Indeterminate > 8 /  > 2 Indeterminate 
29 > 8 / ≤ 0.032 Positive > 8 / ≤ 0.032 Positive 
53 > 8 /  ≤ 0.032 Positive > 8 / ≤ 0.032 Positive 
134 4 / ≤ 0.032 Positive 2 / ≤ 0.032 Positive 
Negative 
Control 
≤ 0.0125 /  
≤ 0.032 Negative 
≤ 0.0125 /  
≤ 0.032 Negative 
Positive 
Control 1.5 / ≤ 0.032 Positive 1.5 / ≤ 0.032 Positive 
Positive Control - Isolate 42 (Confirmed MBL by PCR) 
Negative Control - Klebsiella pneumoniae ATCC® 700603 
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Overall, five of the 75 CRE isolates were resistant to ceftazidime/avibactam (93% 
susceptibility across all CRE tested), and all five are associated with MBL-production. 
All four of the MBL-producing E. cloacae isolates (40, 41, 53, and 134) were resistant to 
ceftazidime/avibactam whereas one isolate (42) of the four MBL-producing K. 
pneumoniae isolates (21, 22, 29, and 42) were resistant to ceftazidime/avibactam. 
Divided by phenotypic (determined by Etest®) compared to genotypic MBL-production 
(determined by PCR from the University of Kentucky Clinical Microbiology 
Laboratory), two of five phenotypic MBL-producing isolates were resistant to 
ceftazidime/avibactam whereas three of four genotypic MBL-producing isolates were 
resistant to ceftazidime/avibactam. 
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Chapter Five: 
 
Discussion and Conclusions 
  
Carbapenem-resistant Enterobacteriaceae (CRE) are a growing national and 
international threat.39,97,98,123-126 In fact, a "Call to Action" has been issues by various 
organizations (e.g. CDC, PACCARB, IDSA) hoping to raise awareness among the 
medical community as well as highlight the dwindling development of novel 
antimicrobial agents showing activity against these hard-to-treat infections.12 
Compounding this issue is the wide variability in types of carbapenem resistance among 
CRE (e.g. KPC, MBL, OXA-48, and ESBL or AmpC with porin mutations) and the large 
differences observed among nations or even among hospitals within the same country, 
state, or province.14 There are no randomized, controlled clinical trials evaluating optimal 
therapy for CRE treatment, and treatment strategies may vary depending on the type of 
resistance. It has also been suggested that strain-to-strain differences or bacteria genotype 
may be more important to optimal therapeutic decision-making than MIC or 
pharmacodynamic indices alone.227 
In order to contribute to the growing knowledge of CRE management, this study 
focused on KPC-producing Klebsiella pneumoniae, the most common CRE in the U.S., 
estimated to comprise up to 80% of CRE cases in some regions.14 More specifically, we 
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evaluated the use of polymyxin B in combination with meropenem because, among the 
four "typically susceptible" antimicrobial agents, fosfomycin is only approved in the U.S. 
for uncomplicated urinary tract infections,177 tigecycline is unable to reach effective 
serum concentrations for treatment of CRE bacteremia167,247 where mortality is estimated 
to be around 50%,11 and colistin is associated with higher rates of nephrotoxicity, 
cumbersome therapeutic drug monitoring, and more difficult rational drug dosing when 
compared to polymyxin B.132,133,147 All of these agents are associated with rapid 
resistance development when used as monotherapy,14 and previous data have indicated 
that combination therapy, in particular combinations including a carbapenem, have a 
mortality benefit over monotherapy.10,68,184,198-202 
This study is among the first to evaluate the in vitro interaction of polymyxin B in 
and meropenem across a wide range of carbapenem resistance, testing multiple 
concentrations and for a longer duration (48 hours) than previous studies which have 
typically evaluated combinations involving colistin.200,204,205,248-250 Meropenem and 
polymyxin B alone and in combination were evaluated against a total of four KPC-
producing K. pneumoniae clinical isolates, representing polymyxin-susceptible (PMB 
MIC  < 2 µg/mL) CRE of varying meropenem resistance (MEM MIC 4 – 128 µg/mL). 
These isolates were evaluated using CLSI-standardized in vitro laboratory 
methodology,237 designed and approved to minimize variability between laboratories to 
facilitate more meaningful comparisons of results. 
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IN VITRO SUSCEPTIBILITY TESTING 
 The antimicrobial susceptibility summaries of KPC-producing Klebsiella 
pneumoniae isolates from the University of Kentucky Clinical Microbiological 
Laboratory (using BD Phoenix™ and broth microdilution) were compared against a 
similar report from isolates submitted to the SENTRY Antimicrobial Surveillance 
Program or the MYSTIC Program recovered from primarily U.S. medical institutions.251 
Chi-squared analysis was used to identify antimicrobial agents for which differences 
existed among U.S. isolates, University of Kentucky isolates tested by BD Phoenix™ and 
UK isolates tested by broth microdilution (Table 5.1). Significant differences between 
groups were identified after a Holm-Bonferroni correction.246 Only one antimicrobial 
agent (amikacin) in the table below was not tested for in the SENTRY/MYSTIC isolates. 
Instead, a study evaluating 50 carbapenem-resistant K. pneumoniae isolates from the 
Pittsburg area was referenced which reported comparable gentamicin and tobramycin 
susceptibilies.194 
 
Table 5.1: Antimicrobial Susceptibility Summary of CR-KP in the U.S. 
Antimicrobial U.S.
251 
(n=123) 
BD Phoenix™ 
(n=44) 
Microdilution 
(n=24)* P-value 
Cefepime     
MIC50 (µg/mL) >16 16 32  
MIC90 (µg/mL) >16 >16 >256  
%S 11% 28%§ 17% 0.0376 
Ceftazidime     
MIC50 (µg/mL) >16 >16 -  
MIC90 (µg/mL) >16 >16 -  
%S 3% 0% - 0.2312 
Ceftriaxone     
MIC50 (µg/mL) >32 >32 -  
MIC90 (µg/mL) >32 >32 -  
%S 2% 2% - 0.7955 
Meropenem     
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MIC50 (µg/mL) >8 8 16  
MIC90 (µg/mL) >8 >8 128  
%S 1% 30%§ 25%§ <0.0001 
Piperacillin/Tazobactam     
MIC50 (µg/mL) >64/4 >64/4 0.25/4  
MIC90 (µg/mL) >64/4 >64/4 >512/4  
%S 3% 2% 50%§ <0.0001 
Amikacin (n=50)194     
MIC50 (µg/mL) 16 ≤8 4  
MIC90 (µg/mL) 32 >32 128  
%S 84% 75% 67% 0.2300 
Gentamicin     
MIC50 (µg/mL) ≤4 >8 -  
MIC90 (µg/mL) >8 >8 -  
%S 61% 46% - 0.0756 
Tobramycin     
MIC50 (µg/mL) >8 >8 -  
MIC90 (µg/mL) >8 >8 -  
%S 6% 25% - 0.0004 
Ciprofloxacin     
MIC50 (µg/mL) >2 >2 -  
MIC90 (µg/mL) >2 >2 -  
%S 11% 34% - 0.0004 
Levofloxacin     
MIC50 (µg/mL) >4 >4 8  
MIC90 (µg/mL) >4 >4 >32  
%S 12% 36%§ 29% 0.0013 
Polymyxin B     
MIC50 (µg/mL) ≤1 - 0.125  
MIC90 (µg/mL) >4 - 8  
%S 89% - 83% 0.3909 
Tigecycline     
MIC50 (µg/mL) 0.5 - 0.125  
MIC90 (µg/mL) 2 - 4  
%S 99% - 88% 0.0018 
* For piperacillin/tazobactam in broth microdilution studies, n=12 and there was only one 
experiment performed in duplicate 
§ Significant Holm-Bonferroni corrected p-value compared to U.S. isolates from literature 
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 Compared to national data, susceptibilities to fluoroquinolones and tobramycin 
were significantly higher at the University of Kentucky (about 30% vs. 10% nationally) 
whereas tigecycline susceptibilities were significantly lower (88% vs. 99%; P = 0.0018). 
Interestingly, susceptibilities to cefepime and meropenem were also significantly higher 
at the University of Kentucky, despite similar carbapenemase production. Wide 
variability in susceptibility patterns has been reported by others, even at the regional level 
between acute care centers.14 Since lower carbapenem MICs are associated with lower 
mortality,120 combinations with antimicrobials associated with less toxicity may be 
equally effective but have improved safety profiles. Specifically, combinations with a 
carbapenem and an agent other than a polymyxin may be worth investigating for use at 
the University of Kentucky. For example, in a setting of higher fluoroquinolone or 
aminoglycoside susceptibility, a susceptible agent in combination with a carbapenem 
may show improved morbidity or mortality not solely due to clinical cure of the infection 
but also avoidance of the limiting toxicities associated with the polymyxins 
(nephrotoxicity or neurotoxicity) or tigecycline (severe nausea, vomiting, diarrhea). 
Additionally, with the exception of piperacillin/tazobactam, susceptibilities 
reported by BD Phoenix™ for antimicrobial agents were consistently higher than those 
reported by broth microdilution, however none of these differences were significant. 
Concerning the difference in piperacillin/tazobactam observed between broth 
microdilution, BD Phoenix™, and national data, a number of possible explanations exist. 
Broth microdilution was performed once (in duplicate) on only 12 isolates where such a 
small sample size could have led to selection bias. An alternative hypothesis is that an 
error occurred in the selection of the piperacillin/tazobactam program in Chapter 3: 
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Methods "Broth Microdilution Procedure". If the tazobactam laying program were run 
instead of serially diluting piperacillin across the 96-well tray, then this would explain the 
polar interpretation of either >512/4 or ≤0.25/4 (all growth in wells vs. no growth 
observed at all) since all wells would have actually contained roughly 
piperacillin/tazobactam 400/3.2 µg/mL in 125 µL (Appendix C, Table C.1). The way to 
confirm this would be to retest these isolates. Finally, similar to national data, we 
observed relatively high susceptibilities among clinical isolates of KPC-producing CRE 
to polymyxin B, tigecycline, colistin, and fosfomycin. 
In order to characterize the in vitro interaction of polymyxin B and meropenem, 
we selected four KPC-3-producing, polymyxin-susceptible, carbapenem-resistant, 
Klebsiella pneumoniae isolates to represent the spectrum of carbapenem resistance most 
commonly encountered Enterobacteriaceae in the United States. The subtype of the KPC 
enzyme was previously evaluated by PCR at the University of Kentucky Clinical 
Microbiology Laboratory for clinical use but the information was released to us for 
research purposes. Table 4.4 displays the MIC data from broth microdilution 
susceptibility testing for each of the four clinical isolates (KP 34, KP 22, KP 24, and KP 
44) and Appendix A, Tables A.1 - A.2 display the MIC data from BD Phoenix™ 
susceptibility testing for these isolates. For most isolates tested, polymyxin susceptibility 
was most frequently observed at polymyxin B/colistin MICs of 0.06 - 0.125 µg/mL 
whereas meropenem resistance ranged from 4 µg/mL - 128 µg/mL. The four isolates 
selected for time-kill studies had MICs within the previously mentioned ranges (Table 
4.4). 
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IN VITRO ACTIVITY OF MEROPENEM AND POLYMYXIN IN TIME-KILL 
STUDIES 
 Polymyxin B alone against polymyxin-susceptible, KPC-producing Klebsiella 
pneumoniae generally exhibited quick bactericidal activity, with rapid regrowth observed 
whereas meropenem alone generally exhibited bacteriostatic activity initially with growth 
observed as well. These results are consistent with in vitro data from other groups.210,252 
When used in combination, results were often bactericidal, synergistic, and maintained 
this activity throughout 48 hours unless resistance to meropenem was high (≥32 µg/mL) 
in which case higher levels of antimicrobial agents were shown to overcome the strains 
with elevated MICs, but such regimens may have limited feasibility in a patient where 
antimicrobial concentrations are not static but change as drug is eliminated. Therefore, 
additional in vitro or animal (or even human) models are needed to elucidate the impact 
of pharmacokinetics and the degree of meropenem resistance on the activity of 
meropenem and polymyxin B in combination against KPC-producing K. pneumoniae. 
 A 2013 meta-analysis on in vitro synergy of polymyxins and carbapenems 
highlighted that most data for comparison involves non-Enterobacteriaceae such as 
Pseudomonas aeruginosa or Acinetobacter baumannii. In fact, the authors included only 
three studies204,248,253 that evaluated polymyxin B in combination with a carbapenem 
(imipenem, doripenem, meropenem, or ertapenem) across a total of 34 unique isolates of 
K. pneumoniae, most of which were polymyxin-susceptible. Synergy rates for polymyxin 
B and a carbapenem were higher than synergy rates for colistin and a carbapenem (64% 
vs. 40%; P = 0.04), but substantial heterogeneity among these studies was present (I2 = 
51%).210 Since the publication of the meta-analysis, only one other study has compared 
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polymyxin B in combination with a carbapenem in vitro against KPC-producing 
Klebsiella pneumoniae.252 
 Among the four studies evaluating the in vitro activity of polymyxin B in 
combination with a carbapenem against KPC-producing K. pneumoniae, two evaluated 
exclusively KPC-2-producing K. pneumoniae (18 isolates total),204,252 one evaluated 
exclusively KPC-3-producing K. pneumoniae (4 isolates),253 and the last evaluated both 
KPC-2- and KPC-3-producing K. pneumoniae (8 and 6 isolates, respectively). Our study 
evaluated KPC-3-producing K. pneumoniae (4 isolates). Although KPC-2 is considered 
the ancestral enzyme, KPC-3 has also been frequently observed in the United States. 
KPC-3 is very similar to KPC-2 in both structure and phenotypic resistance expression, 
differing only by a single nucleotide polymorphism and therefore also a single amino 
acid substitution of histidine for tyrosine (H272Y).254 To date, there is no data to suggest 
distinguishing between KPC-2 or KPC-3 correlates with differences in phenotypic 
resistance or clinical outcome, and so this difference among studies was accepted. 
Finally, definitions of synergy and bactericidality among studies was consistent except 
when noted. 
 
Polymyxin B or a Carbapenem Alone 
Comparing results of monotherapy was not possible among all studies because 
complete time-kill data was only provided by Lee et al.253 Data for 0 hours and 24 hours 
was provided by Bratu et al.,204 but the other studies only provided the difference from 0 
hours to 24 hours.248,252 Lee et al. studied the four KPC-3 isolates most similar to this 
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study, exhibiting polymyxin B MICs ranging from 0.125 - 0.25 µg/mL (this study: MICs 
0.06 - 0.125 µg/mL) and doripenem (DOR) MICs ranging from 16 - 32 µg/mL (this 
study: MEM MICs 4 - 128 µg/mL). Polymyxin B at 2 x MIC displayed similar killing to 
the present study, but we observed regrowth sooner (4 hours) than did Lee et al. (8 
hours), despite our use of higher concentrations relative to the MIC (Figure 5.1 vs. 
Figures 4.1-4.4). Concerning carbapenem therapy, the bacteriostatic activity and growth 
observed with doripenem used alone (Figure 5.1) was similar to the present study, despite 
our use of meropenem instead.253 
 
 
Figure 5.1: Time-kill curves for four KPC-3-producing K. pneumoniae. Reprinted253 
Abbreviations: Dor - Doripenem, Col - Colistin, PolyB - Polymyxin B 
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 Comparing the data provided by Bratu et al., polymyxin B alone at 0.5, 1, 2, and 4 
µg/mL remained bactericidal at 24 hours for 2, 7, 12, and 13 isolates, respectively, out of 
16 total.  Interestingly, isolates from this study had at least 4-fold lower polymyxin B 
MICs than those studied by Bratu et al. (0.06 - 0.125 µg/mL vs. 0.5 - 16 µg/mL), but we, 
in contrast, observed regrowth in all polymyxin B concentrations tested alone before 24 
hours. Comparing carbapenem therapy, imipenem (IPM) 4 µg/mL alone displayed 
growth in all 16 isolates. For the present study, the three isolates most similar to those 
evaluated by Bratu et al. (IPM MICs 8 - >32) were KP 22 (MEM MIC 16 µg/mL), KP 24 
(MEM MIC 32 µg/mL), and KP 44 (MEM MIC 128 µg/mL). Like Bratu et al., 
meropenem alone showed growth at 4 and 16 µg/mL.204 
 
Polymyxin B and a Carbapenem in Combination 
 Lee et al. evaluated colistin or polymyxin B at 2 x MIC in combination with 
doripenem 6 µg/mL against four polymyxin-susceptible, KPC-3-producing Klebsiella 
pneumoniae (DOR MIC 16 - 32 µg/mL). Bactericidal, synergistic activity was observed 
throughout 24 hours for all isolates with some regrowth observed only at 48 hours for 1 
of 4 isolates with polymyxin B and 2 of 4 with colistin.253 Polymyxin B and meropenem 
showed similar activity against KP 22 and KP 24 (MEM MICs 16 and 32 µg/mL, 
respectively) in the present study at comparable concentrations (MEM 4 µg/mL and 16 
µg/mL). One notable difference compared to our study was that meropenem 4 µg/mL in 
combination with polymyxin B at 0.25 or 1 µg/mL (2 and 8 x MIC, respectively) did not 
maintain bactericidal or synergistic activity by 24 hours against KP 24. However, 
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meropenem concentrations ≥1 x MIC in combination with polymyxin B did regain 
bactericidal and synergistic interaction. The difference between meropenem and 
doripenem in combination with polymyxin B cannot be explained with good evidence, 
but clinically, others have observed equivalent efficacy of doripenem compared to other 
carbapenems when being used in lower doses but at extended infusions.255 
 Pankey et al. evaluated polymyxin B at 1/4, 1/2, and 1 x MIC in combination with 
meropenem 1 x MIC against 14 KPC-producing Klebsiella pneumoniae (MER MIC 16 - 
>32 µg/mL, PMB MIC ≤2 for 11 of 14 isolates). Synergy was observed for 9 of 14 
isolates for all concentrations tested with meropenem and polymyxin B. Non-synergistic 
isolates showed indifferent/additive activity, but only 1 of 5 was resistant to polymyxin B 
(PMB MIC 32 µg/mL) before study. The authors did not comment on the killing activity 
(bactericidal vs. bacteriostatic) of meropenem and polymyxin B in combination against 
these isolates. Compared to the present study, we observed a loss of synergistic activity 
between meropenem and polymyxin B related to increasing meropenem MIC. A similar 
assessment is difficult to make in the study by Pankey et al. because detection of synergy 
did not depend on meropenem MIC, but a much smaller range of carbapenem resistance 
was evaluated (MEM MIC 16 - >32 µg/mL). Similarly, carbapenem MIC did not change 
the observation of synergy in the study by Lee et al., but again, a smaller range (16 - 32 
µg/mL) of carbapenem MIC was evaluated whereas we evaluated MEM MICs 4 - 128 
µg/mL.248 
 Bratu et al. evaluated polymyxin B at 1 µg/mL and 1/2 x MIC in combination 
with imipenem 4 µg/mL against 16 KPC-2-producing Klebsiella pneumoniae that were 
mostly polymyxin-susceptible (14 of 16 isolates). Imipenem MICs were all >32 µg/mL 
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except for one isolate which had an imipenem MIC of 8 µg/mL. Data were unavailable 
for each isolate tested individually, but synergy was reported for 10 of 16 isolates with 
polymyxin B at 0.5 x MIC in combination with imipenem. Interestingly, antagonism was 
observed in 3 of 16 isolates. Although antagonism was not observed with polymyxin B 
and meropenem in the present study, the antagonism reported by Bratu et al. is consistent 
with our observed loss or reduction of synergy as the carbapenem MIC increases. It is 
important to note that a majority of isolates evaluated by Bratu et al. had imipenem MICs 
> 32 µg/mL while we observed loss of synergy at lower concentrations of meropenem (4 
µg/mL) when meropenem MICs were at least 32 µg/mL. It is also interesting that 
synergy was still observed in a majority of highly carbapenem-resistant isolates (10 of 16 
isolates) at polymyxin B concentrations close to 1 µg/mL in combination with imipenem 
4 µg/mL when the present study required meropenem concentrations ≥ 16 µg/mL in 
combination with polymyxin B 1 µg/mL to maintain synergy.204 
 In the most recently published study, Barth et al. evaluated polymyxin B at 0.5, 1, 
and 2 µg/mL in combination with meropenem or imipenem at 4 µg/mL against two KPC-
2-producing Klebsiella pneumoniae. Both isolates had a polymyxin B MIC of 2 µg/mL 
and a meropenem MIC of 32 µg/mL, but had different imipenem MICs of 8 and 32 
µg/mL. Synergy was observed in both strains at all combinations studied which is in 
contrast to this study where polymyxin B at 0.5 and 1 µg/mL in combination with 
meropenem 4 µg/mL was not synergistic for KP 24, despite having a lower polymyxin B 
MIC (MEM MIC 32 µg/mL, PMB MIC 0.125 µg/mL). Although not as directly 
comparable, but interesting, Barth et al. also evaluated two strains each of Escherichia 
coli and Serratia marcescens for which synergy was also found in all the same 
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concentrations of polymyxin B in combination with either meropenem or imipenem. This 
result was most surprising for S. marcescens which is intrinsically resistant to 
polymyxins. The E. coli strains had meropenem MICs of 64 µg/mL whereas the S. 
marcescens strains had meropenem MICs of 128 and 256 µg/mL. The polymyxin B 
MICs for E. coli were 2 µg/mL whereas the S. marcescens stains had polymyxin B MICs 
of 64 and >64 µg/mL. The author did characterize the killing of these antimicrobial 
agents against the strains, however their definition of bactericidality was different from 
most studies, including the present one. The authors assessed bactericidal activity based 
on a 103 CFU/mL difference between the colony count of the combination and the colony 
count of the most active agent alone, which, while appropriate for synergy, could actually 
mean that growth (as defined in this and most studies) occurred but to a lesser extent than 
the most active agent. Since only this difference was reported, it is not possible to 
compare the killing activity in the experiments by Barth et al. to the killing activity 
observed in this study.252 
 Overall, other studies evaluating polymyxin B in combination with a carbapenem 
by time-kill assay observed bactericidal activity and synergistic interaction maintained 
throughout 24 hours most of the time204,248,252,253 which is in agreement with our findings. 
Antagonism was rarely observed, and it was only seen in a minority of isolates with high 
carbapenem MICs (IPM MICs > 32)204 which is also similar to our findings because a 
lower extent of synergy was also observed in this study when carbapenem MICs were 
elevated (MEM MICs ≥ 32 µg/mL). A carbapenem alone exhibited similar activity in this 
study as compared to the Lee et al.253 and Bratu et al.204 Polymyxin B alone exhibited 
variable activity depending on the study. Our results were more similar to Lee et al. 
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where growth was consistently observed, but at a slower rate.253 In contrast, Bratu et al. 
observed growth in only a fraction of the isolates, depending on the concentration of 
polymyxin B. This might best be explained by variable heteroresistant subpopulations 
among KPC-producing K. pneumoniae isolates,142 however this has not been well 
characterized and was not discussed by Bratu et al.204 
 
Heteroresistant Subpopulations 
 KP 34, 22, 24, and 44 underwent preliminary characterization of the meropenem 
and polymyxin B MICs of any heteroresistant subpopulations. Table 4.9 displays the 
exact colony counts with respect to a 106 CFU/mL total population concentration. For a 
more complete subpopulation analysis, studies with higher inocula would provide higher 
sensitivity but would reduce the internal validity of comparing observations from the 
subpopulation study to our time-kill results, which was the primary purpose. The most 
interesting result was observing subpopulations with MICs at least 32 x the MIC of the 
total population (e.g. a strain with a population MIC of 0.125 µg/mL growing on an agar 
plate with 4 µg/mL polymyxin B). Better characterization of these heteroresistance 
isolates may elucidate the cause of regrowth observed throughout our experiments when 
polymyxin B was used alone or when combination therapy failed to prevent regrowth. 
 Other studies have also described polymyxin heteroresistance.142 Among the four 
studies recently discussed, only Lee et al. reported post-exposure susceptibility testing on 
their regrowing isolates from time-kill studies. Similar to the present study, Lee et al. 
observed an increase in colistin or polymyxin B MIC from 0.125 - 0.25 µg/mL to 8 - 128 
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µg/mL whereas we observed changes from 0.06 - 0.125 µg/mL to 16 - >64 µg/mL. Lee et 
al. also observed no change in doripenem MICs following polymyxin exposure whereas 
we did not look at change in meropenem MICs. However, we observed no change in 
polymyxin MICs following meropenem exposure, suggesting insignificant (if any) cross-
resistance between these antimicrobial classes. However, both studies observed 
polymyxin B and colistin MICs correlating very strongly together.253 
 Meletis et al. performed more thorough subpopulation studies on 16 
carbapenemase-producing K. pneumoniae clinical isolates. In that study, subpopulations 
growing on agar plates impregnated with up to 8 µg/mL colistin had population MICs 
ranging from 1 - 4 µg/mL. Susceptibility testing on colonies growing on these agar plates 
ranged from 16 - 64 µg/mL, which was similar to both Lee et al. and our study, although 
we analyzed polymyxin B rather than colistin. The colony counts growing on agar plates 
containing colistin 8 µg/mL ranged from 3 x 100 to 4 x 103 CFU/mL whereas the colony 
counts we observed on agar plates containing 4 µg/mL polymyxin B was closer to 2 x 100 
CFU/mL. Accounting for this difference may be the difference in the MIC of the 
populations since this study analyzed strains with much lower polymyxin B/colistin 
MICs (0.06 - 0.125 µg/mL) whereas Meletis et al. analyzed strains with colistin MICs ≥ 
1 µg/mL. In other words, more similar colony counts may be observed in our isolates if 
we were to utilize agar plates impregnated with similar proportions of polymyxin 
B/colistin such as 0.5 - 1 µg/mL (approximately 4 - 8 x MIC).  
Meletis et al. noticed that about 8 of 16 isolates did not exhibit heteroresistance 
which was demonstrated by a lack of growth on agar plates with colistin concentrations 
exceeding the colistin MIC of the population.142 This observation may explain the 
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differences observed between Lee et al., our study, and Bratu et al. concerning regrowth 
with regimens containing either polymyxin alone or in combination. If heteroresistance 
impairs the synergistic interaction between polymyxins and carbapenems, then a lack of 
heteroresistance would explain the complete killing or indeterminate synergy observed by 
Bratu et al. since polymyxins alone seemed to be sufficient in preventing growth at 
concentrations above the MIC.142 
In conclusion, agar plates with lower polymyxin concentrations would better 
characterize the heteroresistance exhibited by KP 34, 22, 24, and 44, but we as well as 
others have observed wide variability in polymyxin MICs, even among the same 
strains.142,253 The clinical role of polymyxin heteroresistance is not known at this time, 
but it is suspected to impair the synergistic interaction between carbapenems and 
polymyxins. Finally, not all carbapenem-producing Klebsiella pneumoniae have 
observable polymyxin heteroresistance.142 
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CEFTAZIDIME-AVIBACTAM IN VITRO SUSCEPTIBILITY AND MBL-
PRODUCTION 
 Among the 75 CRE tested for susceptibility to ceftazidime-avibactam (CZA), 
only five were non-susceptible (7%). All non-susceptible isolates were found to produce 
MBL either phenotypically by Etest® or genotypically by PCR (performed by the 
University of Kentucky Clinical Microbiology Laboratory). Since MBLs are not inhibited 
by avibactam256 but still hydrolyze 3rd-generation cephalosporins such as ceftazidime, 
these results were not surprising. The most interesting results were that the three isolates 
phenotypically positive for MBL-production and the one isolate genotypically positive 
for VIM-production were susceptible to ceftazidime-avibactam when all four (isolates 21, 
KP 22, 26 and 29) were resistant to ceftazidime (MIC >16 µg/mL; Appendix A, Table 
A.1). This may warrant further inquiry. 
 Two other large studies have evaluated the activity of ceftazidime/avibactam 
against CRE. In 2015, Castanheira et al. reported 98% susceptibility (CZA MIC ≤ 8/4 
µg/mL) among 153 CRE isolates collected from 71 U.S. medical centers as part of the 
International Network for Optimal Resistance Monitoring (INFORM) program (P = 
0.07346 when compared to this study). The MIC50 was 0.5 µg/mL and the MIC90 was 2 
µg/mL. Non-susceptibility was observed in two Klebsiella pneumoniae strains isolated 
from a Colorado medical center and one Proteus mirabilis strain of an unnamed source. 
All three CRE had ceftazidime-avibactam MICs > 32 µg/mL. Similar to our non-
susceptible isolates, the K. pneumoniae isolates were found to harbor NDM-1 but the P. 
mirabilis isolate tested negative for CTX-M subgroups 1, 2, 8, 9, and 25; TEM wild type 
and ESBL; SHV wild type and ESBL; AmpC; KPC; and NDM-1 but positive only for 
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TEM-212, a narrow-spectrum β-lactamase inhibitor (e.g. tazobactam, clavulanic acid, 
sulbactam) resistant β-lactamase.257 The authors did not discuss the P. mirabilis strain 
further, but TEM-212 may also be resistant to the β-lactamase inhibitor, avibactam, and 
high ceftazidime MICs (≥32 µg/mL) have been observed in two Providencia stuartii 
isolates.258 However, alternative explanations may exist in non-β-lactamase mediated 
mechanisms of resistance that still warrant exploration. 
 By 2016, de Jonge et al. evaluated ceftazidime-avibactam against 961 
meropenem-non-susceptible Enterobacteriaceae collected from Europe, Asia/Pacific, 
Latin America, and the Middle East/Africa as part of the INFORM program. Of these, 
susceptibility to ceftazidime-avibactam was reported in 83.5%. Upon excluding MBL-
producing isolates, 97.7% susceptibility was observed among 816 isolates, which is not 
significantly different from our study upon also excluding MBL-producing isolates 
(P=0.2113). A most interesting result, however, was the decreased susceptibility observed 
among 207 carbapenemase-negative meropenem-non-susceptible Enterobacteriaceae 
compared to 609 carbapenemase-positive, MBL-negative, meropenem-non-susceptible 
Enterobacteriaceae (94.7% vs. 98.7%; P=0.0009). Among those 207, AmpC, ESBL or 
both genes were identified in only 195 isolates. Among the 12 remaining isolates, 8 
(67%) were susceptible to ceftazidime/avibactam. Although a small subgroup, this 
suggests that non-enzyme mediate resistant may play a role in ceftazidime-avibactam 
non-susceptibility. In total, the authors identified only 19 of 961 isolates for which 
ceftazidime-avibactam non-susceptibility couldn't be explained by the presence of 
MBLs.259 Target site modifications260 and other MBLs not yet identified by PCR were 
among the most suspected whereas upregulation of efflux pumps were considered less 
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likely after direct testing.261 Finally, among 145 MBL-producing isolates, susceptibility 
to ceftazidime-avibactam was 3.4% whereas in the present study, 4 of 9 MBL-producing 
isolates were susceptible (44%; P<0.0001). The implications of this are not understood, 
but regional differences in resistance patterns combined with non-β-lactamase mediated 
resistance provide one hypothesis. Further studies are warranted to better understand this 
observation. 
 Back in the U.S., the first case report of ceftazidime-avibactam resistance in a 
KPC-3-producing Klebsiella pneumoniae clinical isolate was published in October 2015. 
The exact resistance mechanism is still being investigated, but it is not suspected to be 
related to KPC-3-production since the amino acid sequence encoded by blaKPC-3 in this 
isolate was unaltered. This adds to the growing evidence that there may be a non-β-
lactamase mediated resistance mechanism to ceftazidime-avibactam. The clinical 
implications of these reports are that susceptibility testing of ceftazidime-avibactam may 
still be warranted, even in the setting of MBL-negative carbapenem resistance.262 
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FUTURE WORK 
 Data from retrospective human studies have been compelling regarding the 
advantage of combination therapy, especially those containing a carbapenem, for the 
treatment of CRE. However, questions such as which antimicrobials, at what doses, for 
how long, and are there other factors that might determine clinical outcome remain. 
Additionally, significant limitations such as heterogeneity and correlative evidence begs 
for randomized controlled trials evaluating antimicrobial combinations head-to-head. 
However, cost, coordination, and design hurdles nearly render this undertaking infeasible, 
which leads to in vitro and animal studies to scratch at the answers needed. So far, time-
kill studies have identified numerous combinations of antimicrobials with high rates of 
synergy, among the top are polymyxins in combination with a carbapenem. 
Since this study is among the first to suggest that meropenem MICs may correlate 
with synergy between polymyxin B and meropenem, additional time-kill studies using 
this hypothesis against additional isolates could validate this observation. Furthermore, 
Enterobacteriaceae species other than Klebsiella pneumoniae could be evaluated to see if 
synergy dependence on carbapenem MIC still holds across species. Whether or not 
similar results are obtained, this data would fuel the construction of models that could 
describe new pharmacodynamic indices or targets of antimicrobials used in combination. 
As a hypothetical example, if meropenem and polymyxin are used in combination, 
perhaps a pharmacodynamic target of 50% time above the MIC for meropenem is not 
necessary but instead only 25% time above the MIC when the AUC/MIC ratio of the 
combination drug is at least 4. Such data, when modeled, may establish "hybrid" 
breakpoints where agents used in combination have altered susceptibility definitions from 
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traditional single agent breakpoints. This may translate to clinical reports directing 
clinicians about which combination therapies to employ against a particular CRE strain 
rather than trusting that single agent susceptibility data predicts successful clinical 
outcome of a combination. 
Genetic testing has been suggested by others to play a bigger role than previously 
understood in CRE treatment.227 Genetic testing of the four strains studied in addition to 
future strains undergoing in vitro study may better describe the proposed dependence of 
synergy on carbapenem MIC or could lead to alternative categorization. For example, 
instead of carbapenem MIC being the primary variable describing synergy (or hopefully 
clinical success), it may be enzyme copy number, number of unique carbapenemase 
enzymes, enzyme expression level, or some other genetic variable that may describe 
clinical success. In vitro work incorporating genetic variability in the study design is 
certainly opportunity for investigation. 
Data with in vitro pharmacodynamic and animal models more closely emulating 
human pharmacokinetics and the immune system are also warranted. Using the time-kill 
data from this study, models should be constructed which can guide therapeutic drug 
targets of polymyxin B and meropenem based on the level of carbapenem resistance. 
These models can be adjusted to include other factors such as drug elimination through 
the use of bioreactors that mimic dynamic rather than static drug levels. Murine models 
can be used to incorporate the effects of an immune system and other factors of a living, 
infected host. Previous data, although limited, can serve as a foundation for experimental 
design and also for comparison once data is obtained.   
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CONCLUSIONS 
 Infections caused by carbapenem-resistant Enterobacteriaceae are a growing 
international threat where treatment options are very limited and mortality is extremely 
high (about 50%).14 Preventative measures and antimicrobial stewardship may provide 
much needed time to evaluate treatment strategies, but already CRE are receiving 
attention from the European and U.S. government as well as receiving calls to action 
from organizations like the CDC and IDSA. Treatment strategies to date have shown the 
highest reductions in mortality when a carbapenem is used in combination with one or 
two additional antimicrobials, among which polymyxins are the most common.  
This study has corroborated the findings of others regarding the synergy and 
effectiveness of a carbapenem in combination with polymyxin B, but the impact that the 
degree of carbapenem resistance may have on clinical outcome needs to be addressed 
because synergy is just a surrogate endpoint that may not always correlate with clinical 
success. Furthermore, evaluation of traditionally "non-susceptible" antimicrobials such as 
fluoroquinolones and aminoglycosides, especially in areas where susceptibilities to these 
antimicrobials are maintained, may improve clinical outcomes. Finally, this study has 
evaluated local susceptibility of CRE to ceftazidime-avibactam – a recently approved 
antimicrobial treatment for KPC-producing Enterobacteriaceae, but clinical data 
regarding the use of this agent, especially as monotherapy against carbapenem-resistant 
organisms is limited. 
 
  
 157 
 
Appendix A: 
 
 
Minimum Inhibitory Concentrations Determined by BD Phoenix™ 
 
 Tables A.1-A.2 provide the results of in vitro susceptibility testing performed by 
the University of Kentucky Clinical Microbiology Laboratory using BD Phoenix™. 
 The following abbreviations are used in Table A.1: AMP - Ampicillin; AMS - 
Ampicillin/Sulbactam; AZT - Aztreonam; CFZ - Cefazolin; CPM - Cefepime; FOX - 
Cefoxitin; CAZ - Ceftazidime; CAX - Ceftriaxone; CRM - Cefuroxime; ETP - 
Ertapenem; MEM - Meropenem; PTC - Piperacillin/Tazobactam 
 The following abbreviations are used in Table A.2:  AMK - Amikacin; CIP - 
Ciprofloxacin; GEN - Gentamicin; LEV - Levofloxacin; NIT - Nitrofurantoin; TET - 
Tetracycline; TOB - Tobramycin; SXT - Sulfamethoxazole/Trimethoprim 
  
 
 
 
 
Table A.1: Minimum Inhibitory Concentration of β-lactam Antimicrobials for University of Kentucky Clinical Isolates by BD Phoenix™ 
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Acinetobacter baumannii 63 >16 * >16 >16 >16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 75 >16 * >16 >16 >16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 81 >16 * >16 >16 >16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 83 >16 * >16 >16 >16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 86 >16 * >16 >16 16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 191 >16 * >16 >16 >16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 194 >16 * >16 >16 >16 >16 >16 >32 >16 * >8 *  
Acinetobacter baumannii 215 >16 >16/8 >16 >16 >16 >16 >16 >32 * * >8 *  
Acinetobacter baumannii 219 >16 >16/8 >16 >16 >16 >16 >16 >32 * * >8 *  
Acinetobacter baumannii 226 >16 >16/8 >16 >16 >16 >16 >16 >32 * * >8 *  
Burkholderia cepacia 67 >16 >16/8 >16 >16 * >16 4 32 >16 >4 4 32/4  
Citrobacter amalonaticus 36 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 4 4 >64/4  
Citrobacter amalonaticus 91 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 4 >64/4  
Citrobacter freundii 6 >16 >16/8 >16 >16 8 >16 4 >32 >16 2 ≤1 >64/4  
Citrobacter freundii 27 >16 >16/8 >16 >16 8 >16 8 >32 >16 2 ≤1 >64/4  
Citrobacter freundii 50 >16 >16/8 >16 >16 >16 16 >16 >32 >16 4 ≤1 >64/4  
Citrobacter freundii 54 >16 >16/8 >16 >16 4 >16 8 >32 >16 4 ≤1 >64/4  
Citrobacter freundii 101 >16 >16/8 >16 >16 2 >16 >16 32 >16 2 ≤1 >64/4  
Citrobacter freundii 127 >16 >16/8 >16 >16 2 >16 >16 >32 >16 >4 2 >64/4  
Citrobacter freundii 135 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 ≤0.5 4 >64/4  
Citrobacter freundii 145 >16 >16/8 >16 >16 2 >16 >16 >32 >16 2 ≤1 >64/4  
Citrobacter freundii 147 >16 >16/8 >16 >16 8 >16 >16 >32 >16 2 ≤1 >64/4  
Citrobacter freundii 225 >16 >16/8 >16 >16 * 16 >16 >32 * ≤0.25 ≤0.5 >64/4  
Citrobacter youngae 136 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 4 >64/4  
Enterobacter aerogenes 97 >16 >16/8 >16 >16 2 >16 >16 >32 >16 1 ≤1 >64/4  
Enterobacter aerogenes 163 >16 >16/8 4 >16 ≤1 ≤4 8 >32 >16 ≤0.5 ≤1 ≤2/4  
Enterobacter aerogenes 179 >16 >16/8 ≤2 >16 ≤1 >16 >16 >32 >16 4 >8 >64/4  
Enterobacter aerogenes 187 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 ≤1 >64/4  
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Enterobacter cloacae 1 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4  
Enterobacter cloacae 3 >16 >16/8 >16 >16 8 >16 >16 >32 >16 >4 ≤1 >64/4  
Enterobacter cloacae 4 >16 >16/8 >16 >16 4 >16 >16 >32 >16 >4 ≤1 >64/4  
Enterobacter cloacae 5 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 2 >64/4  
Enterobacter cloacae 9 >16 >16/8 >16 >16 16 >16 >16 >32 >16 4 >8 >64/4  
Enterobacter cloacae 10 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Enterobacter cloacae 12 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Enterobacter cloacae 15 >16 >16/8 >16 >16 4 >16 >16 >32 >16 2 ≤1 >64/4  
Enterobacter cloacae 16 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 ≤1 >64/4  
Enterobacter cloacae 17 >16 >16/8 >16 >16 4 >16 >16 >32 >16 >4 ≤1 >64/4  
Enterobacter cloacae 19 >16 >16/8 >16 >16 8 >16 >16 >32 >16 2 ≤1 >64/4  
Enterobacter cloacae 20 >16 >16/8 >16 >16 8 >16 >16 >32 >16 >4 8 >64/4  
Enterobacter cloacae 23 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 2 >64/4  
Enterobacter cloacae 30 >16 >16/8 >16 >16 * >16 >16 >32 >16 >4 ≤1 >64/4  
Enterobacter cloacae 39 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 ≤1 >64/4  
Enterobacter cloacae 40 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 8 >64/4  
Enterobacter cloacae 41 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 >8 >64/4  
Enterobacter cloacae 52 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 >8 >64/4  
Enterobacter cloacae 53 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4  
Enterobacter cloacae 61 >16 >16/8 >16 >16 ≤1 >16 >16 16 >16 ≤0.5 ≤1 4/4  
Enterobacter cloacae 70 >16 >16/8 >16 >16 2 >16 >16 >32 >16 2 ≤1 8/4  
Enterobacter cloacae 73 >16 >16/8 >16 >16 ≤1 >16 >16 8 >16 ≤0.5 ≤1 4/4  
Enterobacter cloacae 96 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 1 >8 64/4  
Enterobacter cloacae 107 >16 >16/8 >16 >16 8 >16 8 >32 >16 >4 8 >64/4  
Enterobacter cloacae 121 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4  
Enterobacter cloacae 126 >16 >16/8 >16 >16 >16 >16 4 >32 >16 >4 >8 >64/4  
Enterobacter cloacae 134 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 8 >64/4  
Enterobacter cloacae 144 >16 >16/8 >16 >16 2 >16 16 >32 >16 >4 4 >64/4  
Enterobacter cloacae 167 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 4 >64/4  
Enterobacter cloacae 168 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 >8 >64/4  
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Enterobacter cloacae 169 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 4 >64/4  
Enterobacter cloacae 171 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Enterobacter cloacae 175 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 2 4 >64/4  
Enterobacter cloacae 189 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 4 >64/4  
Enterobacter cloacae 200 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 ≤1 >64/4  
Enterobacter cloacae 203 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Enterobacter cloacae 209 >16 >16/8 >16 >16 >16 >16 16 >32 >16 >4 >8 >64/4  
Enterobacter gergoviae 13 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Enterobacter gergoviae 95 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 ≤1 >64/4  
Enterobacter hormaechei 186 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Enterobacter sp. 146 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 >8 >64/4  
Enterobacter sp. 210 >16 >16/8 >16 >16 >16 >16 16 >32 >16 >4 >8 >64/4  
Escherichia coli 25 >16 >16/8 4 >16 ≤1 8 4 >32 >16 4 ≤1 >64/4  
Escherichia coli 33 >16 >16/8 >16 >16 8 >16 >16 >32 >16 4 ≤1 >64/4  
Escherichia coli 58 >16 16/8 4 >16 8 8 1 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 60 >16 >16/8 >16 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 64 >16 >16/8 >16 >16 >16 8 4 >32 >16 ≤0.5 ≤1 >64/4  
Escherichia coli 71 >16 >16/8 >16 >16 16 16 >16 >32 >16 ≤0.5 ≤1 16/4  
Escherichia coli 72 >16 >16/8 16 >16 16 ≤4 2 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 78 >16 >16/8 >16 >16 >16 16 >16 >32 >16 ≤0.5 ≤1 >64/4  
Escherichia coli 79 >16 >16/8 >16 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 84 >16 >16/8 >16 >16 >16 16 >16 >32 >16 ≤0.5 ≤1 32/4  
Escherichia coli 85 >16 >16/8 >16 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 8/4  
Escherichia coli 87 >16 >16/8 16 >16 4 ≤4 4 >32 >16 ≤0.5 ≤1 >64/4  
Escherichia coli 90 >16 16/8 ≤2 >16 2 ≤4 1 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 94 >16 >16/8 >16 >16 16 16 16 >32 >16 ≤0.5 ≤1 8/4  
Escherichia coli 103 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 1 ≤1 32/4  
Escherichia coli 106 >16 >16/8 >16 >16 4 ≤4 16 >32 >16 ≤0.5 ≤1 16/4  
Escherichia coli 111 >16 >16/8 >16 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 >64/4  
Escherichia coli 112 >16 >16/8 4 >16 2 8 2 >32 >16 ≤0.5 ≤1 16/4  
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Escherichia coli 113 >16 >16/8 >16 >16 8 8 8 >32 >16 ≤0.5 ≤1 16/4  
Escherichia coli 114 >16 >16/8 >16 >16 >16 8 >16 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 115 >16 >16/8 >16 >16 ≤1 ≤4 >16 16 16 ≤0.5 ≤1 8/4  
Escherichia coli 117 >16 2/4 8 >16 8 8 2 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 118 >16 16/8 4 >16 >16 ≤4 2 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 120 >16 8/4 >16 >16 8 8 8 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 124 >16 >16/8 >16 >16 >16 16 16 >32 >16 ≤0.5 ≤1 8/4  
Escherichia coli 125 >16 >16/8 >16 >16 16 ≤4 16 >32 >16 ≤0.5 ≤1 8/4  
Escherichia coli 131 >16 >16/8 8 >16 8 8 2 >32 >16 ≤0.5 ≤1 >64/4  
Escherichia coli 132 >16 >16/8 >16 >16 >16 8 >16 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 137 >16 8/4 ≤2 16 ≤1 16 8 ≤2 >16 ≤0.5 ≤1 16/4  
Escherichia coli 138 >16 >16/8 >16 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 139 >16 >16/8 >16 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 140 >16 >16/8 >16 >16 >16 8 >16 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 141 >16 >16/8 >16 >16 16 ≤4 16 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 151 >16 >16/8 >16 >16 16 16 16 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 158 >16 8/4 8 >16 4 ≤4 4 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 160 >16 >16/8 16 >16 16 8 2 >32 >16 ≤0.5 ≤1 4/4  
Escherichia coli 172 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 2 8 >64/4  
Escherichia coli 176 >16 >16/8 >16 >16 16 16 >16 >32 >16 >4 ≤1 >64/4  
Escherichia coli 188 >16 >16/8 >16 >16 >16 ≤4 >16 >32 >16 ≤0.5 ≤1 64/4  
Escherichia coli 190 >16 >16/8 16 >16 8 ≤4 8 >32 >16 ≤0.5 ≤1 8/4  
Escherichia coli 195 >16 8/4 16 >16 4 ≤4 8 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 201 >16 8/4 16 >16 8 ≤4 8 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 206 >16 >16/8 16 >16 16 8 2 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 213 >16 16/8 >16 >16 >16 8 8 >32 >16 ≤0.5 ≤1 ≤2/4  
Escherichia coli 216 >16 >16/8 >16 >16 >16 ≤4 16 >32 * ≤0.25 ≤0.5 ≤2/4  
Escherichia coli 223 >16 >16/8 >16 >16 >16 ≤4 >16 >32 * ≤0.25 ≤0.5 >64/4  
Escherichia vulneris 155 >16 4/2 8 >16 ≤1 ≤4 >16 16 16 ≤0.5 ≤1 ≤2/4  
Klebsiella oxytoca 8 >16 >16/8 >16 >16 ≤1 8 4 16 >16 >4 ≤1 >64/4  
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Klebsiella oxytoca 14 >16 >16/8 >16 >16 8 8 8 >32 >16 >4 ≤1 >64/4  
Klebsiella oxytoca 166 >16 >16/8 >16 >16 8 ≤4 2 >32 >16 >4 8 64/4  
Klebsiella oxytoca 177 >16 >16/8 >16 >16 ≤1 8 8 >32 >16 4 2 >64/4  
Klebsiella oxytoca 197 >16 >16/8 16 >16 ≤1 ≤4 ≤0.5 ≤2 >16 ≤0.5 ≤1 >64/4  
Klebsiella ozaenae 128 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae 2 >16 >16/8 8 >16 2 ≤4 4 32 >16 4 ≤1 >64/4  
Klebsiella pneumoniae 7 >16 >16/8 >16 >16 >16 16 8 >32 >16 >4 8 >64/4  
Klebsiella pneumoniae 11 >16 >16/8 >16 >16 8 >16 4 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae 18 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae 21 >16 >16/8 16 >16 2 >16 >16 32 >16 2 ≤1 >64/4  
Klebsiella pneumoniae KP 22 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae KP 24 >16 >16/8 >16 >16 16 >16 >16 >32 >16 >4 2 >64/4  
Klebsiella pneumoniae 26 >16 >16/8 >16 >16 ≤1 >16 >16 8 >16 >4 8 >64/4  
Klebsiella pneumoniae 28 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 29 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 31 >16 >16/8 8 >16 4 ≤4 4 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae 32 >16 >16/8 >16 >16 >16 >16 4 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae KP 34 >16 >16/8 ≤2 >16 ≤1 ≤4 2 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae 35 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 37 >16 >16/8 16 >16 * 16 16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 42 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 2 ≤1 >64/4  
Klebsiella pneumoniae 43 >16 >16/8 >16 >16 16 >16 16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae KP 44 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 45 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 46 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 47 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 48 >16 >16/8 >16 >16 >16 16 >16 >32 >16 >4 ≤1 >64/4  
Klebsiella pneumoniae 49 >16 >16/8 >16 >16 16 >16 16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 51 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 55 >16 >16/8 >16 >16 8 8 >16 >32 >16 >4 >8 >64/4  
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Klebsiella pneumoniae 65 >16 >16/8 >16 >16 >16 16 >16 >32 >16 ≤0.5 ≤1 8/4  
Klebsiella pneumoniae 66 >16 >16/8 >16 >16 >16 >16 16 >32 >16 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 69 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 2 ≤1 8/4  
Klebsiella pneumoniae 76 >16 >16/8 ≤2 >16 ≤1 ≤4 8 ≤2 8 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 77 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 2 >64/4  
Klebsiella pneumoniae 92 >16 16/8 ≤2 >16 4 ≤4 ≤0.5 >32 >16 ≤0.5 ≤1 ≤2/4  
Klebsiella pneumoniae 93 >16 >16/8 >16 >16 >16 >16 16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 98 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 2 ≤1 >64/4  
Klebsiella pneumoniae 99 >16 >16/8 >16 >16 8 >16 8 >32 >16 >4 8 >64/4  
Klebsiella pneumoniae 102 >16 >16/8 ≤2 >16 ≤1 ≤4 8 ≤2 ≤4 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 104 >16 >16/8 ≤2 >16 ≤1 ≤4 8 ≤2 ≤4 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 105 >16 >16/8 >16 >16 8 8 16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 116 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4  
Klebsiella pneumoniae 119 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 122 >16 >16/8 ≤2 >16 2 ≤4 8 ≤2 8 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 123 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 129 >16 >16/8 >16 >16 8 8 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 130 >16 >16/8 >16 >16 >16 8 >16 >32 >16 >4 8 >64/4  
Klebsiella pneumoniae 142 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Klebsiella pneumoniae 143 >16 >16/8 >16 >16 ≤1 >16 >16 >32 >16 4 2 >64/4  
Klebsiella pneumoniae 148 >16 16/8 ≤2 >16 >16 ≤4 4 >32 >16 ≤0.5 ≤1 ≤2/4  
Klebsiella pneumoniae 149 >16 >16/8 8 >16 >16 ≤4 2 >32 >16 ≤0.5 ≤1 16/4  
Klebsiella pneumoniae 150 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 152 >16 >16/8 ≤2 >16 16 >16 16 ≤2 >16 4 ≤1 >64/4  
Klebsiella pneumoniae 154 >16 >16/8 >16 >16 * * >16 >32 >16 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 159 >16 >16/8 >16 >16 >16 ≤4 >16 >32 >16 ≤0.5 ≤1 32/4  
Klebsiella pneumoniae 164 >16 >16/8 >16 >16 8 ≤4 16 >32 >16 ≤0.5 ≤1 16/4  
Klebsiella pneumoniae 165 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 8 >64/4  
Klebsiella pneumoniae 170 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 4 >8 >64/4  
Klebsiella pneumoniae 173 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 2 8 >64/4  
 
 
 
 
Table A.1: Minimum Inhibitory Concentration of β-lactam Antimicrobials for University of Kentucky Clinical Isolates by BD Phoenix™ 
Abbreviations: AMP - Ampicillin; AMS - Ampicillin/Sulbactam; AZT - Aztreonam; CFZ - Cefazolin; CPM - Cefepime; FOX - Cefoxitin; CAZ - 
Ceftazidime; CAX - Ceftriaxone; CRM - Cefuroxime; ETP - Ertapenem; MEM - Meropenem; PTC - Piperacillin/Tazobactam 
 
 
164 
ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Klebsiella pneumoniae 174 >16 >16/8 ≤2 >16 >16 >16 >16 >32 >16 2 >8 >64/4  
Klebsiella pneumoniae 180 >16 >16/8 >16 >16 >16 ≤4 >16 >32 >16 ≤0.5 ≤1 4/4  
Klebsiella pneumoniae 193 >16 >16/8 >16 >16 16 ≤4 >16 >32 >16 ≤0.5 ≤1 16/4  
Klebsiella pneumoniae 196 >16 >16/8 8 >16 >16 ≤4 16 >32 >16 ≤0.5 ≤1 >64/4  
Klebsiella pneumoniae 198 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 ≤0.5 ≤1 32/4  
Klebsiella pneumoniae 204 >16 >16/8 8 >16 16 >16 2 >32 >16 ≤0.5 ≤1 16/4  
Klebsiella pneumoniae 212 >16 >16/8 >16 >16 >16 ≤4 >16 >32 >16 ≤0.5 ≤1 4/4  
Klebsiella pneumoniae 217 >16 >16/8 >16 >16 ≤1 8 >16 >32 * 0.5 ≤0.5 >64/4  
Klebsiella pneumoniae 230 >16 >16/8 >16 >16 >16 >16 >16 >32 * >1 >8 >64/4  
Pantoea agglomerans 178 >16 16/8 ≤2 >16 4 >16 2 32 16 ≤0.5 ≤1 ≤2/4  
Pantoea agglomerans 185 >16 >16/8 ≤2 >16 4 16 1 32 >16 ≤0.5 ≤1 ≤2/4  
Pantoea agglomerans 214 >16 16/8 ≤2 >16 2 16 2 32 16 ≤0.5 ≤1 ≤2/4  
Proteus mirabilis 162 >16 * ≤2 >16 >16 8 2 >32 >16 ≤0.5 ≤1 ≤2/4  
Proteus mirabilis 227 >16 >16/8 ≤2 >16 >16 8 2 >32 * ≤0.25 * 8/4  
Pseudomonas aeruginosa 56 >16 >16/8 16 >16 >16 >16 >16 >32 >16 >4 ≤1 >64/4  
Pseudomonas aeruginosa 57 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 4 >64/4  
Pseudomonas aeruginosa 62 >16 >16/8 16 >16 16 >16 4 >32 >16 >4 >8 32/4  
Pseudomonas aeruginosa 68 >16 >16/8 >16 >16 16 >16 16 >32 >16 >4 8 64/4  
Pseudomonas aeruginosa 74 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 64/4  
Pseudomonas aeruginosa 80 >16 >16/8 >16 >16 16 >16 >16 >32 >16 4 ≤1 >64/4  
Pseudomonas aeruginosa 82 >16 >16/8 8 >16 16 >16 >16 >32 >16 >4 8 >64/4  
Pseudomonas aeruginosa 88 >16 >16/8 16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4  
Pseudomonas aeruginosa 100 >16 >16/8 >16 >16 16 >16 >16 >32 >16 >4 8 >64/4  
Pseudomonas aeruginosa 108 >16 >16/8 16 >16 16 >16 16 >32 >16 >4 ≤1 64/4  
Pseudomonas aeruginosa 109 >16 >16/8 16 >16 16 >16 8 >32 >16 >4 >8 32/4  
Pseudomonas aeruginosa 110 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 2 >64/4  
Pseudomonas aeruginosa 133 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 32/4  
Pseudomonas aeruginosa† 153 * * R * R * * * * * R R  
Pseudomonas aeruginosa 157 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 64/4  
 
 
 
 
Table A.1: Minimum Inhibitory Concentration of β-lactam Antimicrobials for University of Kentucky Clinical Isolates by BD Phoenix™ 
Abbreviations: AMP - Ampicillin; AMS - Ampicillin/Sulbactam; AZT - Aztreonam; CFZ - Cefazolin; CPM - Cefepime; FOX - Cefoxitin; CAZ - 
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ORGANISM ISOLATE AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ETP MEM PTC  
Pseudomonas aeruginosa 161 >16 >16/8 >16 >16 >16 >16 4 >32 >16 >4 >8 16/4  
Pseudomonas aeruginosa 181 >16 >16/8 >16 >16 16 >16 4 32 >16 >4 >8 32/4  
Pseudomonas aeruginosa 182 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 8 64/4  
Pseudomonas aeruginosa 183 >16 >16/8 16 >16 16 >16 8 >32 >16 >4 8 32/4  
Pseudomonas aeruginosa 184 >16 >16/8 >16 >16 16 >16 >16 >32 >16 >4 >8 >64/4  
Pseudomonas aeruginosa 192 >16 >16/8 16 >16 16 >16 >16 >32 >16 >4 2 >64/4  
Pseudomonas aeruginosa 199 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 64/4  
Pseudomonas aeruginosa 202 >16 >16/8 >16 >16 16 >16 >16 >32 >16 >4 8 64/4  
Pseudomonas aeruginosa 205 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 ≤1 32/4  
Pseudomonas aeruginosa 207 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 >8 16/4  
Pseudomonas aeruginosa 208 >16 >16/8 16 >16 16 >16 16 >32 >16 >4 >8 >64/4  
Pseudomonas aeruginosa 211 >16 >16/8 16 >16 16 >16 >16 >32 >16 >4 8 >64/4  
Pseudomonas aeruginosa 218 >16 >16/8 16 >16 16 >16 >16 >32 * >1 8 >64/4  
Pseudomonas aeruginosa 220 >16 8/4 8 >16 16 >16 8 >32 * >1 >8 >64/4  
Pseudomonas aeruginosa 221 >16 >16/8 >16 >16 >16 >16 16 >32 * >1 >8 64/4  
Pseudomonas aeruginosa 222 >16 >16/8 >16 >16 16 >16 >16 >32 * >1 2 >64/4  
Pseudomonas aeruginosa 224 >16 >16/8 >16 >16 16 >16 16 >32 * >1 >8 32/4  
Pseudomonas aeruginosa 228 >16 >16/8 16 >16 16 >16 16 >32 * >1 4 64/4  
Pseudomonas aeruginosa 231 >16 >16/8 >16 >16 16 >16 16 >32 * >1 >8 64/4  
Pseudomonas putida 38 >16 >16/8 >16 >16 8 >16 >16 >32 >16 * >8 64/4  
Pseudomonas putida 156 >16 >16/8 8 >16 8 >16 1 >32 >16 >4 >8 64/4  
Sphingomonas paucimobilis† 59 * * R * R * * * * * R R  
*Not tested by University of Kentucky Microbiology Laboratory 
†Organism tested by Etest® and reported only as S, I, or R 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Acinetobacter baumannii 63 >32 >2 >8 >4 >64 >8 >8 >2/38 
Acinetobacter baumannii 75 >32 >2 >8 >4 >64 >8 >8 >2/38 
Acinetobacter baumannii 81 ≤8 >2 8 >4 >64 >8 ≤2 >2/38 
Acinetobacter baumannii 83 >32 >2 >8 >4 >64 >8 >8 >2/38 
Acinetobacter baumannii 86 ≤8 >2 8 >4 >64 >8 ≤2 >2/38 
Acinetobacter baumannii 191 ≤8 >2 ≤2 >4 >64 >8 8 >2/38 
Acinetobacter baumannii 194 >32 >2 >8 >4 >64 >8 >8 >2/38 
Acinetobacter baumannii 215 >32 >2 >8 >4 >64 >8 >8 >2/38 
Acinetobacter baumannii 219 >32 >2 >8 >4 >64 >8 >8 >2/38 
Acinetobacter baumannii 226 >32 >2 >8 >4 >64 >8 >8 >2/38 
Burkholderia cepacia 67 >32 2 >8 4 >64 >8 >8 ≤0.5/9.5 
Citrobacter amalonaticus 36 ≤8 >2 >8 >4 32 4 >8 >2/38 
Citrobacter amalonaticus 91 ≤8 >2 >8 >4 64 4 >8 >2/38 
Citrobacter freundii 6 ≤8 >2 ≤2 4 ≤16 4 ≤2 >2/38 
Citrobacter freundii 27 >32 >2 >8 >4 ≤16 ≤2 >8 >2/38 
Citrobacter freundii 50 ≤8 >2 >8 4 ≤16 4 >8 >2/38 
Citrobacter freundii 54 ≤8 >2 >8 >4 ≤16 4 >8 ≤0.5/9.5 
Citrobacter freundii 101 ≤8 >2 8 >4 ≤16 >8 4 >2/38 
Citrobacter freundii 127 ≤8 >2 >8 >4 ≤16 >8 >8 >2/38 
Citrobacter freundii 135 ≤8 ≤0.5 ≤2 ≤1 ≤16 ≤2 8 >2/38 
Citrobacter freundii 145 ≤8 >2 ≤2 >4 ≤16 4 ≤2 ≤0.5/9.5 
Citrobacter freundii 147 ≤8 ≤0.5 ≤2 ≤1 ≤16 ≤2 ≤2 ≤0.5/9.5 
Citrobacter freundii 225 ≤8 2 ≤2 2 ≤16 >8 ≤2 ≤0.5/9.5 
Citrobacter youngae 136 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Enterobacter aerogenes 97 ≤8 ≤0.5 ≤2 ≤1 ≤16 ≤2 ≤2 ≤0.5/9.5 
Enterobacter aerogenes 163 ≤8 1 ≤2 ≤1 32 ≤2 ≤2 >2/38 
Enterobacter aerogenes 179 ≤8 ≤0.5 8 ≤1 >64 ≤2 >8 >2/38 
Enterobacter aerogenes 187 ≤8 ≤0.5 ≤2 ≤1 >64 >8 ≤2 ≤0.5/9.5 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Enterobacter cloacae 1 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Enterobacter cloacae 3 ≤8 1 >8 ≤1 64 ≤2 >8 >2/38 
Enterobacter cloacae 4 ≤8 1 >8 ≤1 64 ≤2 >8 >2/38 
Enterobacter cloacae 5 ≤8 ≤0.5 >8 ≤1 64 ≤2 >8 >2/38 
Enterobacter cloacae 9 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter cloacae 10 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter cloacae 12 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter cloacae 15 ≤8 1 8 ≤1 32 ≤2 >8 ≤0.5/9.5 
Enterobacter cloacae 16 ≤8 >2 >8 >4 32 8 >8 >2/38 
Enterobacter cloacae 17 ≤8 >2 >8 >4 64 4 >8 >2/38 
Enterobacter cloacae 19 ≤8 1 8 ≤1 64 ≤2 >8 ≤0.5/9.5 
Enterobacter cloacae 20 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter cloacae 23 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter cloacae 30 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Enterobacter cloacae 39 ≤8 >2 >8 2 32 ≤2 >8 ≤0.5/9.5 
Enterobacter cloacae 40 ≤8 >2 >8 >4 >64 4 >8 >2/38 
Enterobacter cloacae 41 16 1 >8 ≤1 64 >8 >8 >2/38 
Enterobacter cloacae 52 ≤8 >2 8 >4 32 8 >8 ≤0.5/9.5 
Enterobacter cloacae 53 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Enterobacter cloacae 61 ≤8 >2 >8 >4 >64 8 8 >2/38 
Enterobacter cloacae 70 ≤8 >2 >8 >4 >64 >8 8 >2/38 
Enterobacter cloacae 73 ≤8 ≤0.5 >8 ≤1 >64 ≤2 8 >2/38 
Enterobacter cloacae 96 ≤8 ≤0.5 ≤2 ≤1 ≤16 ≤2 ≤2 ≤0.5/9.5 
Enterobacter cloacae 107 ≤8 >2 >8 >4 32 4 >8 ≤0.5/9.5 
Enterobacter cloacae 121 ≤8 1 >8 ≤1 >64 4 >8 >2/38 
Enterobacter cloacae 126 ≤8 >2 >8 >4 32 8 >8 ≤0.5/9.5 
Enterobacter cloacae 134 ≤8 1 >8 ≤1 >64 ≤2 >8 >2/38 
Enterobacter cloacae 144 ≤8 >2 >8 2 ≤16 ≤2 >8 ≤0.5/9.5 
Enterobacter cloacae 167 ≤8 1 ≤2 * 64 ≤2 8 >2/38 
Enterobacter cloacae 168 ≤8 >2 8 >4 64 8 >8 ≤0.5/9.5 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Enterobacter cloacae 169 ≤8 1 ≤2 ≤1 64 ≤2 8 >2/38 
Enterobacter cloacae 171 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter cloacae 175 ≤8 1 >8 ≤1 32 ≤2 >8 >2/38 
Enterobacter cloacae 189 ≤8 ≤0.5 ≤2 ≤1 64 ≤2 8 >2/38 
Enterobacter cloacae 200 ≤8 >2 >8 >4 64 8 >8 >2/38 
Enterobacter cloacae 203 ≤8 1 >8 ≤1 64 ≤2 >8 >2/38 
Enterobacter cloacae 209 ≤8 >2 >8 >4 >64 8 >8 ≤0.5/9.5 
Enterobacter gergoviae 13 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter gergoviae 95 ≤8 ≤0.5 ≤2 ≤1 64 >8 ≤2 ≤0.5/9.5 
Enterobacter hormaechei 186 ≤8 >2 >8 4 >64 8 >8 >2/38 
Enterobacter sp. 146 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Enterobacter sp. 210 ≤8 >2 8 >4 ≤16 4 >8 ≤0.5/9.5 
Escherichia coli 25 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 33 ≤8 >2 >8 >4 >64 ≤2 8 ≤0.5/9.5 
Escherichia coli 58 ≤8 >2 ≤2 >4 32 >8 ≤2 >2/38 
Escherichia coli 60 ≤8 1 ≤2 ≤1 ≤16 >8 ≤2 >2/38 
Escherichia coli 64 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 >2/38 
Escherichia coli 71 ≤8 >2 ≤2 >4 64 >8 >8 >2/38 
Escherichia coli 72 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 >2/38 
Escherichia coli 78 >32 >2 >8 >4 ≤16 >8 >8 >2/38 
Escherichia coli 79 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 84 ≤8 >2 >8 >4 ≤16 >8 >8 ≤0.5/9.5 
Escherichia coli 85 ≤8 >2 ≤2 >4 >64 >8 >8 >2/38 
Escherichia coli 87 16 >2 ≤2 >4 >64 >8 >8 >2/38 
Escherichia coli 90 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 94 ≤8 >2 >8 >4 ≤16 >8 >8 ≤0.5/9.5 
Escherichia coli 103 ≤8 >2 ≤2 >4 64 >8 >8 >2/38 
Escherichia coli 106 ≤8 >2 ≤2 >4 ≤16 >8 >8 >2/38 
Escherichia coli 111 ≤8 >2 >8 >4 ≤16 ≤2 8 >2/38 
Escherichia coli 112 ≤8 >2 ≤2 >4 ≤16 ≤2 >8 >2/38 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Escherichia coli 113 ≤8 >2 ≤2 >4 ≤16 ≤2 >8 >2/38 
Escherichia coli 114 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 115 >32 ≤0.5 >8 ≤1 ≤16 >8 >8 >2/38 
Escherichia coli 117 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 118 ≤8 >2 ≤2 >4 32 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 120 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 124 ≤8 >2 >8 >4 ≤16 >8 >8 >2/38 
Escherichia coli 125 ≤8 >2 >8 >4 ≤16 >8 >8 ≤0.5/9.5 
Escherichia coli 131 ≤8 >2 >8 >4 ≤16 ≤2 8 >2/38 
Escherichia coli 132 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 137 ≤8 ≤0.5 ≤2 ≤1 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 138 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 139 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 140 ≤8 >2 8 >4 ≤16 ≤2 8 ≤0.5/9.5 
Escherichia coli 141 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 ≤0.5/9.5 
Escherichia coli 151 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 158 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 160 ≤8 >2 >8 >4 ≤16 >8 8 >2/38 
Escherichia coli 172 ≤8 1 ≤2 ≤1 ≤16 ≤2 >8 >2/38 
Escherichia coli 176 ≤8 >2 ≤2 >4 ≤16 ≤2 ≤2 >2/38 
Escherichia coli 188 ≤8 >2 ≤2 >4 ≤16 >8 >8 >2/38 
Escherichia coli 190 ≤8 >2 >8 >4 ≤16 >8 >8 >2/38 
Escherichia coli 195 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 201 ≤8 ≤0.5 ≤2 ≤1 ≤16 >8 ≤2 ≤0.5/9.5 
Escherichia coli 206 ≤8 >2 >8 >4 ≤16 ≤2 8 ≤0.5/9.5 
Escherichia coli 213 ≤8 ≤0.5 ≤2 ≤1 ≤16 >8 ≤2 ≤0.5/9.5 
Escherichia coli 216 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 >2/38 
Escherichia coli 223 ≤8 >2 ≤2 >4 ≤16 >8 ≤2 ≤0.5/9.5 
Escherichia vulneris 155 ≤8 ≤0.5 ≤2 ≤1 64 ≤2 ≤2 ≤0.5/9.5 
Klebsiella oxytoca 8 ≤8 ≤0.5 ≤2 ≤1 ≤16 ≤2 ≤2 1/19 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Klebsiella oxytoca 14 ≤8 2 >8 2 ≤16 4 >8 >2/38 
Klebsiella oxytoca 166 ≤8 ≤0.5 ≤2 ≤1 32 ≤2 ≤2 ≤0.5/9.5 
Klebsiella oxytoca 177 ≤8 ≤0.5 >8 ≤1 ≤16 ≤2 >8 ≤0.5/9.5 
Klebsiella oxytoca 197 ≤8 ≤0.5 ≤2 ≤1 32 ≤2 ≤2 ≤0.5/9.5 
Klebsiella ozaenae 128 ≤8 >2 4 >4 ≤16 4 4 >2/38 
Klebsiella pneumoniae 2 ≤8 ≤0.5 >8 ≤1 64 >8 >8 >2/38 
Klebsiella pneumoniae 7 ≤8 ≤0.5 ≤2 ≤1 64 ≤2 ≤2 >2/38 
Klebsiella pneumoniae 11 ≤8 ≤0.5 ≤2 ≤1 >64 8 ≤2 2/38 
Klebsiella pneumoniae 18 ≤8 ≤0.5 ≤2 ≤1 >64 8 ≤2 >2/38 
Klebsiella pneumoniae 21 ≤8 1 4 ≤1 ≤16 ≤2 >8 >2/38 
Klebsiella pneumoniae KP 22 32 >2 >8 >4 >64 >8 >8 >2/38 
Klebsiella pneumoniae KP 24 ≤8 >2 8 >4 >64 4 >8 ≤0.5/9.5 
Klebsiella pneumoniae 26 >32 >2 >8 >4 >64 ≤2 >8 >2/38 
Klebsiella pneumoniae 28 32 >2 4 >4 >64 8 >8 >2/38 
Klebsiella pneumoniae 29 32 >2 4 >4 >64 4 >8 2/38 
Klebsiella pneumoniae 31 ≤8 ≤0.5 >8 ≤1 >64 ≤2 >8 2/38 
Klebsiella pneumoniae 32 ≤8 >2 ≤2 4 64 8 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae KP 34 ≤8 ≤0.5 ≤2 ≤1 64 ≤2 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae 35 ≤8 >2 >8 >4 >64 8 >8 ≤0.5/9.5 
Klebsiella pneumoniae 37 >32 ≤0.5 >8 ≤1 32 ≤2 >8 ≤0.5/9.5 
Klebsiella pneumoniae 42 ≤8 2 >8 ≤1 ≤16 ≤2 >8 >2/38 
Klebsiella pneumoniae 43 ≤8 >2 >8 >4 64 4 >8 ≤0.5/9.5 
Klebsiella pneumoniae KP 44 ≤8 >2 >8 >4 >64 >8 >8 1/19 
Klebsiella pneumoniae 45 ≤8 >2 >8 >4 >64 4 >8 2/38 
Klebsiella pneumoniae 46 >32 >2 >8 >4 >64 4 >8 >2/38 
Klebsiella pneumoniae 47 >32 >2 >8 >4 >64 ≤2 >8 >2/38 
Klebsiella pneumoniae 48 >32 >2 >8 >4 >64 4 >8 ≤0.5/9.5 
Klebsiella pneumoniae 49 ≤8 >2 >8 4 32 4 >8 ≤0.5/9.5 
Klebsiella pneumoniae 51 ≤8 >2 8 >4 64 4 8 ≤0.5/9.5 
Klebsiella pneumoniae 55 16 >2 ≤2 >4 64 >8 >8 >2/38 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Klebsiella pneumoniae 65 ≤8 >2 ≤2 >4 >64 8 ≤2 >2/38 
Klebsiella pneumoniae 66 ≤8 ≤0.5 ≤2 ≤1 64 4 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae 69 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 76 ≤8 ≤0.5 ≤2 ≤1 32 >8 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae 77 ≤8 >2 >8 4 >64 ≤2 8 ≤0.5/9.5 
Klebsiella pneumoniae 92 ≤8 1 >8 ≤1 64 >8 >8 >2/38 
Klebsiella pneumoniae 93 ≤8 >2 >8 >4 64 4 >8 ≤0.5/9.5 
Klebsiella pneumoniae 98 ≤8 ≤0.5 4 ≤1 ≤16 >8 >8 ≤0.5/9.5 
Klebsiella pneumoniae 99 ≤8 ≤0.5 ≤2 ≤1 >64 >8 ≤2 2/38 
Klebsiella pneumoniae 102 ≤8 ≤0.5 ≤2 ≤1 32 ≤2 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae 104 ≤8 ≤0.5 ≤2 ≤1 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 105 ≤8 ≤0.5 ≤2 ≤1 64 ≤2 ≤2 1/19 
Klebsiella pneumoniae 116 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 119 16 >2 >8 >4 >64 4 >8 >2/38 
Klebsiella pneumoniae 122 ≤8 ≤0.5 ≤2 ≤1 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 123 ≤8 >2 >8 >4 >64 4 >8 >2/38 
Klebsiella pneumoniae 129 16 >2 ≤2 >4 32 ≤2 >8 >2/38 
Klebsiella pneumoniae 130 ≤8 1 >8 ≤1 >64 ≤2 >8 ≤0.5/9.5 
Klebsiella pneumoniae 142 ≤8 ≤0.5 ≤2 ≤1 64 ≤2 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae 143 ≤8 >2 >8 >4 >64 >8 8 >2/38 
Klebsiella pneumoniae 148 ≤8 ≤0.5 ≤2 ≤1 32 ≤2 ≤2 ≤0.5/9.5 
Klebsiella pneumoniae 149 ≤8 1 >8 ≤1 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 150 ≤8 >2 8 >4 >64 4 8 >2/38 
Klebsiella pneumoniae 152 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 154 ≤8 >2 >8 >4 64 >8 >8 2/38 
Klebsiella pneumoniae 159 ≤8 >2 >8 >4 >64 ≤2 8 ≤0.5/9.5 
Klebsiella pneumoniae 164 ≤8 >2 ≤2 ≤1 32 ≤2 8 >2/38 
Klebsiella pneumoniae 165 ≤8 >2 >8 >4 64 8 >8 ≤0.5/9.5 
Klebsiella pneumoniae 170 ≤8 >2 >8 4 32 >8 >8 >2/38 
Klebsiella pneumoniae 173 ≤8 1 ≤2 ≤1 32 ≤2 8 >2/38 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Klebsiella pneumoniae 174 ≤8 1 >8 ≤1 ≤16 >8 >8 >2/38 
Klebsiella pneumoniae 180 ≤8 1 ≤2 ≤1 64 ≤2 ≤2 >2/38 
Klebsiella pneumoniae 193 ≤8 >2 >8 ≤1 64 >8 >8 >2/38 
Klebsiella pneumoniae 196 ≤8 >2 >8 ≤1 >64 >8 >8 >2/38 
Klebsiella pneumoniae 198 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Klebsiella pneumoniae 204 ≤8 >2 >8 >4 >64 >8 8 >2/38 
Klebsiella pneumoniae 212 ≤8 2 ≤2 ≤1 >64 ≤2 ≤2 >2/38 
Klebsiella pneumoniae 217 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Klebsiella pneumoniae 230 ≤8 >2 4 >4 >64 8 >8 >2/38 
Pantoea agglomerans 178 ≤8 ≤0.5 ≤2 ≤1 >64 ≤2 ≤2 ≤0.5/9.5 
Pantoea agglomerans 185 ≤8 ≤0.5 ≤2 ≤1 >64 ≤2 ≤2 ≤0.5/9.5 
Pantoea agglomerans 214 ≤8 ≤0.5 ≤2 ≤1 >64 ≤2 ≤2 ≤0.5/9.5 
Proteus mirabilis 162 ≤8 >2 ≤2 >4 >64 >8 >8 >2/38 
Proteus mirabilis 227 16 >2 >8 >4 >64 >8 >8 ≤0.5/9.5 
Pseudomonas aeruginosa 56 32 >2 >8 >4 >64 >8 4 >2/38 
Pseudomonas aeruginosa 57 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 62 16 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 68 ≤8 2 ≤2 2 >64 >8 ≤2 * 
Pseudomonas aeruginosa 74 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 80 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 82 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 88 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 100 ≤8 ≤0.5 ≤2 ≤1 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 108 >32 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 109 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 110 ≤8 >2 ≤2 * >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 133 >32 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa† 153 R * R R * * R * 
Pseudomonas aeruginosa 157 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
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ORGANISM ISOLATE AMK CIP GEN LEV NIT TET TOB SXT 
Pseudomonas aeruginosa 161 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 181 ≤8 >2 4 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 182 ≤8 >2 4 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 183 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 184 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 192 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 199 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 202 ≤8 ≤0.5 ≤2 ≤1 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 205 ≤8 2 ≤2 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 207 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 208 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 211 ≤8 >2 >8 >4 >64 8 8 >2/38 
Pseudomonas aeruginosa 218 ≤8 >2 8 >4 >64 8 ≤2 >2/38 
Pseudomonas aeruginosa 220 ≤8 >2 >8 4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 221 32 >2 8 >4 >64 >8 4 >2/38 
Pseudomonas aeruginosa 222 ≤8 2 ≤2 4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 224 ≤8 >2 4 >4 >64 >8 ≤2 >2/38 
Pseudomonas aeruginosa 228 ≤8 >2 >8 >4 >64 >8 >8 >2/38 
Pseudomonas aeruginosa 231 ≤8 >2 ≤2 >4 >64 >8 ≤2 >2/38 
Pseudomonas putida 38 ≤8 2 4 4 >64 >8 4 * 
Pseudomonas putida 156 ≤8 2 8 4 >64 >8 4 * 
Sphingomonas paucimobilis† 59 R * R * * * R S 
*Not tested by University of Kentucky Clinical Microbiology Laboratory 
†Organism tested by Etest® and reported only as S, I, or R 
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Appendix B: 
 
 
Cumulative Antimicrobial Susceptibility Summary Report from BD Phoenix™ 
 
 Tables B.1-B.4 provide the cumulative summary antimicrobial susceptibility 
results from the in vitro susceptibility testing performed by the University of Kentucky 
Clinical Microbiology Laboratory using BD Phoenix™. 
 Reports were only generated for species with testing data for ≥ 30 isolates.245 
Duplicate isolates were not collected so that only the first isolate (i.e. one species per 
patient per collection period) is represented in the tables. Percentage intermediate or 
resistant were not included in the report. 
 The following abbreviations are used in Tables B.1-B.4: MIC50 - Minimum 
Inhibitory Concentration (MIC) for 50% of isolates, MIC90 - Minimum Inhibitory 
Concentration (MIC) for 90% of isolates, %S - percentage susceptible. 
 
 
 
 
 
Table B.1: Cumulative Antimicrobial Susceptibility Summary Report for all 64 Klebsiella pneumoniae Clinical Isolates 
Abbreviations: PMB - Polymyxin B; COL - Colistin; RIF - Rifampin; AMI - Amikacin; MIN - Minocycline; TIG - Tigecycline; MEM - Meropenem; LEV - 
Levofloxacin; CPM - Cefepime; PTC - Piperacillin/Tazobactam; FOS - Fosfomycin 
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Antimicrobial MIC50 MIC90 MIC Range %S 
Ampicillin >16 >16 >16 0% 
Ampicillin/Sulbactam >16/8 >16/8 16/8 - >16/8 0% 
Aztreonam >16 >16 ≤2 - >16 19% 
Cefazolin >16 >16 >16 0% 
Cefepime 16 >16 ≤1 - >16 27% 
Cefoxitin >16 >16 ≤4 - >16 33% 
Ceftazidime >16 >16 ≤0.5 - >16 14% 
Ceftriaxone >32 >32 ≤2 - >32 8% 
Cefuroxime >16 >16 ≤4 - >16 6% 
Ertapenem >4 >4 ≤0.5 - >4 31% 
Meropenem ≤1 >8 ≤1 - >8 52% 
Piperacillin/Tazobactam >64/4 >64/4 ≤2/4 - >64/4 16% 
Amikacin ≤8 32 ≤8 - >32 88% 
Ciprofloxacin >2 >2 ≤0.5 - >2 38% 
Gentamicin 8 >8 ≤2 - >8 47% 
Levofloxacin 4 >4 ≤1 - >4 45% 
Nitrofurantoin >64 >64 ≤16 - >64 22% 
Tetracycline 4 >8 ≤2 - >8 52% 
Tobramycin >8 >8 ≤2 - >8 34% 
Sulfamethoxazole/Trimethoprim >2/38 >2/38 ≤0.5/9.5 - >2/38 44% 
 
 
 
 
 
Table B.2: Cumulative Antimicrobial Susceptibility Summary Report for all 37 Enterobacter cloacae Clinical Isolates 
Abbreviations: PMB - Polymyxin B; COL - Colistin; RIF - Rifampin; AMI - Amikacin; MIN - Minocycline; TIG - Tigecycline; MEM - Meropenem; LEV - 
Levofloxacin; CPM - Cefepime; PTC - Piperacillin/Tazobactam; FOS - Fosfomycin 
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Antimicrobial MIC50 MIC90 MIC Range %S 
Ampicillin >16 >16 >16 0% 
Ampicillin/Sulbactam >16/8 >16/8 >16/8 0% 
Aztreonam >16 >16 ≤2 - >16 3% 
Cefazolin >16 >16 >16 0% 
Cefepime >16 >16 ≤1 - >16 14% 
Cefoxitin >16 >16 >16 0% 
Ceftazidime >16 >16 4 - >16 3% 
Ceftriaxone >32 >32 8 - >32 0% 
Cefuroxime >16 >16 >16 0% 
Ertapenem >4 >4 ≤0.5 - >4 5% 
Meropenem 4 >8 ≤1 - >8 32% 
Piperacillin/Tazobactam >64/4 >64/4 4/4 - >64/4 8% 
Amikacin ≤8 ≤8 ≤8 - 16 100% 
Ciprofloxacin >2 >2 ≤0.5 - >2 41% 
Gentamicin >8 >8 ≤2 - >8 11% 
Levofloxacin >4 >4 ≤1 - >4 44% 
Nitrofurantoin 64 >64 ≤16 - >64 24% 
Tetracycline 8 8 ≤2 - >8 49% 
Tobramycin >8 >8 ≤2 - >8 3% 
Sulfamethoxazole/Trimethoprim >2/38 >2/38 ≤0.5/9.5 - >2/38 43% 
 
 
 
 
Table B.3: Cumulative Antimicrobial Susceptibility Summary Report for all 46 Escherichia coli Clinical Isolates 
Abbreviations: PMB - Polymyxin B; COL - Colistin; RIF - Rifampin; AMI - Amikacin; MIN - Minocycline; TIG - Tigecycline; MEM - Meropenem; LEV - 
Levofloxacin; CPM - Cefepime; PTC - Piperacillin/Tazobactam; FOS - Fosfomycin 
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Antimicrobial MIC50 MIC90 MIC Range %S 
Ampicillin >16 >16 >16 0% 
Ampicillin/Sulbactam >16/8 >16/8 4/2 - 16/8 13% 
Aztreonam >16 >16 ≤2 - >16 15% 
Cefazolin >16 >16 16 - >16 0% 
Cefepime 16 >16 ≤1 - >16 11% 
Cefoxitin 8 16 ≤4 - >16 76% 
Ceftazidime 16 >16 1 - >16 28% 
Ceftriaxone >32 >32 ≤2 - >32 2% 
Cefuroxime >16 >16 16 - >16 0% 
Ertapenem ≤0.5 1 ≤0.5 - >4 89% 
Meropenem ≤1 ≤1 ≤1 - 8 98% 
Piperacillin/Tazobactam 4/4 >64/4 ≤2/4 - 64/4 72% 
Amikacin ≤8 ≤8 ≤8 - >32 93% 
Ciprofloxacin >2 >2 ≤0.5 - >2 13% 
Gentamicin ≤2 >8 ≤2 - >8 72% 
Levofloxacin >4 >4 ≤1 - >4 13% 
Nitrofurantoin ≤16 64 ≤16 - >64 89% 
Tetracycline >8 >8 ≤2 - >8 41% 
Tobramycin ≤2 >8 ≤2 - >8 52% 
Sulfamethoxazole/Trimethoprim >2/38 >2/38 ≤0.5/9.5 - >2/38 37% 
 
 
 
 
Table B.4: Cumulative Antimicrobial Susceptibility Summary Report for all 34 Pseudomonas aeruginosa Clinical Isolates 
Abbreviations: PMB - Polymyxin B; COL - Colistin; RIF - Rifampin; AMI - Amikacin; MIN - Minocycline; TIG - Tigecycline; MEM - Meropenem; LEV - 
Levofloxacin; CPM - Cefepime; PTC - Piperacillin/Tazobactam; FOS - Fosfomycin 
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Antimicrobial MIC50 MIC90 MIC Range %S 
Ampicillin >16 >16 >16 * 
Ampicillin/Sulbactam >16/8 >16/8 8/4 - >16/8 * 
Aztreonam >16 >16 8 - >16 6% 
Cefazolin >16 >16 >16 * 
Cefepime 16 >16 8 - >16 6% 
Cefoxitin >16 >16 >16 * 
Ceftazidime >16 >16 4 - >16 9% 
Ceftriaxone >32 >32 32 - >32 * 
Cefuroxime >16 >16 >16 * 
Ertapenem >4 >4 >1 * 
Meropenem 8 >8 ≤1 - >8 21% 
Piperacillin/Tazobactam 64/4 >64/4 16/4 - >64/4 6% 
Amikacin ≤8 32 ≤8 - >32 85% 
Ciprofloxacin >2 >2 ≤0.5 - >2 6% 
Gentamicin >8 >8 ≤2 - >8 41% 
Levofloxacin >4 >4 ≤1 - >4 9% 
Nitrofurantoin >64 >64 >64 * 
Tetracycline >8 >8 8 - >8 * 
Tobramycin 4 >8 ≤2 - >8 50% 
Sulfamethoxazole/Trimethoprim >2/38 >2/38 >2/38 * 
*No CLSI or FDA breakpoints 
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Appendix C: 
 
 
Minimum Inhibitory Concentrations Determined by Broth Microdilution 
Susceptibility Testing and Etest ® 
 
 Table C.1 provide the results of in vitro susceptibility testing performed by broth 
microdilution and Etest®. 
 
The following abbreviations are used in Table C.1:  
PMB - Polymyxin B 
COL - Colistin 
RIF - Rifampin 
AMI - Amikacin 
MIN - Minocycline 
TIG - Tigecycline 
MEM - Meropenem 
LEV - Levofloxacin 
CPM - Cefepime 
PTC - Piperacillin/Tazobactam 
FOS - Fosfomycin 
 
 
 
 
Table C.1: Minimum Inhibitory Concentration (MIC) Values for 24 Klebsiella pneumoniae Clinical Isolates Determined by Broth Microdilution 
Abbreviations: PMB - Polymyxin B; COL - Colistin; RIF - Rifampin; AMI - Amikacin; MIN - Minocycline; TIG - Tigecycline; MEM - Meropenem; LEV - 
Levofloxacin; CPM - Cefepime; PTC - Piperacillin/Tazobactam; FOS - Fosfomycin 
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Isolate PMB COL* RIF* AMI MIN TIG MEM LEV CPM PTC FOS† 
7 0.06 ≤0.03 32 1 2* 0.125* 0.015 ≤0.03 ≤0.125* ≤0.25/4 32 
21 0.5 0.5 32 1 4* 0.25* 1 ≤0.03 4* ≤0.25/4 48 
KP 22 0.06 0.06 >32 64 16* 2* 16 64 32* 512/4 16 
KP 24 0.125 0.125 32 4 4* 0.25* 32 64 64* >512/4 24 
28 8 8 >32 64 32 2 128 64 >256 >512/4 64 
29 2 - - 32 8* 2* 32 >64 32* - - 
31 0.25 0.125 32 4 4* 0.125* 0.015 ≤0.03 ≤0.125* ≤0.25/4 12 
32 0.125 0.06 16 2 4* 0.25* 8 2 256* ≤0.25/4 256 
KP 34 0.125 0.125 32 1 2* 0.25* 4 0.06 2* ≤0.25/4 12 
35 0.125 0.06 >32 2 32* 2* 16 4 32* >512/4 >1024 
37 0.125 0.25 >32 128 4* 0.25* 16 ≤0.03 >256* >512/4 32 
43 0.06 0.06 >32 4 16* 1* 16 8 32* ≤0.25/4 >1024 
KP 44 0.06 0.06 >32 4 1* 4* 128 64 256* >512/4 48 
45 >256 - - 4 16 4 128 >32 >256 - - 
46 0.25 - - 128 8 2 32 >32 >256 - - 
47 128 - - 128 8 2 32 >32 >256 - - 
48 2* - - 64 8 1* 8* >32* 16* - - 
49 0.125* - - 1 8* 1* 16* 4* 8* - - 
51 0.125* - - 0.5 16* 4* 32* 8* 32* - - 
55 0.125* - - 128 4 0.5 8* 16 1 - - 
69 0.25* - - 0.5 >64 2 ≤0.125* 32 256 - - 
77 0.125* - - 2 4 1 0.25* 8 16 - - 
93 4* - - 2 32 2 8* 32 32 - - 
98 0.5* - - 1 8* 2* 0.06* 0.125* 4* - - 
MIC values expressed in the table are in units of µg/mL 
*Only a single experiment performed, but in duplicate 
†Etest® only 
- Not tested
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Appendix D: 
 
Time-kill Studies 
 
 Figures D.1-D.24 illustrate four carbapenem-resistant Klebsiella pneumoniae 
clinical isolates exposed to polymyxin B and meropenem alone and in combination. 
Graphs are separated by antimicrobial used and by isolate. The order begins with the least 
resistant isolate and ends with the most resistant isolate by meropenem MIC. For each 
isolate, the time-kill curves for meropenem, polymyxin, and then their combination are 
displayed. Ultimately, each antimicrobial and isolate combination (12 total combinations) 
is represented by two graphs, the first showing all experimental data for comparison, and 
the second showing the geometric mean of replicate experiments with error bars 
indicating one standard deviation. 
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